Klhdc compounds for targeted protein degradation

Abstract

This disclosure relates to bifunctional compounds useful for binding of KLHDC1 and KLHDC2 and targeted protein degradation. This disclosure also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions in the treatment of various diseases, conditions, and / or disorders.

Description

[0001]Attorney Docket No.: 121843.00295 NU-3700 PCT KLHDC COMPOUNDS FOR TARGETED PROTEIN DEGRADATION CROSS REFERENCE This patent application claims the benefit under 35 U.S.C. § 119 of U.S. Provisional Patent Application No. 63 / 681,358, filed August 9, 2024, the contents of which are incorporated herein by reference in their entirety. FIELD This disclosure provides bifunctional compounds that bind KLHDC1 and KLHDC2, useful for targeted protein degradation, pharmaceutical compositions comprising the same, and methods of their use for therapy. BACKGROUND Kelch domain containing protein 2 (KLHDC2) was first identified in 2001 as a unique and widely expressed protein ligase related to cellular transcriptional cofactors HCF-1 and HCF-2. Zhou et al. J. Biol. Chem. 2001, 276, 28933. KLHDC2 inhibits LZIP-mediated transcription. Zhou et al. LZIP is a cellular transcription factor that has been implicated in cell proliferation. Zhou et al. KLHDC2 inhibits LZIP via modulation of or interference with the DNA binding activity or capability of LZIP leading to less transcription. Zhou et al. Since LZIP has tumor suppressive activity, expression of KLHDC2 might influence cell proliferation via the inhibition of LZIP. Chin et al. Mol. Cell Biochem.2007, 296, 109. Kelch domain containing protein 1 (KLHDC1) was first identified in 2007 and is a close homolog to KLHDC2, sharing 47% identity and 65% similarity at the amino acid sequence level Chin et al. KLHDC1 degrades truncated oxidoreductive-inactive SELENOS, which is linked to reactive oxygen species production and ER stress induced cell death. Okumura et al. Science, 2020, 23, 100970. Both KLHDC1 and KLHDC2 have broad expression in all tissues, with elevated expression in some cancers. Notably, KLHDC2 is localized in the nucleus and KLHDC1 is localized in the cytosol. Targeted protein degradation (TPD) has been an active area of research since 2001. TPD functions via bringing a target protein into close proximity with, for example, an E3 ubiquitin ligase for subsequent ubiquitination and degradation of the target protein. To date there are only fourteen E3 ligases for E3 substrate receptors that have been accessed via proteolysis targeting chimera (PROTAC) technology for use in subsequent TPD technology. - 1 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT Roth et al. Cell Chemical Biology 2023, 30, 1. Thus, there is substantial potential and need for new TPD approaches that interact with new or existing E3 ligases for the purpose of treating unmet medical needs via TPD. KLHDC2 has been identified as a relatively new E3 ligase that is amendable to TPD. KLHDC2 can be used to ubiquitinate elusive and deleterious target proteins ultimately leading to the degradation of the elusive and deleterious target protein. Roth et al. KLHDC2 has broad expression in all tissues, with elevated expression in some cancers. For example, KLHDC2 has elevated expression in B-cell lymphomas and thymomas. Target proteins that possess a diGly moiety or degron at the C-terminus of the target protein are recognized by KLHDC2. KLHDC2 then ubiquitinates the target protein for subsequent (target) protein degradation. Described herein are novel bifunctional compounds that target KLHDC2 and / or KLHDC1, useful for TPD. SUMMARY Provided herein are bifunctional compounds and compositions comprising the compounds, methods of producing the compounds, and methods of using the compounds and compositions in treatment(s) of a disease or disorder mediated by a target protein. In certain embodiments, the compounds degrade the target protein via a ubiquitin proteolysis pathway. In particular embodiments, the compounds bind KLHDC protein. In certain embodiments, the compounds are capable of scaffolding the target protein and the KLHDC protein. In certain embodiments, the compounds are capable of inducing degradation of the target protein. In one aspect, provided herein are compounds of Formula (I), or a stereoisomer and / or a pharmaceutically acceptable salt thereof The left side of the molecule (X) is a protein targeting moiety (PTM). The right side of the molecule (K) is a KLHDC targeting moiety (KTM). The middle portion of the molecule (L) is a linker. Useful protein targeting moieties, KLHDC targeting moieties, and linkers are described herein. In another aspect, provided herein are compositions comprising the compound of any Formulae described herein or a conjugate thereof. In some embodiments, the compositions are pharmaceutical compositions. The pharmaceutical compositions comprise the compound and any suitable pharmaceutically acceptable carrier, excipient, or diluent. - 2 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided is a compound of Formula (II) o , y g , - y, y; y g or C1-5 alkyl; R2is ; each R5is independently hydrogen or alkyl; R6is -CH2-C(O)OR7or ; each R7hydrogen or C1-5 alkyl; aa is one or two; R3cis hydrogen, halogen, or CN; L1is a bond or selected from the one to ten; L is a bond or a linker; and is a protein targeting moiety (PTM). - 3 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In another aspect, provided herein are methods of making bifunctional compounds. In certain embodiments, the methods comprise the step of linking (X), a target binding moiety, to a KTM (K), directly or via a linker L, to form the bifunctional compound. In certain embodiments, the target binding moiety (X) is a moiety described herein. In certain embodiments, the KTM (K) is a moiety described herein. In certain embodiments, the linker L is a linker described herein. The KTM can be linked to L then linked to (X), or (X) can be linked to L then linked to the KTM. In certain embodiments, provided are methods comprising the step of contacting a target protein with the bifunctional compound. In another aspect, provided herein are methods of using the compounds or compositions described herein. In some embodiments, the methods are for the treatment of a disease or disorder mediated by a target protein in a patient in need thereof. Suitable diseases and disorders are described herein. In some embodiments, the target is a kinase, and the disease or disorder is a kinase-modulated disease or disorder. In certain embodiments, the disease or disorder is a cancer, an autoimmune disease, or an inflammatory disease. Also provided herein are uses of compounds described herein, and compositions thereof, for therapy. In certain embodiments, the therapy is the treatment of cancer. In certain embodiments, the therapy is treatment of an autoimmune disease or an inflammatory disease. Disclosed herein is a drug-antibody conjugate including an antibody or an antigen binding fragment thereof covalently linked to one or more compounds described herein. DETAILED DESCRIPTION Definitions For purposes herein, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in “Organic Chemistry,” Thomas Sorrell, University Science Books, Sausalito: 1999, and “March’s Advanced Organic Chemistry,” 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated herein by reference. When referring to the compounds and conjugates provided herein, the following terms have the following meanings unless indicated otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood - 4 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT by one of ordinary skill in the art. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise. As used herein, the term “combinations thereof” includes every possible combination of elements to which the term refers to. As described herein, compounds herein optionally may be substituted with one or more substituents, such as those illustrated generally herein, or as exemplified by particular classes, subclasses, and / or species of this description. As used herein, an “acetate” refers to -OC(O)RX, wherein RXis defined elsewhere herein. In one embodiment, acetate is -OC(O)Me As used herein, an “acyl” group refers to a RX-C(O)- (such as alkyl-C(O)-, also referred to as “alkylcarbonyl”) where RXand “alkyl” are defined elsewhere herein. Acetyl and pivaloyl are examples of acyl groups. As used herein, the term “aliphatic” encompasses the terms alkyl, alkenyl, and alkynyl, each of which are optionally substituted as set forth below. As used herein, an “aliphatic chain” refers to a branched or straight aliphatic group (e.g., alkyl groups, alkenyl groups, or alkynyl groups). A straight aliphatic chain has the structure -[CH2]v-, where v is one to twelve. A branched aliphatic chain is a straight aliphatic chain that is substituted with one or more aliphatic groups. A branched aliphatic chain has the structure -[CQQ]v-, where each Q is independently a hydrogen (H or –H) or an aliphatic group; however, Q shall be an aliphatic group in at least one instance. The term aliphatic chain includes alkyl chains, alkenyl chains, and alkynyl chains, where alkyl, alkenyl, and alkynyl are defined elsewhere herein. As used herein, an “alkenyl” group refers to an aliphatic carbon group that contains two to eight (e.g., two to four or two to six) carbon atoms and at least one double bond. Like an alkyl group, an alkenyl group can be straight or branched. Examples of an alkenyl group include, but are not limited to, allyl, 1- or 2-isopropenyl, 2-butenyl, and 2-hexenyl. An alkenyl group can be optionally substituted with one or more substituents such as halo, phospho, cycloaliphatic (e.g., cycloalkyl, cycloalkenyl, or cycloalkynyl), heterocycloaliphatic (e.g., heterocycloalkyl, heterocycloalkenyl, or heterocycloalkynyl), aryl, heteroaryl, alkoxy, aroyl, heteroaroyl, acyl (e.g., (aliphatic)carbonyl, (cycloaliphatic)carbonyl, or - 5 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT (heterocycloaliphatic)carbonyl), nitro, cyano, amido (e.g., (cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkylalkyl)carbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, alkylaminocarbonyl, cycloalkylaminocarbonyl, heterocycloalkylaminocarbonyl, arylaminocarbonyl, or heteroarylaminocarbonyl), amino (e.g., aliphaticamino, cycloaliphaticamino, heterocycloaliphaticamino, or aliphaticsulfonylamino), sulfonyl (e.g., alkyl-SO2-, cycloaliphatic-SO2-, or aryl-SO2-), sulfinyl, sulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, carboxy, carbamoyl, cycloaliphaticoxy, heterocycloaliphaticoxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkoxy, alkoxycarbonyl, alkylcarbonyloxy, or hydroxy. Without limitation, some examples of substituted alkenyls include cyanoalkenyl, alkoxyalkenyl, acylalkenyl, hydroxyalkenyl, aralkenyl, (alkoxyaryl)alkenyl, (sulfonylamino)alkenyl (such as (alkyl-SO2-amino)alkenyl), aminoalkenyl, amidoalkenyl, (cycloaliphatic)alkenyl, or haloalkenyl. As used herein, an “alkoxy” group refers to an alkyl-O- group where “alkyl” is defined elsewhere herein. As used herein, an “alkoxyalkyl” refers to an alkyl group modified with an alkoxy group, such as alkyl-O-alkyl- or ethers, wherein alkyl is defined elsewhere herein. As used herein, an “alkyl” or divalent “alkylene” group refers to a saturated aliphatic hydrocarbon group containing one to twelve (e.g., one to eight, one to six, one to five, or one to four) carbon atoms. An alkyl or alkylene group can be straight or branched. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-heptyl, or 2-ethylhexyl. Examples of alkylene groups include, but are not limited to, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2-, or -CH2CH2CH2CH2CH2CH2- An alkyl or alkylene group can be substituted (i.e., optionally substituted) with one or more substituents such as halo, phospho, cycloaliphatic (e.g., cycloalkyl or cycloalkenyl), heterocycloaliphatic (e.g., heterocycloalkyl or heterocycloalkenyl), aryl, heteroaryl, alkoxy, aroyl, heteroaroyl, acyl (e.g., (aliphatic)carbonyl, (cycloaliphatic)carbonyl, or (heterocycloaliphatic)carbonyl), nitro, cyano (i.e., -CN), amido (e.g., (cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkylalkyl)carbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, alkylaminocarbonyl, - 6 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT cycloalkylaminocarbonyl, heterocycloalkylaminocarbonyl, arylaminocarbonyl, or heteroarylaminocarbonyl), amino (e.g., aliphaticamino, cycloaliphaticamino, or heterocycloaliphaticamino), sulfonyl (e.g., aliphatic-SO2-, cycloaliphatic-SO2-, or aryl-SO2-), sulfinyl, sulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, carboxy, carbamoyl, cycloaliphaticoxy, heterocycloaliphaticoxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, alkoxycarbonyl, alkylcarbonyloxy, or hydroxy. Without limitation, some examples of substituted alkyls include carboxyalkyl (such as HOOC-alkyl, alkoxycarbonylalkyl, and alkylcarbonyloxyalkyl), cyanoalkyl, hydroxyalkyl, alkoxyalkyl, acylalkyl, aralkyl, (alkoxyaryl)alkyl, (sulfonylamino)alkyl (such as (alkyl-SO2-amino)alkyl), aminoalkyl, amidoalkyl, (cycloaliphatic)alkyl, or haloalkyl. As used herein, an “alkynyl” group refers to an aliphatic carbon group that contains two to eight (e.g., two to four or two to six) carbon atoms and has at least one triple bond. An alkynyl group can be straight or branched. Examples of an alkynyl group include, but are not limited to, propargyl and butynyl. An alkynyl group can be optionally substituted with one or more substituents such as aroyl, heteroaroyl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, nitro, carboxy, cyano, halo, hydroxy, sulfo, mercapto, sulfanyl (e.g., aliphaticsulfanyl or cycloaliphaticsulfanyl), sulfinyl (e.g., aliphaticsulfinyl or cycloaliphaticsulfinyl), sulfonyl (e.g., aliphatic-SO2-, aliphaticamino-SO2-, or cycloaliphatic-SO2-), amido (e.g., aminocarbonyl, alkylaminocarbonyl, alkylcarbonylamino, cycloalkylaminocarbonyl, heterocycloalkylaminocarbonyl, cycloalkylcarbonylamino, arylaminocarbonyl, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (cycloalkylalkyl)carbonylamino, heteroaralkylcarbonylamino, heteroarylcarbonylamino, or heteroarylaminocarbonyl), urea, thiourea, sulfamoyl, sulfamide, alkoxycarbonyl, alkylcarbonyloxy, cycloaliphatic, heterocycloaliphatic, aryl, heteroaryl, acyl (e.g., (cycloaliphatic)carbonyl or (heterocycloaliphatic)carbonyl), amino (e.g., aliphaticamino), sulfoxy, oxo, carboxy, carbamoyl, (cycloaliphatic)oxy, (heterocycloaliphatic)oxy, or (heteroaryl)alkoxy. As used herein, the term “amidino” refers to the formula -C(NRX)NRXRYwherein RXand RYhave been defined elsewhere herein. As used herein, an “amido” group encompasses both “aminocarbonyl” and “carbonylamino.” These terms when used alone or in connection with another group refer to - 7 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT an amido group such as -N(RX)-C(O)-RYor -C(O)-N(RX)2 when used terminally, and -C(O)-N(RX)- or -N(RX)-C(O)- when used internally, wherein RXand RYcan be aliphatic, cycloaliphatic, aryl, araliphatic, heterocycloaliphatic, heteroaryl, or heteroaraliphatic. Examples of amido groups include alkylamido (such as alkylcarbonylamino or alkylaminocarbonyl), (heterocycloaliphatic)amido, (heteroaralkyl)amido, (heteroaryl)amido, (heterocycloalkyl)alkylamido, arylamido, aralkylamido, (cycloalkyl)alkylamido, or cycloalkylamido. As used herein, an “amino” group refers to -NRXRYwherein each of RXand RYis independently hydrogen (H or –H), aliphatic, cycloaliphatic, (cycloaliphatic)aliphatic, aryl, araliphatic, heterocycloaliphatic, (heterocycloaliphatic)aliphatic, heteroaryl, carboxy, sulfanyl, sulfinyl, sulfonyl, (aliphatic)carbonyl, (cycloaliphatic)carbonyl, ((cycloaliphatic)aliphatic)carbonyl, arylcarbonyl, (araliphatic)carbonyl, (heterocycloaliphatic)carbonyl, ((heterocycloaliphatic)aliphatic)carbonyl, (heteroaryl)carbonyl, or (heteroaraliphatic)carbonyl, each of which being defined elsewhere herein and being optionally substituted. Examples of amino groups include alkylamino, dialkylamino, or arylamino. When the term “amino” is not the terminal group (e.g., alkylcarbonylamino), it is represented by -NRX-, where RXhas the same meaning as defined elsewhere herein. As used herein, “amino acid side chain” refers to the additional chemical moiety on the same carbon that bears a primary or secondary amine and a carboxylic acid of an amino acid. As would be appreciated by a person of ordinary skill in the art, there are twenty-one “standard” amino acids. Exemplary “standard” amino acids include, without limitation, alanine, serine, proline, arginine, and aspartic acid. Other amino acids include cysteine, selenocysteine, and glycine (e.g., wherein the additional chemical moiety on the same carbon that bears the primary amine and carboxylic acid of glycine is hydrogen). Exemplary amino acid side chains include, without limitation, methyl (i.e., alanine), sec-butyl (i.e., isoleucine), iso-butyl (i.e., leucine), –CH2CH2SCH3 (i.e., methionine), –CH2Ph (i.e., phenylalanine), (i.e., tyrosine), iso-propyl (i.e., valine), hydroxymethyl (i.e., serine), –CH(OH)CH3 (i.e., threonine), –CH2C(O)NH2 (i.e., asparagine), –CH2CH2C(O)NH2(i.e., glutamine), –CH2SH (i.e., cysteine), –CH2SeH (i.e., selenocysteine), - 8 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT –CH2NH2 (i.e., glycine), propylene or -CH2CH2CH2- (i.e., proline), –CH2CH2CH2NHC(=NH)NH2 (i.e., arginine), (i.e., histidine), –CH2CH2CH2CH2NH2 (i.e., lysine), –CH2COOH (i.e., aspartic acid), and –CH2CH2COOH (i.e., glutamic acid). As used herein, an “aminoalkyl” refers to the formula (RX)2N-alkyl- where RXhas been defined elsewhere herein. As used herein, an “araliphatic” such as an “aralkyl” group refers to an aliphatic group (e.g., a C1-4 alkyl group) that is substituted with an aryl group. “Aliphatic,” “alkyl,” and “aryl” are defined elsewhere herein. An example of an araliphatic such as an aralkyl group is benzyl. As used herein, an “aralkyl” group refers to an alkyl group (e.g., a C1-4alkyl group) that is substituted with an aryl group. Both “alkyl” and “aryl” are defined elsewhere herein. An example of an aralkyl group is benzyl. An aralkyl is optionally substituted with one or more substituents such as aliphatic (e.g., alkyl, alkenyl, or alkynyl, including carboxyalkyl, hydroxyalkyl, or haloalkyl such as trifluoromethyl), cycloaliphatic (e.g., cycloalkyl or cycloalkenyl), (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, amido (e.g., aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkylalkyl)carbonylamino, heteroarylcarbonylamino, or heteroaralkylcarbonylamino), cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl. As used herein, an “aroyl” or “heteroaroyl” refers to an aryl-C(O)- or a heteroaryl-C(O)-. The aryl and heteroaryl portion of the aroyl or heteroaroyl is optionally substituted as defined elsewhere herein. For example, aroyl includes benzoyl. As used herein, an “aryl” group used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl” refers to a monocyclic (e.g., phenyl); bicyclic (e.g., indenyl, naphthalenyl, tetrahydronaphthyl, or tetrahydroindenyl); or tricyclic (e.g., fluorenyl tetrahydrofluorenyl, tetrahydroanthracenyl, or anthracenyl) ring systems in which the monocyclic ring system is aromatic or at least one of the rings in a bicyclic or tricyclic ring - 9 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT system is aromatic. The bicyclic and tricyclic groups include benzofused (e.g., 2- or 3- membered, or bi- or tricyclic carbocyclic) rings. For example, a benzofused group includes a phenyl moiety fused with two or more C3-8 or C4-8 carbocyclic moieties. An aryl is optionally substituted with one or more substituents including aliphatic (e.g., alkyl, alkenyl, or alkynyl); cycloaliphatic; (cycloaliphatic)aliphatic; heterocycloaliphatic; (heterocycloaliphatic)aliphatic; aryl; heteroaryl; alkoxy; (cycloaliphatic)oxy; (heterocycloaliphatic)oxy; aryloxy; heteroaryloxy; (araliphatic)oxy; (heteroaraliphatic)oxy; aroyl; heteroaroyl; amino; oxo or carbonyl (i.e., on a non-aromatic carbon within a carbocyclic ring of a benzofused bicyclic or tricyclic aryl); nitro; carboxy; amido; acyl (e.g., (aliphatic)carbonyl; (cycloaliphatic)carbonyl; ((cycloaliphatic)aliphatic)carbonyl; (araliphatic)carbonyl; (heterocycloaliphatic)carbonyl; ((heterocycloaliphatic)aliphatic)carbonyl; or (heteroaraliphatic)carbonyl); sulfonyl (e.g., aliphatic-SO2- or amino-SO2-); sulfinyl (e.g., aliphatic-S(O)- or cycloaliphatic-S(O)-); sulfanyl (e.g., aliphatic-S-); cyano; halo; hydroxy; mercapto; sulfoxy; urea; thiourea; sulfamoyl; sulfamide; or carbamoyl. Alternatively, an aryl can be unsubstituted. Non-limiting examples of substituted aryls include haloaryl (e.g., mono-, di- (such as p,m-dihaloaryl), and (tri-halo)aryl); (carboxy)aryl (e.g., (alkoxycarbonyl)aryl, ((aralkyl)carbonyloxy)aryl, and (alkoxycarbonyl)aryl); (amido)aryl (e.g., (aminocarbonyl)aryl, (((alkylamino)alkyl)aminocarbonyl)aryl, (alkylcarbonyl)aminoaryl, (arylaminocarbonyl)aryl, and (((heteroaryl)amino)carbonyl)aryl); aminoaryl (e.g., ((alkylsulfonyl)amino)aryl or ((dialkyl)amino)aryl); (cyanoalkyl)aryl; (alkoxy)aryl; (sulfamoyl)aryl (e.g., (aminosulfonyl)aryl); (alkylsulfonyl)aryl; (cyano)aryl; (hydroxyalkyl)aryl; ((alkoxy)alkyl)aryl; (hydroxy)aryl, ((carboxy)alkyl)aryl; (((dialkyl)amino)alkyl)aryl; (nitroalkyl)aryl; (((alkylsulfonyl)amino)alkyl)aryl; ((heterocycloaliphatic)carbonyl)aryl; ((alkylsulfonyl)alkyl)aryl; (cyanoalkyl)aryl; (hydroxyalkyl)aryl; (alkylcarbonyl)aryl; alkylaryl; (trihaloalkyl)aryl; p-amino-m-alkoxycarbonylaryl; p-amino-m-cyanoaryl; p-halo-m- aminoaryl; or (m-(heterocycloaliphatic)-o-(alkyl))aryl. As used herein, “arylalkyl” refers to a monovalent moiety that is a radical of an alkyl compound, wherein the alkyl compound is substituted with an aromatic substituent (i.e., the aromatic compound includes a single bond to an alkyl group and wherein the radical is localized on the alkyl group). An arylalkyl group bonds to the illustrated chemical structure via the alkyl group. An arylalkyl can be represented by the structure, for example, , wherein B is an aromatic - 10 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT moiety, for example, aryl or phenyl. Arylalkyl is optionally substituted (i.e., the aryl group and / or the alkyl group, can be substituted as disclosed herein). Examples of arylalkyl include, but are not limited to, benzyl. As used herein, a “bicyclic ring system” includes 6- to 12-membered (e.g., 8- to 12- or 9-, 10-, or 11-membered) structures that form two rings, wherein the two rings have at least one atom in common (e.g., two atoms in common). Bicyclic ring systems include bicycloaliphatics (e.g., bicycloalkyl or bicycloalkenyl), bicycloheteroaliphatics, bicyclic aryls, and bicyclic heteroaryls. As used herein, a “bridged bicyclic ring system” refers to a bicyclic heterocyclicalipahtic (or heterocycloaliphatic) ring system or bicyclic cycloaliphatic ring system in which the rings are bridged. Examples of bridged bicyclic ring systems include, but are not limited to, adamantanyl, norbornanyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, bicyclo[3.3.2]decyl, 2-oxabicyclo[2.2.2]octyl, 1-azabicyclo[2.2.2]octyl, 3-azabicyclo[3.2.1]octyl, and 2,6-dioxa-tricyclo[3.3.1.03,7]nonyl. A bridged bicyclic ring system can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkylalkyl)carbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl. As used herein, a “carbamoyl” group refers to a group having the formula -O-CO-NRXRYor -NRX-CO-O-RZ, wherein RXand RYhave been defined elsewhere herein and RZcan be aliphatic, aryl, araliphatic, heterocycloaliphatic, heteroaryl, or heteroaraliphatic. As used herein, a “carbonyl” or “oxo” refers to -C(O)- or =O. As used herein, a “carboxy” group refers to –COOH, when used as a terminal group; or -OC(O)-, or -C(O)O- when used as an internal group. As used herein, a “cyanoalkyl” refers to the formula (NC)-alkyl-. - 11 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT As used herein, “cyclic moiety” and “cyclic group” refer to mono-, bi-, and tri- cyclic ring systems including cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl, each of which has been previously defined. As used herein, a “cycloaliphatic” group encompasses a “cycloalkyl” group and a “cycloalkenyl” group, each of which are optionally substituted as set forth below. A “cycloalkenyl” group, as used herein, refers to a non-aromatic carbocyclic ring of three to ten (e.g., four to eight) carbon atoms having one or more double bonds. Examples of cycloalkenyl groups include cyclopentenyl, 1,4-cyclohexa-di-enyl, cycloheptenyl, cyclooctenyl, hexahydro-indenyl, octahydro-naphthyl, cyclohexenyl, bicyclo[2.2.2]octenyl, or bicyclo[3.3.1]nonenyl. As used herein, a “cycloalkyl” group refers to a saturated carbocyclic mono- or bicyclic (fused, bridged, or spiro) ring of three to ten (e.g., five to ten) carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, norbornyl, cubyl, octahydro-indenyl, decahydro-naphthyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, bicyclo[3.3.2]decyl, bicyclo[2.2.2]octyl, adamantyl, spiro[3.3]heptanyl, or ((aminocarbonyl)cycloalkyl)cycloalkyl. A “cycloalkyl” or “cycloalkenyl” group can be optionally substituted with one or more substituents such as phospho, aliphatic (e.g., alkyl, alkenyl, or alkynyl), cycloaliphatic, (cycloaliphatic)aliphatic, heterocycloaliphatic, (heterocycloaliphatic)aliphatic, aryl, heteroaryl, alkoxy, (cycloaliphatic)oxy, (heterocycloaliphatic)oxy, aryloxy, heteroaryloxy, (araliphatic)oxy, (heteroaraliphatic)oxy, aroyl, heteroaroyl, amino, amido (e.g., (aliphatic)carbonylamino, (cycloaliphatic)carbonylamino, ((cycloaliphatic)aliphatic)carbonylamino, (aryl)carbonylamino, (araliphatic)carbonylamino, (heterocycloaliphatic)carbonylamino, ((heterocycloaliphatic)aliphatic)carbonylamino, (heteroaryl)carbonylamino, or (heteroaraliphatic)carbonylamino), nitro, carboxy (e.g., HOOC-, alkoxycarbonyl, or alkylcarbonyloxy), acyl (e.g., (cycloaliphatic)carbonyl, ((cycloaliphatic)aliphatic)carbonyl, (araliphatic)carbonyl, (heterocycloaliphatic)carbonyl, ((heterocycloaliphatic)aliphatic)carbonyl, or (heteroaraliphatic)carbonyl, cyano, halo, hydroxy, mercapto, sulfonyl (e.g., alkyl-SO2- and aryl-SO2-), sulfinyl (e.g., alkyl-S(O)-), sulfanyl (e.g., alkyl-S-), sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl. As used herein, an “ester” refers to –COORXwhen used as a terminal group; or –COORX– when used as an internal group, wherein RXhas been defined above. As used herein, - 12 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT an “alkoxycarbonyl,” which is encompassed by the term ester, used alone or in connection with another group refers to a group such as alkyl-O-C(O)- (i.e., a carbonate ester). As used herein, a “formate” refers to –OC(O)H. As used herein, a “haloaliphatic” or “haloalkyl” group refers to an aliphatic or alkyl group substituted with one to three halogen atoms. For instance, haloalkyl includes -CF3. As used herein, “haloalkoxy” refers to alkoxy, as defined above, wherein the alkoxy includes at least one substituent selected from a halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)). As used herein, a “halogen” or “halo” group refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I). As used herein, “heteroalkyl” refers to an alkyl in which one or more carbon atoms are replaced by heteroatoms. As used herein, “heteroalkenyl” refers to an alkenyl in which one or more carbon atoms are replaced by heteroatoms. As used herein, “heteroalkynyl” refers to an alkynyl in which one or more carbon atoms are replaced by heteroatoms. Suitable heteroatoms include, but are not limited to, nitrogen, oxygen, and sulfur atoms. Heteroalkyl, heteroalkenyl, and heteroalkynyl are optionally substituted. Examples of heteroalkyl moieties include, but are not limited to, aminoalkyl, sulfonylalkyl, and sulfinylalkyl. Examples of heteroalkyl moieties also include, but are not limited to, methylamino, methylsulfonyl, and methylsulfinyl. As used herein, a “heteroaraliphatic” (such as a heteroaralkyl group) refers to an aliphatic group (e.g., a C1-4 alkyl group) that is substituted with a heteroaryl group. “Aliphatic,” “alkyl,” and “heteroaryl” have been defined above. As used herein, a “heteroaralkyl” group refers to an alkyl group (e.g., a C1-4 alkyl group) that is substituted with a heteroaryl group. Both “alkyl” and “heteroaryl” have been defined above. A heteroaralkyl is optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralkylcarbonylamino, - 13 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT (heterocycloalkyl)carbonylamino, (heterocycloalkylalkyl)carbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl. A “heteroaryl” group, as used herein, refers to a monocyclic, bicyclic, or tricyclic ring system having four to fifteen ring atoms wherein one or more of the ring atoms is a heteroatom (e.g., N, O, S, or combinations thereof) and in which the monocyclic ring system is aromatic or at least one of the rings in the bicyclic or tricyclic ring systems is aromatic. A heteroaryl group includes a benzofused ring system having two to three rings. For example, a benzofused group includes one or two 4- to 8-membered heterocycloaliphatic moieties (e.g., indolizyl, indolyl, isoindolyl, isoindolinyl-1,3-dione, isoindolinyl-1-one, 3H- indolyl, indolinyl, benzo[b]furyl, benzo[b]thiopheneyl, quinolinyl, or isoquinolinyl). Some examples of heteroaryl are pyridyl, 1H-indazolyl, furyl or furanyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, tetrazolyl, benzofuryl or benzofuranyl, isoquinolinyl, 1-oxoisoquinolin- 2(1H)-yl, benzthiazolyl, xanthene, thioxanthene, phenothiazine, dihydroindole, benzo[1,3]dioxole, benzo[b]furyl, benzo[b]thiopheneyl, indazolyl, benzimidazolyl, 3-methyl- 2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl, benzthiazolyl, puryl or purinyl, cinnolyl, quinolyl, quinazolyl, phthalazyl, quinazolyl, quinoxalyl, isoquinolyl, 4H-quinolizyl, benzo- 1,2,5-thiadiazolyl, or 1,8-naphthyridyl. Other examples of heteroaryls include 1,2,3,4- tetrahydroisoquinoline and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine. Without limitation, monocyclic heteroaryls include furyl, thiophene-yl, 2H- pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,3,4-thiadiazolyl, pyridyl, pyridazyl, pyrimidyl, pyrazolyl, pyrazyl, or 1,3,5-triazyl. Monocyclic heteroaryls are numbered according to standard chemical nomenclature. Without limitation, bicyclic heteroaryls include indolizyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furyl, benzo[b]thiopheneyl, quinolinyl, isoquinolinyl, indazolyl, benzimidazyl, benzthiazolyl, purinyl, 4H-quinolizyl, quinolyl, isoquinolyl, cinnolyl, phthalazyl, quinazolyl, quinoxalyl, 1,8-naphthyridyl, or pteridyl. Bicyclic heteroaryls are numbered according to standard chemical nomenclature. A heteroaryl is optionally substituted with one or more substituents such as aliphatic (e.g., alkyl, alkenyl, or alkynyl); cycloaliphatic; (cycloaliphatic)aliphatic; heterocycloaliphatic; (heterocycloaliphatic)aliphatic; aryl; heteroaryl; alkoxy; (cycloaliphatic)oxy; (heterocycloaliphatic)oxy; aryloxy; heteroaryloxy; (araliphatic)oxy; - 14 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT (heteroaraliphatic)oxy; aroyl; heteroaroyl; amino; oxo (on a non-aromatic carbocyclic or heterocyclic ring of a bicyclic or tricyclic heteroaryl); carboxy; amido; acyl (e.g., (aliphatic)carbonyl; (cycloaliphatic)carbonyl; ((cycloaliphatic)aliphatic)carbonyl; (araliphatic)carbonyl; (heterocycloaliphatic)carbonyl; ((heterocycloaliphatic)aliphatic)carbonyl; or (heteroaraliphatic)carbonyl); sulfonyl (e.g., aliphaticsulfonyl or aminosulfonyl); sulfinyl (e.g., aliphaticsulfinyl); sulfanyl (e.g., aliphaticsulfanyl); nitro; cyano; halo; hydroxy; mercapto; sulfoxy; urea; thiourea; sulfamoyl; sulfamide; or carbamoyl. Alternatively, a heteroaryl can be unsubstituted. Non-limiting examples of substituted heteroaryls include (halo)heteroaryl (e.g., mono- and di-(halo)heteroaryl); (carboxy)heteroaryl (e.g., (alkoxycarbonyl)heteroaryl); cyanoheteroaryl; aminoheteroaryl (e.g., ((alkylsulfonyl)amino)heteroaryl and ((dialkyl)amino)heteroaryl); (amido)heteroaryl (e.g., aminocarbonylheteroaryl, ((alkylcarbonyl)amino)heteroaryl, ((((alkyl)amino)alkyl)aminocarbonyl)heteroaryl, (((heteroaryl)amino)carbonyl)heteroaryl, ((heterocycloaliphatic)carbonyl)heteroaryl, and ((alkylcarbonyl)amino)heteroaryl); (cyanoalkyl)heteroaryl; (alkoxy)heteroaryl; (sulfamoyl)heteroaryl (e.g., (aminosulfonyl)heteroaryl); (sulfonyl)heteroaryl (e.g., (alkylsulfonyl)heteroaryl); (hydroxyalkyl)heteroaryl; (alkoxyalkyl)heteroaryl; (hydroxy)heteroaryl; ((carboxy)alkyl)heteroaryl; (((dialkyl)amino)alkyl)heteroaryl; (heterocycloaliphatic)heteroaryl; (cycloaliphatic)heteroaryl; (nitroalkyl)heteroaryl; (((alkylsulfonyl)amino)alkyl)heteroaryl; ((alkylsulfonyl)alkyl)heteroaryl; (cyanoalkyl)heteroaryl; (acyl)heteroaryl (e.g., (alkylcarbonyl)heteroaryl); (alkyl)heteroaryl; or (haloalkyl)heteroaryl (e.g., trihaloalkylheteroaryl). As used herein, the term “heterocycloaliphatic” encompasses heterocycloalkyl groups and heterocycloalkenyl groups, each of which being optionally substituted as set forth below. A “heterocycloalkenyl” group, as used herein, refers to a mono- or bicylic (e.g., 5- to 10-membered mono- or bicyclic) non-aromatic ring structure having one or more double bonds, and wherein one or more of the ring atoms is a heteroatom (e.g., nitrogen (N), oxygen (O), or sulfur (S)). Monocyclic and bicyclic heterocycloalkenyls are numbered according to standard chemical nomenclature. As used herein, a “heterocycloalkyl” or divalent “heterocycloalklene” group refers to a 3- to 15-membered mono- or bicylic (e.g., 5- to 10-membered mono- or bicyclic) - 15 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT saturated ring structure (e.g., fused, bridged, or spiro), in which one or more of the ring atoms is a heteroatom (e.g., nitrogen (N), oxygen (O), sulfur (S), or combinations thereof). Non- limiting examples of a heterocycloalkyl (or a divalent heterocycloalkylene) group include piperidyl or piperidinyl, piperazyl or piperazinyl, tetrahydropyranyl, tetrahydrofuryl or tetrahydrofuranyl, 1,4-dioxolanyl, 1,4-dithianyl, 1,3-dioxolanyl, oxazolidyl or oxazolidinyl, isoxazolidyl or isoxazolidinyl, morpholinyl, thiomorpholinyl, octahydrobenzofuryl or octahydrobenzofuranyl, octahydrochromenyl, octahydrothiochromenyl, octahydroindolyl or octahydroindolinyl, octahydropyrindinyl or octahydro-1H-cyclopenta[x]pyridine where x is b or c, decahydroquinolinyl, octahydrobenzo[b]thiopheneyl, 2-oxa-bicyclo[2.2.2]octyl, 1-aza- bicyclo[2.2.2]octyl, 3-aza-bicyclo[3.2.1]octyl, 3,8-diazabicyclo[3.2.1]octyl, decahydro-2,7- naphthyridine, 2,8-diazaspiro[4.5]decane, 2-azaspiro[3.3]heptane, 2-azaspiro[3.5]nonane, 3- azaspiro[5.5]undecane, 2,7-diazaspiro[3.5]nonane, octahydropyrrolo[3,4-c]pyrrole, octahydro-1H-pyrrolo[3,4-b]pyridine, 2,5-diazabicyclo[2.2.1]heptane, 1-oxa-8- azaspiro[4.5]decane, and 2,6-dioxa-tricyclo[3.3.1.03,7]nonyl. A monocyclic heterocycloalkyl group can be fused with a phenyl moiety to form, for example, tetrahydroisoquinoline, that could be categorized as a heteroaryl as defined elsewhere herein. A heterocycloalkyl or heterocycloalkenyl group can be optionally substituted with one or more substituents such as phospho, aliphatic (e.g., alkyl, alkenyl, or alkynyl), cycloaliphatic, (cycloaliphatic)aliphatic, heterocycloaliphatic, (heterocycloaliphatic)aliphatic, aryl, heteroaryl, alkoxy, (cycloaliphatic)oxy, (heterocycloaliphatic)oxy, aryloxy, heteroaryloxy, (araliphatic)oxy, (heteroaraliphatic)oxy, aroyl, heteroaroyl, amino, amido (e.g., (aliphatic)carbonylamino, (cycloaliphatic)carbonylamino, ((cycloaliphatic)aliphatic)carbonylamino, (aryl)carbonylamino, (araliphatic)carbonylamino, (heterocycloaliphatic)carbonylamino, ((heterocycloaliphatic)aliphatic)carbonylamino, (heteroaryl)carbonylamino, or (heteroaraliphatic)carbonylamino, nitro, carboxy (e.g., HOOC-, alkoxycarbonyl, or alkylcarbonyloxy), acyl (e.g., (cycloaliphatic)carbonyl, ((cycloaliphatic)aliphatic)carbonyl, (araliphatic)carbonyl, (heterocycloaliphatic)carbonyl, ((heterocycloaliphatic)aliphatic)carbonyl, or (heteroaraliphatic)carbonyl), nitro, cyano, halo, hydroxy, mercapto, sulfonyl (e.g., alkylsulfonyl or arylsulfonyl), sulfinyl (e.g., alkylsulfinyl), sulfanyl (e.g., alkylsulfanyl), sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl. As used herein, the term “hydroxyl” or “hydroxy” refers to an –OH moiety. As used herein, a “mercapto” or “sulfhydryl” group refers to –SH. - 16 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT As used herein, the term “phospho” refers to phosphinates, phosphonates, phosphine oxides, phosphoramidates, phosphinic amides, and phosphonamidates. Examples of phosphinates, phosphonates, phosphine oxides, phosphoramidates, phosphinic amides, and phosphonamidates include -P(O)(RP)2, (RP)2P(O)ORP, and RP-PO(ORP)2, wherein RPis aliphatic, alkoxy, aryloxy, heteroaryloxy, (cycloaliphatic)oxy, (heterocycloaliphatic)oxy, aryl, heteroaryl, cycloaliphatic, or amino. As described herein, “protecting group” refers to a moiety or functionality that is introduced into a molecule by chemical modification of a functional group in order to obtain chemoselectivity in a subsequent chemical reaction. Standard protecting groups are provided in Wuts and Greene: “Greene’s Protective Groups in Organic Synthesis,” 4th Ed, Wuts, P.G.M. and Greene, T.W., Wiley-Interscience, New York: 2006. As used herein, a “residue” is the portion of a first compound that remains in a product after a condensation reaction with a second compound. In certain embodiments, reaction of the first compound with the second compound forms the product. In certain embodiments, there is loss of a small compound, for instance water, to form the product. The residue of the first compound is the moiety in the product that corresponds to the first compound. In certain embodiments, the residue is an amino acid residue within a larger compound. In certain embodiments, the residue is a KLHDC binding residue in a bifunctional compound described herein. As used herein, a “sulfamide” group refers to the formula -NRX-S(O)2-NRYRZwhen used terminally and -NRX-S(O)2-NRY- when used internally, wherein RX, RY, and RZare defined elsewhere herein. As used herein, a “sulfamoyl” group refers to the formula -S(O)2-NRYRZwherein RY, and RZare defined elsewhere herein. In one embodiment, -O-S(O)2-NRYRZis a sulfamate. As used herein a “sulfide” group refers to -S-RXwhen used terminally and -S- when used internally, wherein RXis defined elsewhere herein. Examples of sulfanyls include aliphatic-S-, cycloaliphatic-S-, aryl-S-, or the like. As used herein, a “sulfinate” group refers to -O-S(O)-RX, or -S(O)-O-RX, when used terminally and -O-S(O)- or -S(O)-O- when used internally, where RXis defined elsewhere herein. - 17 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT As used herein a “sulfinyl” group refers to -S(O)-RXwhen used terminally and -S(O)- when used internally, wherein RXis defined elsewhere herein. Examples of sulfinyl groups include aliphatic-S(O)-, aryl-S(O)-, (cycloaliphatic(aliphatic))-S(O)-, cycloalkyl-S(O)-, heterocycloaliphatic-S(O)-, heteroaryl-S(O)-, and / or the like. As used herein, a “sulfo” group refers to -SO3H, or -SO3RXwhen used terminally or -S(O)3- when used internally. In one embodiment, -SO3H is a sulfonic acid. In one embodiment, RXSO3- is a sulfonate. As used herein, a “sulfonamide” group refers to the formula RZ-S(O)2-NRXRYor -NRX-S(O)2-RZwhen used terminally; or -S(O)2-NRX-, or -NRX-S(O)2- when used internally, wherein RX, RY, and RZare defined elsewhere herein. As used herein, a “sulfonyl” group refers to -S(O)2-RXwhen used terminally and -S(O)2- when used internally, wherein RXis defined elsewhere herein. Examples of sulfonyl groups include aliphatic-S(O)2-, aryl-S(O)2-, (cycloaliphatic(aliphatic))-S(O)2-, cycloaliphatic-S(O)2-, heterocycloaliphatic-S(O)2-, heteroaryl-S(O)2-, (cycloaliphatic(amido(aliphatic)))-S(O)2-, and / or the like. As used herein, a “urea” group refers to the formula -NRX-CO-NRYRZand a “thiourea” refers to the formula -NRX-CS-NRYRZeach when used terminally and -NRX-CO-NRY- or -NRX-CS-NRY- each when used internally, wherein RX, RY, and RZare defined elsewhere herein. As used herein, a “guanidine” group refers to the formula -N=C(N(RXRY))(N(RXRY)) or -NRX-C(=NRX)NRXRYwherein RXand RYare defined elsewhere herein. As used herein, the term “vicinal” generally refers to the placement of substituents on a group that includes two or more carbon atoms, wherein the substituents are attached to adjacent carbon atoms. As used herein, the term “geminal” generally refers to the placement of substituents on the same carbon atom. The phrase “optionally substituted” is used interchangeably herein with the phrase “substituted or unsubstituted.” As described herein, compounds herein can optionally be substituted with one or more substituents, as illustrated generally herein, or as exemplified by particular classes, subclasses, and species within this description. As described herein, the - 18 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT variables R, X, L, and Z, and other variables contained in Formulae described herein encompass specific groups, for example, alkyl and aryl. Unless otherwise noted, each of the specific groups within the variables R, X, L, and Z, and other variables contained therein can be optionally substituted with one or more substituents described herein. Each substituent of a specific group is further optionally substituted with one to three halo, cyano, oxo, alkoxy, hydroxy, amino, nitro, aryl, cycloaliphatic, heterocycloaliphatic, heteroaryl, haloalkyl, and / or alkyl. For instance, an alkyl group can be substituted with alkylsulfanyl and the alkylsulfanyl can be optionally substituted with one to three halo, cyano, oxo, alkoxy, hydroxy, amino, nitro, aryl, haloalkyl, and alkyl. As an additional example, the cycloalkyl portion of a (cycloalkyl)carbonylamino can be optionally substituted with one to three halo, cyano, alkoxy, hydroxy, nitro, haloalkyl, and alkyl. When two alkoxy groups are bound to the same atom or adjacent atoms, the two alkoxy groups can form a ring together with the atom(s) to which they are bound. As used herein, the term “substituted,” whether preceded by the term “optionally” or not, refers generally to the replacement of one or more hydrogen atoms in a given chemical structure with the radical of a specified substituent. Specific substituents are defined above and described below within the compounds and examples thereof. Unless otherwise indicated, an optionally substituted group can have a substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted with more than one substituent selected from a specified group, the substituent can be either the same or different at every position. A ring substituent, such as a heterocycloalkyl, can be bound to another ring, such as a cycloalkyl, to form a spiro-bicyclic ring system, for example, both rings share one common atom. Non-limiting examples of spiro heterocycloalkyls include ; ; ; ; and . Spiro compounds depicted with overlapping rings indicate that the spirocyclic rings can bond at any vertex. For instance, in the - 19 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT spiro group , the two rings can bond at any of the three available vertex atoms in either ring. As one of ordinary skill in the art will recognize, combinations of substituents envisioned by this description are those combinations that result in the formation of stable or chemically feasible compounds. As used herein, the phrase “stable or chemically feasible” refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, recovery, purification, and / or use for one or more of the purposes disclosed herein. In some embodiments, a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40 °C or less, in the absence of moisture or other chemically reactive conditions, for at least a week. As used herein, an “effective amount” is defined as the amount required to confer a therapeutic effect on the treated subject or patient, and is typically determined based on age, surface area, weight, and / or condition of the subject or patient. The interrelationship between dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al., Cancer Chemother. Rep., 50: 219 (1966). Body surface area may be approximately determined from height and weight of the subject or patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardsley, New York, 537 (1970). As used herein, “patient” refers to an animal, alternatively a mammal, including a human. The terms “pharmaceutical formulation” and “pharmaceutical composition” refer to preparations that are in such form as to permit the biological activity of the active ingredient to be effective, and that contain no additional components that are unacceptably toxic to an individual or subject to which the formulation or composition would be administered. Such formulations or compositions may be sterile. The term “excipients” as used herein includes pharmaceutically acceptable excipients, carriers, vehicles, or stabilizers that are nontoxic to the subject, cell, or mammal being exposed thereto at the dosages and concentrations employed. In certain embodiments, the physiologically acceptable excipient is an aqueous pH buffered solution. - 20 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT The terms “treating” or “treatment” of a disease refer to executing a protocol, which may include administering one or more therapeutic agent to a subject and / or an individual (human or otherwise), in an effort to obtain beneficial or desired results in the subject or individual, including clinical results. In certain embodiments, beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total). In certain embodiments, “treatment” can also mean prolonging survival as compared to expected survival of an individual not receiving treatment. In certain embodiments, “treating” and “treatment” may occur by administration of one dose of a therapeutic agent or therapeutic agents, or may occur upon administration of a series of doses of a therapeutic agent or therapeutic agents. In certain embodiments, “treating” or “treatment” does not require complete alleviation of signs or symptoms, and does not require a cure. In certain embodiments, “treatment” can also refer to clinical intervention, such as administering one or more therapeutic agents to a subject and / or an individual, designed to alter the natural course of the subject, individual, or cell being treated (i.e., to alter the course of the individual or cell that would occur in the absence of the clinical intervention). In certain embodiments, the term “therapeutic agent” can refer to a compound or drug that induces or modulates KLHDC2 activity, or compositions thereof. The term “individual,” “patient,” or “subject” refers to a mammal. In certain embodiments, a “mammal” for purposes of treatment includes humans; non-human primates; domestic and farm animals; and zoo, sports, or pet animals, such as dogs, horses, rabbits, cattle, pigs, hamsters, gerbils, mice, ferrets, rats, cats, etc. In some embodiments, the individual or subject is human. As used herein, the term “about” means within ± 10% of a stated value. For example, a dose that is about 100 mg / kg provides that the dose can be 90 mg / kg to 110 mg / kg. By way of further example, an amount of an additional therapeutic agent ranging from about 50% to about 100% provides that the amount of additional therapeutic agent ranges from 45- 55% to 90-110%. A person of skill in the art will appreciate the scope and application of the term “about” when used to describe other stated values disclosed herein. Unless otherwise stated, structures depicted herein also are meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the - 21 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT chemical structure; for example, the (R)- and (S)- configurations for each asymmetric center, (Z)- and (E)- double bond isomers, and syn- / cis- and anti- / trans-conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the description. Alternatively, as used herein, “enantiomeric excess (ee)” refers to a dimensionless mol ratio describing the purity of chiral substances that contain, for example, a single stereogenic center. For instance, an enantiomeric excess of zero would indicate a racemic (e.g., 50:50 mixture of enantiomers, or no excess of one enantiomer over the other). By way of further example, an enantiomeric excess of ninety-nine would indicate a nearly stereopure enantiomeric compound (i.e., large excess of one enantiomer over the other). The percentage enantiomeric excess, % ee = ([(R)-compound]-[(S)-compound]) / ([(R)-compound]+[(S)- compound]) x 100, where the (R)-compound > (S)-compound; or % ee = ([(S)-compound]- [(R)-compound]) / ([(S)-compound]+[(R)-compound]) x 100, where the (S)-compound > (R)- compound. Also as used herein, “diastereomeric excess (de)” refers to a dimensionless mol ratio describing the purity of chiral substances that contain more than one stereogenic center. For example, a diastereomeric excess of zero would indicate an equimolar mixture of diastereoisomers. By way of further example, diastereomeric excess of ninety-nine would indicate a nearly stereopure diastereomeric compound (i.e., large excess of one diastereomer over the other). Diastereomeric excess may be calculated via a similar method to ee. As would be appreciated by a person of skill, de is usually reported as percent de (% de). % de may be calculated in a similar manner to % ee. In certain embodiments, the compounds described herein have an ee, de, % ee, or % de greater than zero. For example, in certain embodiments, the compounds described herein have an ee, de, % ee, or % de of ten. In certain embodiments, the compounds described herein have an ee, de, % ee, or % de of twenty-five. In certain embodiments, the compounds described herein have an ee, de, % ee, or % de of fifty. In certain embodiments, the compounds described herein have an ee, de, % ee, or % de of seventy-five. In certain embodiments, the compounds described herein have an ee, de, % ee, or % de of ninety-nine. In certain embodiments, the compounds described herein have an ee, de, % ee, or % de range from ninety to one hundred. In certain embodiments, the compounds described herein have an ee, de, % ee, or % de range from ninety-five to one hundred. In certain embodiments, the compounds described herein have an ee, de, % ee, or % de range from ninety- seven to one hundred. In certain embodiments, the compounds described herein have an ee, de, - 22 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT % ee, or % de range from ninety-eight to one hundred. In certain embodiments, the compounds described herein have an ee, de, % ee, or % de range from ninety-nine to one hundred. In one embodiment of a compound described herein, the ee, de, % ee, or % de is one. In one embodiment of a compound described herein, the ee, de, % ee, or % de is two. In one embodiment of a compound described herein, the ee, de, % ee, or % de is three. In one embodiment of a compound described herein, the ee, de, % ee, or % de is four. In one embodiment of a compound described herein, the ee, de, % ee, or % de is five. In one embodiment of a compound described herein, the ee, de, % ee, or % de is six. In one embodiment of a compound described herein, the ee, de, % ee, or % de is seven. In one embodiment of a compound described herein, the ee, de, % ee, or % de is eight. In one embodiment of a compound described herein, the ee, de, % ee, or % de is nine. In one embodiment of a compound described herein, the ee, de, % ee, or % de is ten. In one embodiment of a compound described herein, the ee, de, % ee, or % de is eleven. In one embodiment of a compound described herein, the ee, de, % ee, or % de is twelve. In one embodiment of a compound described herein, the ee, de, % ee, or % de is thirteen. In one embodiment of a compound described herein, the ee, de, % ee, or % de is fourteen. In one embodiment of a compound described herein, the ee, de, % ee, or % de is fifteen. In one embodiment of a compound described herein, the ee, de, % ee, or % de is sixteen. In one embodiment of a compound described herein, the ee, de, % ee, or % de is seventeen. In one embodiment of a compound described herein, the ee, de, % ee, or % de is eighteen. In one embodiment of a compound described herein, the ee, de, % ee, or % de is nineteen. In one embodiment of a compound described herein, the ee, de, % ee, or % de is twenty. In one embodiment of a compound described herein, the ee, de, % ee, or % de is twenty-one. In one embodiment of a compound described herein, the ee, de, % ee, or % de is twenty-two. In one embodiment of a compound described herein, the ee, de, % ee, or % de is twenty-three. In one embodiment of a compound described herein, the ee, de, % ee, or % de is twenty-four. In one embodiment of a compound described herein, the ee, de, % ee, or % de is twenty-five. In one embodiment of a compound described herein, the ee, de, % ee, or % de is twenty-six. In one embodiment of a compound described herein, the ee, de, % ee, or % de is twenty-seven. In one embodiment of a compound described herein, the ee, de, % ee, or % de is twenty-eight. In one embodiment of a compound described herein, the ee, de, % ee, or % de is twenty-nine. In one embodiment of a compound described herein, the ee, de, % ee, or % de is thirty. In one embodiment of a compound described herein, the ee, de, % ee, or % de is thirty-one. In one - 23 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT embodiment of a compound described herein, the ee, de, % ee, or % de is thirty-two. In one embodiment of a compound described herein, the ee, de, % ee, or % de is thirty-three. In one embodiment of a compound described herein, the ee, de, % ee, or % de is thirty-four. In one embodiment of a compound described herein, the ee, de, % ee, or % de is thirty-five. In one embodiment of a compound described herein, the ee, de, % ee, or % de is thirty-six. In one embodiment of a compound described herein, the ee, de, % ee, or % de is thirty-seven. In one embodiment of a compound described herein, the ee, de, % ee, or % de is thirty-eight. In one embodiment of a compound described herein, the ee, de, % ee, or % de is thirty-nine. In one embodiment of a compound described herein, the ee, de, % ee, or % de is forty. In one embodiment of a compound described herein, the ee, de, % ee, or % de is forty-one. In one embodiment of a compound described herein, the ee, de, % ee, or % de is forty-two. In one embodiment of a compound described herein, the ee, de, % ee, or % de is forty-three. In one embodiment of a compound described herein, the ee, de, % ee, or % de is forty-four. In one embodiment of a compound described herein, the ee, de, % ee, or % de is forty-five. In one embodiment of a compound described herein, the ee, de, % ee, or % de is forty-six. In one embodiment of a compound described herein, the ee, de, % ee, or % de is forty-seven. In one embodiment of a compound described herein, the ee, de, % ee, or % de is forty-eight. In one embodiment of a compound described herein, the ee, de, % ee, or % de is forty-nine. In one embodiment of a compound described herein, the ee, de, % ee, or % de is fifty. In one embodiment of a compound described herein, the ee, de, % ee, or % de is fifty-one. In one embodiment of a compound described herein, the ee, de, % ee, or % de is fifty-two. In one embodiment of a compound described herein, the ee, de, % ee, or % de is fifty-three. In one embodiment of a compound described herein, the ee, de, % ee, or % de is fifty-four. In one embodiment of a compound described herein, the ee, de, % ee, or % de is fifty-five. In one embodiment of a compound described herein, the ee, de, % ee, or % de is fifty-six. In one embodiment of a compound described herein, the ee, de, % ee, or % de is fifty-seven. In one embodiment of a compound described herein, the ee, de, % ee, or % de is fifty-eight. In one embodiment of a compound described herein, the ee, de, % ee, or % de is fifty-nine. In one embodiment of a compound described herein, the ee, de, % ee, or % de is sixty. In one embodiment of a compound described herein, the ee, de, % ee, or % de is sixty-one. In one embodiment of a compound described herein, the ee, de, % ee, or % de is sixty-two. In one embodiment of a compound described herein, the ee, de, % ee, or % de is sixty-three. In one embodiment of a compound described herein, the ee, de, % ee, or % de is sixty-four. In one - 24 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT embodiment of a compound described herein, the ee, de, % ee, or % de is sixty-five. In one embodiment of a compound described herein, the ee, de, % ee, or % de is sixty-six. In one embodiment of a compound described herein, the ee, de, % ee, or % de is sixty-seven. In one embodiment of a compound described herein, the ee, de, % ee, or % de is sixty-eight. In one embodiment of a compound described herein, the ee, de, % ee, or % de is sixty-nine. In one embodiment of a compound described herein, the ee, de, % ee, or % de is seventy. In one embodiment of a compound described herein, the ee, de, % ee, or % de is seventy-one. In one embodiment of a compound described herein, the ee, de, % ee, or % de is seventy-two. In one embodiment of a compound described herein, the ee, de, % ee, or % de is seventy-three. In one embodiment of a compound described herein, the ee, de, % ee, or % de is seventy-four. In one embodiment of a compound described herein, the ee, de, % ee, or % de is seventy-five. In one embodiment of a compound described herein, the ee, de, % ee, or % de is seventy-six. In one embodiment of a compound described herein, the ee, de, % ee, or % de is seventy-seven. In one embodiment of a compound described herein, the ee, de, % ee, or % de is seventy-eight. In one embodiment of a compound described herein, the ee, de, % ee, or % de is seventy-nine. In one embodiment of a compound described herein, the ee, de, % ee, or % de is eighty. In one embodiment of a compound described herein, the ee, de, % ee, or % de is eighty-one. In one embodiment of a compound described herein, the ee, de, % ee, or % de is eighty-two. In one embodiment of a compound described herein, the ee, de, % ee, or % de is eighty-three. In one embodiment of a compound described herein, the ee, de, % ee, or % de is eighty-four. In one embodiment of a compound described herein, the ee, de, % ee, or % de is eighty-five. In one embodiment of a compound described herein, the ee, de, % ee, or % de is eighty-six. In one embodiment of a compound described herein, the ee, de, % ee, or % de is eighty-seven. In one embodiment of a compound described herein, the ee, de, % ee, or % de is eighty-eight. In one embodiment of a compound described herein, the ee, de, % ee, or % de is eighty-nine. In one embodiment of a compound described herein, the ee, de, % ee, or % de is ninety. In one embodiment of a compound described herein, the ee, de, % ee, or % de is ninety-one. In one embodiment of a compound described herein, the ee, de, % ee, or % de is ninety-two. In one embodiment of a compound described herein, the ee, de, % ee, or % de is ninety-three. In one embodiment of a compound described herein, the ee, de, % ee, or % de is ninety-four. In one embodiment of a compound described herein, the ee, de, % ee, or % de is ninety-five. In one embodiment of a compound described herein, the ee, de, % ee, or % de is ninety-six. In one embodiment of a compound described herein, the ee, de, % ee, or % de is ninety-seven. In one - 25 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT embodiment of a compound described herein, the ee, de, % ee, or % de is ninety-eight. In one embodiment of a compound described herein, the ee, de, % ee, or % de is ninety-nine. In one embodiment of a compound described herein, the ee, de, % ee, or % de is one hundred. In certain embodiments, compounds described within Table 1 herein have an ee, de, % ee, or % de as described within this paragraph. In certain embodiments, compounds described in the Examples and / or Biological Examples have an ee, de, % ee, or % de as described within this paragraph. Unless otherwise stated, all tautomeric forms of the compounds of this description are within the scope of this description. Additionally, unless otherwise stated, structures depicted herein also are meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen with deuterium or tritium, or the replacement of a carbon with a13C- or14C-enriched carbon are within the scope of this description. Such compounds are useful, for example, as analytical tools or probes in biological assays, or as therapeutic agents. As used herein, the term “immunoglobulin” refers to a class of structurally related proteins generally comprising two pairs of polypeptide chains: one pair of light (L) chains and one pair of heavy (H) chains. In an “intact immunoglobulin,” all four of these chains are interconnected by disulfide bonds. The structure of immunoglobulins has been well characterized. See, e.g., Paul, Fundamental Immunology 7th ed., Ch. 5 (2013) Lippincott Williams & Wilkins, Philadelphia, PA. Briefly, each heavy chain typically comprises a heavy chain variable region (VH or VH) and a heavy chain constant region (CH or CH). The heavy chain constant region typically comprises three domains, abbreviated CH1 (or CH1), CH2 (or CH2), and CH3 (or CH3). Each light chain typically comprises a light chain variable region (VL or VL) and a light chain constant region. The light chain constant region typically comprises one domain, abbreviated CLor CL. The term “antibody” is used herein in its broadest sense. An antibody includes intact antibodies (e.g., intact immunoglobulins) and antibody fragments (e.g., antigen binding fragments of antibodies). Antibodies comprise at least one antigen-binding domain. One example of an antigen-binding domain is an antigen binding domain formed by a VH-VLdimer. The VH and VL regions may be further subdivided into regions of hypervariability (viz., “hypervariable regions” (HVRs); also called “complementarity determining regions” (CDRs)) interspersed with regions that are more conserved. The more - 26 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT conserved regions are called framework regions (FRs). Each VH and VL generally comprises three CDRs and four FRs arranged in the following order (from N-terminus to C-terminus): FR1 - CDR1 - FR2 - CDR2 - FR3 - CDR3 - FR4. The CDRs are involved in antigen binding, and influence antigen specificity and binding affinity of the antibody. See Kabat et al., Sequences of Proteins of Immunological Interest 5th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, MD, incorporated by reference herein in its entirety. The light chain from any vertebrate species can be assigned to one of two types, called kappa and lambda, based on the sequence of the constant domain. The heavy chain from any vertebrate species can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also designated α, δ, ε, γ, and µ, respectively. The IgG and IgA classes are further divided into subclasses based on differences in sequence and function. Humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The amino acid sequence boundaries of a CDR can be determined by one of skill in the art using any of a number of known numbering schemes, including those described by Kabat et al., supra (viz., the “Kabat” numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 (viz., the “Chothia” numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 (viz., the “Contact” numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 (viz., the “IMGT” numbering scheme); and Honegge and Plückthun, J. Mol. Biol., 2001, 309:657-70 (viz., the “AHo” numbering scheme), each of which is incorporated herein by reference in its entirety. Table A provides the positions of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR- H2, and CDR-H3 as identified by the Kabat and Chothia schemes. For CDR-H1, residue numbering is provided using both the Kabat and Chothia numbering schemes. Table A. Residues in CDRs according to Kabat and Chothia numbering schemes. - 27 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT * The C-terminus of CDR-H1, when numbered using the Kabat numbering convention, varies between H32 and H34, depending on the length of the CDR. Unless otherwise specified, the numbering scheme used for identification of a particular CDR herein is the Kabat / Chothia numbering scheme. Where the residues encompassed by these two numbering schemes diverge (e.g., CDR-H1 and / or CDR-H2), the numbering scheme is specified as either Kabat or Chothia. For convenience, CDR-H3 is sometimes referred to herein as either Kabat or Chothia. However, this is not intended to imply differences in sequence where they do not exist, and one of skill in the art can readily confirm whether the sequences are the same or different by examining the sequences. CDRs may be assigned, for example, using antibody numbering software, such as Abnum, available at www.bioinf.org.uk / abs / abnum / , and described in Abhinandan and Martin, Immunology, 2008, 45:3832-3839, incorporated herein by reference in its entirety. The “EU numbering scheme” is generally used herein when referring to a residue in an antibody heavy chain constant region (e.g., as reported in Kabat et al., supra). Unless stated otherwise, the EU numbering scheme is used to refer to residues in antibody heavy chain constant regions described herein. An “antibody fragment” as used herein comprises a portion of an intact antibody, such as the antigen binding or variable region of an intact antibody. Antibody fragments include, for example, Fv fragments, Fab fragments, F(ab’)2fragments, Fab’ fragments, scFv (sFv) fragments, scFv-Fc fragments, diabodies, triabodies, tertrabodies, minibodies, nanobodies, and the like. “Fv” fragments as used herein comprise a non-covalently-linked dimer of one heavy chain variable domain and one light chain variable domain. “Fab” fragments as used herein comprise, in addition to the heavy and light chain variable domains, the constant domain of the light chain and the first constant domain - 28 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT (CH1) of the heavy chain. Fab fragments may be generated, for example, by recombinant methods or by papain digestion of a full-length antibody. “F(ab′)2” fragments as used herein contain two Fab′ fragments joined, near the hinge region, by disulfide bonds. F(ab′)2 fragments may be generated, for example, by recombinant methods or by pepsin digestion of an intact antibody. The F(ab′) fragments can be dissociated, for example, by treatment with β-mercaptoethanol. “Single-chain Fv” or “sFv” or “scFv” antibody fragments as used herein comprise a VHdomain and a VLdomain in a single polypeptide chain. The VHand VLare generally linked by a peptide linker. See Plückthun A. (1994). In some embodiments, the linker is GGGGSGGGGSGGGGS (SEQ ID NO.:1). In some embodiments, the linker is AAGSDQEPKSS (SEQ ID NO.:2). Antibodies from Escherichia coli. In Rosenberg M. & Moore G.P. (Eds.), The Pharmacology of Monoclonal Antibodies vol. 113 (pp. 269-315). Springer-Verlag, New York, incorporated herein by reference in its entirety. “scFv-Fc” fragments as used herein comprise an scFv attached to an Fc domain. For example, an Fc domain may be attached to the C-terminus of the scFv. The Fc domain may follow the VHor VL, depending on the orientation of the variable domains in the scFv (i.e., VH-VL or VL-VH). Any suitable Fc domain known in the art or described herein may be used. In some cases, the Fc domain comprises an IgG1 Fc domain. In some embodiments, the IgG1 Fc domain comprises SEQ ID NO.:3, or a portion thereof. SEQ ID NO.:3 provides the sequence of CH1, CH2, and CH3 of the human IgG1 constant region: AAGSDQEPKSSDKTHTCPPCSAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK. As used herein, the term “monoclonal antibody” refers to an antibody from a population of substantially homogeneous antibodies. A population of substantially homogeneous antibodies comprises antibodies that are substantially similar and that bind the same epitope(s), except for variants that may normally arise during production of the monoclonal antibody. Such variants are generally present in only minor amounts. A monoclonal antibody is typically obtained by a process that includes the selection of a single antibody from a plurality of antibodies. For example, the selection process can be the selection - 29 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody can be further altered, for example, to improve affinity for the target (“affinity maturation”), to humanize the antibody, to improve its production in cell culture, and / or to reduce its immunogenicity in a subject. As used herein, term “chimeric antibody” refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species. As used herein, “humanized” forms of non-human antibodies are chimeric antibodies that contain minimal sequences derived from the non-human antibody. A humanized antibody is generally a human immunoglobulin (recipient antibody) in which residues from one or more CDRs are replaced by residues from one or more CDRs of a non-human antibody (donor antibody). The donor antibody can be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken, or non-human primate antibody having a desired specificity, affinity, or biological effect. In some instances, selected framework region residues of the recipient antibody are replaced by the corresponding framework region residues from the donor antibody. Humanized antibodies may also comprise residues that are not found in either the recipient antibody or the donor antibody. Such modifications may be made to further refine antibody function. For further details, see Jones et al., Nature, 1986, 321:522-525; Riechmann et al., Nature, 1988, 332:323-329; and Presta, Curr. Op. Struct. Biol., 1992, 2:593-596, each of which is incorporated herein by reference in its entirety. As used herein, a “human antibody” is one which possesses an amino acid sequence corresponding to that of an antibody produced by a human or a human cell, or derived from a non-human source that utilizes a human antibody repertoire or human antibody- encoding sequences (e.g., obtained from human sources or designed de novo). Human antibodies specifically exclude humanized antibodies. As used herein, an “isolated antibody” is one that has been separated and / or recovered from a component of its natural environment. Components of the natural environment may include enzymes, hormones, and other proteinaceous or nonproteinaceous materials. In some embodiments, an isolated antibody is purified to a degree sufficient to obtain at least fifteen residues of N-terminal or internal amino acid sequence, for example by use of a spinning cup sequenator. In some embodiments, an isolated antibody is purified to - 30 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT homogeneity by gel electrophoresis (e.g., SDS-PAGE) under reducing or nonreducing conditions, with detection by Coomassie blue or silver stain. An isolated antibody includes an antibody in situ within recombinant cells, since at least one component of the antibody’s natural environment is not present. In some aspects, an isolated antibody is prepared by at least one purification step. In some embodiments, an isolated antibody is purified to at least 80%, 85%, 90%, 95%, or 99% by weight. In some embodiments, an isolated antibody is purified to at least 80%, 85%, 90%, 95%, or 99% by volume. In some embodiments, an isolated antibody is provided as a solution comprising at least 85%, 90%, 95%, 98%, or 99% to 100% by weight. In some embodiments, an isolated antibody is provided as a solution comprising at least 85%, 90%, 95%, 98%, or 99% to 100% by volume. As used herein, “affinity” refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can be represented by the dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein. Affinity can be determined, for example, using surface plasmon resonance (SPR) technology, such as a Biacore®instrument. In some embodiments, the affinity is determined at 25 °C. With regard to the binding of an antibody to a target molecule, the terms “specific binding,” “specifically binds to,” “specific for,” “selectively binds,” and “selective for” a particular antigen (e.g., a polypeptide target) or an epitope on a particular antigen mean binding that is measurably different from a non-specific or non-selective interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule. Specific binding can also be determined by competition with a control molecule that mimics the antibody binding site on the target. In that case, specific binding is indicated if the binding of the antibody to the target is competitively inhibited by the control molecule. As used herein, the term “amino acid” refers to the twenty common naturally occurring amino acids. Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C); glutamic acid (Glu; - 31 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT E), glutamine (Gln; Q), Glycine (Gly; G); histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V), and the less common pyrrolysine and selenocysteine. Natural amino acids also include citrulline. Naturally encoded amino acids include post-translational variants of the twenty-two naturally occurring amino acids such as prenylated amino acids, isoprenylated amino acids, myristoylated amino acids, palmitoylated amino acids, N-linked glycosylated amino acids, O-linked glycosylated amino acids, phosphorylated amino acids, and acylated amino acids. The term “amino acid” also includes “non-natural amino acids” and “modified amino acids.” The terms “non-natural amino acids” and “modified amino acids” are used herein interchangeably. As used herein, the term “conjugate” or “antibody conjugate” refers to an antibody linked to one or more payload moieties. The antibody can be any antibody described herein. The payload can be any payload described herein. The antibody can be directly linked to the payload via a covalent bond, or the antibody can be linked to the payload indirectly via a linker. Typically, the linker is covalently bonded to the antibody and also covalently bonded to the payload. The term “antibody drug conjugate” or “ADC” refers to a conjugate wherein at least one payload is a therapeutic moiety such as a drug. The term “drug-antibody conjugate” or “degrader-antibody conjugate” or “DAC” refers to a conjugate wherein at least one payload is a therapeutic moiety such as a drug. As used herein, term “epitope” means a portion of an antigen capable of specific binding to an antibody. Epitopes frequently consist of surface-accessible amino acid residues and / or sugar side chains and may have specific three-dimensional structural characteristics, as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents. An epitope may comprise amino acid residues that are directly involved in the binding, and other amino acid residues, which are not directly involved in the binding. The epitope to which an antibody binds can be determined using known techniques for epitope determination. Percent “identity” between a polypeptide sequence and a reference sequence, is defined as the percentage of amino acid residues in the polypeptide sequence that are identical to the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment - 32 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW, CLUSTAL OMEGA, or MUSCLE software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. As used herein, a “conservative substitution” or a “conservative amino acid substitution” refers to the substitution of an amino acid with a chemically or functionally similar amino acid. Conservative substitution tables providing similar amino acids are well known in the art. Polypeptide sequences having such substitutions are known as “conservatively modified variants.” Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles. By way of example, the groups of amino acids provided in Tables B-D are, in some embodiments, considered conservative substitutions for one another. Table B. Selected groups of amino acids that are considered conservative substitutions for one another, in certain embodiments. - 33 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT Table C. Additional selected groups of amino acids that are considered conservative substitutions for one another, in certain embodiments. Table D. Further selected groups of amino acids that are considered conservative substitutions for one another, in certain embodiments. - 34 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT Additional conservative substitutions may be found, for example, in Creighton, Proteins: Structures and Molecular Properties 2nd ed. (1993) W. H. Freeman & Co., New York, NY. An antibody generated by making one or more conservative substitutions of amino acid residues in a parent antibody is referred to as a “conservatively modified variant.” As used herein, the term “linker” refers to a molecular moiety that is capable of forming at least two covalent bonds. Typically, a linker is capable of forming at least one covalent bond to an antibody and at least another covalent bond to a payload. In certain embodiments, a linker can form more than one covalent bond to an antibody. In certain embodiments, a linker can form more than one covalent bond to a payload or can form covalent bonds to more than one payload. After a linker forms a bond to an antibody, or a payload, or both, the remaining structure, meaning, the residue of the linker after one or more covalent bonds are formed, may still be referred to as a “linker” herein. The term “linker precursor” refers to a linker having one or more reactive groups (RGs) capable of forming a covalent bond with an antibody or payload, or both. In some embodiments, the linker is a cleavable linker. For example, a cleavable linker can be one that is released by a bio-labile function, which may or may not be engineered. In some embodiments, the linker is a non-cleavable linker. For example, a non-cleavable linker can be one that is released upon degradation of the antibody. As used herein, the term “&1” means that a compound including the “&1” notation at a particular chemical element or atom (e.g., carbon) within the compound was prepared as a mixture of two stereoisomers at the noted chemical element or atom (e.g., a diastereomeric mixture having a de or % de as described above). Chemical structures and nomenclature are derived from ChemDraw, version 23.0, Cambridge, MA. It is noted that the use of the descriptors “first,” “second,” “third,” or the like is used to differentiate separate elements (e.g., solvents, reaction steps, processes, reagents, or the like) and may or may not refer to the relative order or relative chronology of the elements described. Compounds Provided herein are bifunctional compounds. In certain embodiments, the bifunctional compounds comprise at least two moieties. A first moiety is capable of specifically binding to a target protein. The target protein can be any target protein deemed suitable by the - 35 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT person of ordinary skill. Useful target proteins are described herein. In certain embodiments, the target protein is a kinase. A second moiety is capable of specifically binding to a KLHDC protein. In certain embodiments, the first and second moiety are connected by a linker. In certain embodiments, the second moiety specifically binds KLHDC2. In certain embodiments, the second moiety specifically binds KLHDC1. In certain embodiments, the second moiety specifically binds KLHDC2 or KLHDC1. In certain embodiments, the first and second moieties are linked by a linker. The linker can be any linker deemed suitable by the person of ordinary skill. Useful linkers are described herein. The KLHDC1 or KLHDC2 ligand binders, and compounds described herein may be employed to induce ubiquitination and proteasomal degradation of intracellular proteins across a range of therapeutic indications including, but not limited to, oncology, immunology, inflammation, autoimmune disease, neurodegeneration, and metabolic or infectious disease. In certain embodiments, these binders are incorporated into bifunctional degraders (e.g., PROTACs) comprising a KLHDC1 / 2-binding ligand, a linker, and a target- binding ligand (TBD). The KLHDC1 / 2 ligases may be selected in lieu of cereblon (CRBN), von Hippel–Lindau (VHL), or other ligases for one or more reasons, including: (i) broad and favorable tissue expression, including spleen, lymph node, CNS, and thymus; (ii) structural compatibility with degron-tagging strategies due to KLHDC2’s recognition of short C-terminal motifs such as Gly-Gly; (iii) the absence of known neo-substrate burden as seen with CRBN; (iv) targeting of proteins that are traditionally and endogenously degraded through KLHDC1 or KLHDC2 binding; and (v) the availability of co-crystal structures and synthetic ligand scaffolds that support rational ligand design and degrader development. In some embodiments, the KLHDC1 / 2-binding ligands described herein may be substituted for a CRBN-binding ligand (e.g., a thalidomide analog) or a VHL-binding ligand (e.g., a hydroxyproline analog) in a known degrader scaffold, without modifying the target- binding ligand. In other embodiments, new target-binding ligands and / or linkers may be generated and coupled with KLHDC1 / 2-recruiting ligands to target proteins of interest for the indications described herein. In one aspect, provided herein are compounds of Formula (I), and stereoisomers and pharmaceutically acceptable salts thereof: - 36 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In Formula (I), , or (K), is a Kelch Domain Containing Protein (KLHDC) targeting moiety (KTM); L is a bond or a linker; and , or (X), is a protein targeting moiety (PTM). In certain embodiments, (K) binds KLHDC2. In certain embodiments, (K) binds KLHDC1. In certain embodiments, (K) binds KLHDC2 or KLHDC1. The linker and protein targeting moiety can be any such moieties deemed suitable by the person of ordinary skill. Useful linkers, protein targets, and protein targeting moieties are described in detail herein. In certain embodiments, provided herein are compounds of Formula (II), and stereoisomers and pharmaceutically acceptable salt thereof In Formula (II), one he other is hydrogen or C1-5 alkyl; R1is hydrogen or C1-5alkyl; each R5is independently hydrogen or alkyl; R6is -C(O)OR7or ; each R7hydrogen or C1-5 alkyl; aa is one or two; R3cis hydrogen, halogen, or CN; L1is a bond or selected from the group consisting of , , , , - 37 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT is a protein targeting moiety (PTM). In certain embodiments, provided herein are compounds of Formula (III), and stereoisomers and pharmaceutically acceptable salts thereof In Formula (III), R1, R2, and R3care as described above; R3bis hydrogen or C1-5alkyl; L1is a bond or selected from the group consisting of , , and is a protein targeting moiety (PTM). In certain embodiments, provided herein are compounds of Formula (IV), and stereoisomers and pharmaceutically acceptable salts thereof - 38 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In Formula (IV), R1, R2, and R3care as described above; R4is hydrogen or C1-5 alkyl; L1is a bond or selected from the group consisting of , is a protein targeting moiety (PTM). - 39 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT , . In certain embodiment, . one embodiment, is one, two, three, four, five, six, seven, eight, nine, or ten. In one embodiment, L1is and m is one, two, three, four, five, six, seven, eight, nine, or ten. In one embodiment, one, two, three, four, five, six, seven, eight, - 40 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT nine, or ten. In one embodiment, one, two, three, four, five, six, seven, eight, nine, or ten. In one embodiment, one, two, three, four, five, six, seven, eight, nine, or ten. In one embodiment, L1is and m is one, two, three, four, five, six, seven, eight, nine, or ten. In one embodiment, L1is one, two, three, four, five, six, seven, eight, nine, or ten. In one embodiment, one, two, three, four, five, six, seven, eight, nine, or ten. In certain embodiments, . certain embodiments, each R5is hydrogen. In certain embodiments, aa is one. In certain embodiments, aa is two. In certain embodiments, R6is -C(O)OH, -C(O)OMe, -C(O)(OC(CH3)3, -CH2-C(O)OH, -CH2-C(O)OMe, or -CH2-C(O)(OC(CH3)3. In certain embodiments, each R5is hydrogen; R6is -C(O)OH, -C(O)OMe, -C(O)(OC(CH3)3, -CH2-C(O)OH, -CH2-C(O)OMe, or -CH2-C(O)(OC(CH3)3; and aa is one. In certain embodiments, each R5is hydrogen; R6is -C(O)OH, -C(O)OMe, -C(O)(OC(CH3)3, -CH2-C(O)OH, -CH2-C(O)OMe, or -CH2-C(O)(OC(CH3)3; and aa is two. In certain embodiments, each R5is hydrogen; R6is -C(O)OH or -CH2-C(O)OH; and aa is one. In certain embodiments, each R5is hydrogen; R6is -C(O)OH or -CH2-C(O)OH; and aa is two. In certain embodiments, each R5is hydrogen; R6is -C(O)OMe or -CH2-C(O)OMe; and aa is one. In certain embodiments, each R5is hydrogen; R6is -C(O)OMe -CH2-C(O)OMe; and aa is two. - 41 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, . In certain embodiments, each R5is hydrogen. In certain embodiments, aa is one. In certain embodiments, aa is two. In certain embodiments, R7is hydrogen, methyl, or t-butyl. In certain embodiments, each R5is hydrogen; R7is hydrogen, methyl, or t-butyl; and aa is one. In certain embodiments, each R5is hydrogen; R7is hydrogen, methyl, or t-butyl; and aa is two. In certain embodiments, each R5is hydrogen; R7is hydrogen; and aa is one. In certain embodiments, each R5is hydrogen; R7is hydrogen; and aa is two. In certain embodiments, each R5is hydrogen; R7is methyl; and aa is one. In certain embodiments, each R5is hydrogen; R7is methyl; and aa is two. In certain embodiments, each R5is hydrogen; R7is t-butyl; and aa is one. In certain embodiments, each R5is hydrogen; R7is t-butyl; and aa is two. In certain embodiments, provided herein are compounds of Formula (V), and stereoisomers and pharmaceutically acceptable salts thereof wherein R3bis hydrogen, methyl, or isopropyl; R3cis hydrogen or fluoro; and R7is hydrogen, methyl, or t-butyl. In certain embodiments, provided herein are compounds of Formula (Va), (Vb), (Vc), (Vd), (Ve), (Vf), (Vg), or (Vh), and stereoisomers and pharmaceutically acceptable salts thereof , - 42 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 43 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (VI), and stereoisomers and pharmaceutically acceptable salts thereof wherein R7is hydrogen, methyl or t-butyl. In certain embodiments, provided herein are compounds of Formula (VIa), (VIb), and (VIc), and stereoisomers and pharmaceutically acceptable salts thereof - 44 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (VII), and stereoisomers and pharmaceutically acceptable salts thereof wherein R7is hydrogen, methyl or t-butyl. In certain embodiments, provided herein are compounds of Formulae (VIIa), (VIIb), (VIIc), (VIId), (VIIe), (VIIf), (VIIg), (VIIh), (VIIi), (VIIj), (VIIk), and (VIIl) and stereoisomers and pharmaceutically acceptable salts thereof - 45 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 46 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 47 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (VIII), and stereoisomers and pharmaceutically acceptable salts thereof wherein R7is hydrogen, methyl or t-butyl. In certain embodiments, provided herein are compounds of Formula (VIIIa), (VIIIb), (VIIIc), (VIIId), or (VIIIf) and stereoisomers and pharmaceutically acceptable salts thereof , - 48 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (IX), and stereoisomers and pharmaceutically acceptable salts thereof - 49 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT wherein Rbis hydrogen, methyl or isopropyl, R3cis hydrogen or fluoro, and R7is hydrogen, methyl or t-butyl. In certain embodiments, provided herein are compounds of Formula (IXa) and (IXb) and stereoisomers and pharmaceutically acceptable salts thereof In certain embodiments, provided herein are compounds of Formula (X) and stereoisomers and pharmaceutically acceptable salts thereof - 50 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT wherein R7is hydrogen, methyl, or t-butyl. In certain embodiments, provided herein are compounds of Formula (Xa), (Xb), and (Xc) and stereoisomers and pharmaceutically acceptable salts thereof In certain embodiments, provided herein are compounds of Formula (XI), and stereoisomers and pharmaceutically acceptable salts thereof - 51 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT wherein R7is hydrogen, methyl, or t-butyl. In certain embodiments, provided herein are compounds of Formula (XIa), (XIb), and (XIc) and stereoisomers and pharmaceutically acceptable salts thereof In certain embodiments, provided herein are compounds of Formula (XII) and stereoisomers and pharmaceutically acceptable salts thereof - 52 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT wherein R7is hydrogen, methyl or t-butyl. In certain embodiments, provided herein are compounds of Formula (XIIa), (XIIb), and (XIIc) and stereoisomers and pharmaceutically acceptable salts thereof In certain embodiments, provided herein are compounds of Formula (XIII) and stereoisomers and pharmaceutically acceptable salts thereof wherein R7is hydrogen, methyl or t-butyl. In certain embodiments, provided herein are compounds of Formula (XIIIa), (XIIIb), and (XIIIc) and stereoisomers and pharmaceutically acceptable salts thereof - 53 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (XIV) and stereoisomers and pharmaceutically acceptable salts thereof wherein R7is hydrogen, methyl, or t-butyl. In certain embodiments, provided herein are compounds of Formula (XIVa), (XIVb), and (XIVc) and stereoisomers and pharmaceutically acceptable salts thereof - 54 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (XV) and stereoisomers and pharmaceutically acceptable salts thereof wherein R7is hydrogen, methyl or t-butyl. In certain embodiments, provided herein are compounds of Formula (XVa), (XVb), and (XVIc) and stereoisomers and pharmaceutically acceptable salts thereof - 55 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (XVI) and stereoisomers and pharmaceutically acceptable salts thereof wherein R7is hydrogen, methyl or t-butyl. In certain embodiments, provided herein are compounds of Formula (XVIa), (XVIb), and (XVIc) and stereoisomers and pharmaceutically acceptable salts thereof - 56 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT KLHDC Targeting Moieties In certain embodiments, the KTM is according to Formula (5a) and stereoisomers and pharmaceutically acceptable salts thereof - 57 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, the KTM is according to Formula (5b) and stereoisomers and pharmaceutically acceptable salts thereof In certain embodiments, the KTM is according to Formula (7a) or (7b) and stereoisomers and pharmaceutically acceptable salts thereof In certain embodiments, the KTM is according to Formula (8a) or (8b) and stereoisomers and pharmaceutically acceptable salts thereof - 58 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, the KTM is according to Formula (9a) or (9b) and stereoisomers and pharmaceutically acceptable salts thereof In certain embodiments, the KTM is according to Formula (10a) or (10b), and stereoisomers and pharmaceutically acceptable salts thereof: - 59 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, the KTM is according to Formula (11a) or (11b) and stereoisomers and pharmaceutically acceptable salts thereof In certain embodiments, the KTM is according to Formula (12a) or (12b) and stereoisomers and pharmaceutically acceptable salts thereof - 60 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, the KTM is according to Formula (13a) or (13b), and stereoisomers and pharmaceutically acceptable salts thereof In certain embodiments, the KTM is according to Formula (14a) or (14b) and stereoisomers and pharmaceutically acceptable salts thereof - 61 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, the KTM is according to Formula (15a) or (15b) and stereoisomers and pharmaceutically acceptable salts thereof In certain embodiments, the KTM is according to Formula (16a) or (16b) and stereoisomers and pharmaceutically acceptable salts thereof - 62 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, the KTM is according to Formula (17a) or (17b) and stereoisomers and pharmaceutically acceptable salts thereof: - 63 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, the KTM is a residue of a compound selected from the , - 64 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT comprise a KTM residue as described herein, where the depicted piperidine nitrogen is bonded to the L group of any of Formulae I-X1b. - 65 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, the KTM is a residue of the compound selected from one embodiment, the KTM is a residue of the compound . - 66 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT one embodiment, the KTM is a residue of the compound . In certain embodiments, the KTM residue is as described above wherein the piperidine nitrogen is bonded to the L group of any of Formulae I-X1b. In certain embodiments, the KTM is a residue of a compound having the following formula certain embodiments, R4, when present, is three- to eight-membered heterocycloalkyl comprising at least one nitrogen, wherein the at least one nitrogen is unsubstituted or substituted with alkyl. In certain embodiments, R4is or . In certain embodiments, . certain embodiments, the KTM is a residue of a - 67 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT compound selected from the group consisting of . In one embodiment, the KTM is a residue of the compound - 68 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT . In certain embodiments, the KTM is a residue of a compound having the certain embodiments, R4, when present, is a five- to fifteen-membered spiro bicyclic heterocycloalkyl comprising at least one nitrogen, wherein the at least one nitrogen is unsubstituted or substituted with alkyl, heteroalkyl, alkenyl, alkynyl, acyl, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, arylalkyl, or heteroaryl. In certain embodiments, the five- to fifteen-membered spiro bicyclic heterocycloalkyl comprising at least one nitrogen is further wherein n1is zero to six, n2is zero to three, and n3is one to three. In - 69 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT certain embodiments, . certain embodiments, . one embodiment, the KTM is a residue of the compound . In one embodiment, the KTM is a residue of the compound - 70 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT . Protein Targeting Moieties In certain embodiments, the target protein can be any protein target deemed suitable by the person of ordinary skill without limitation. In certain embodiments, the target protein is a nuclear receptor. In certain embodiments, the target protein is an androgen receptor. In certain embodiments, the target protein is an estrogen receptor. In certain embodiments, the target protein is a nuclear factor. In certain embodiments, the target protein is BRD9. In certain embodiments, the target protein is STAT3. In certain embodiments, the target protein is an anti-apoptopic protein. In certain embodiments, the target protein is BCL-XL. In certain embodiments, the target protein is a cell surface receptor. In certain embodiments, the target protein is a growth factor receptor. In certain embodiments, the target protein is EGFR. In certain embodiments, the target protein is a kinase. In certain embodiments, the target protein is a IRAK4. In certain embodiments, the target protein is a tyrosine kinase. In certain embodiments, the target protein is BTK. - 71 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In particular embodiments, the target protein is a kinase. In certain embodiments, the kinase is selected from AGC kinases, CAMK kinases, CK1 kinases, CMGC kinases, RGC kinases, STE kinases, tyrosine kinases, tyrosine kinase-like kinases, atypical kinases, and other kinases. In certain embodiments, the kinase is selected from the group consisting of ABL1, ACK, ACTR2, ACTR2B, ADCK4, Trb1, BRSK2, Wnk2, AKT1, AKT2, AKT3, CaMK1g, ALK, ALK1, ALK2, BMPR1A, ALK4, TGFbR1, BMPR1B, AMPKa1, AMPKa2, ANPa, ANPb, ARAF, ABL2, ATM, ATR, AurC, AXL, BARK1, BCKDK, GCK, BLK, BRAF, BRK, BTK, BUBR1, CDK7, CaMK1a, CaMK2a, CaMK2b, CaMK2g, CaMK4, VACAMKL, DCAMKL1, CASK, CDC2, CDC7, CDK2, CDK3, CDK4, CDK5, CDK6, CDK8, PKG1, PKG2, CHED, CHK1, CHK2, CK1a, CK1d, CK1e, CK1g2, CK1g3, CK2a1, CK2a2, CLK1, CLK2, CLK3, COT, FMS, CSK, MARK3, CYGD, CYGF, DAPK1, DAPK2, DLK, DMPK1, DMPK2, DNAPK, DYRK1B, DYRK2, DYRK4, eEF2K, EGFR, PKR, MARK2, EphA1, EphA2, EphA3, EphA4, EphA5, EphA8, EphB1, EphB2, EphB3, EphB4, EphB6, Erk1, Erk2, Erk3, Erk4, FAK, FER, FES, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT3, FLT1, FLT4, FRAP, FYN, GAK, GPRK4, GPRK5, GPRK6, Trb2, GSK3A, GSK3B, HCK, ErbB2, ErbB3, ErbB4, HIPK1, HPK1, HSER, IGF1R, IKKa, IKKb, ILK, INSR, IRAK1, IRAK2, IRAK3, IRE1, IRR, ITK, JAK1, JAK2, JAK3, JNK1, JNK2, JNK3, KHS1, IKKe, NuaK1, MAST3, Fused, PIM3, KIT, CDKL2, CDKL1, KSR1, LCK, LIMK2, LKB1, LTK, LYN, MAK, MAPKAPK2, MAPKAPK3, MAPKAPK5, MARK1, MAST2, MAP2K1, MAP2K2, MAP2K5, MAP2K6, MAP3K1, MAP3K2, MAP3K3, MAP3K4, MAP3K5, MER, MET, MISR2, MAP2K7, smMLCK, MLK1, MLK2, DYRK1A, MNK1, MNK2, MOS, MAP2K3, MAP2K4, MRCKb, MSK1, MSK2, MST1, MST2, MST3, MUSK, MYT1, NDR1, NEK1, NEK2, NEK3, NIK, NLK, NEK4, IRAK4, PIK3R4, ROCK2, p38a, p70S6K, p70S6Kb, PAK1, PAK2, PAK3, PKCh, PCTAIRE1, PCTAIRE2, PCTAIRE3, PDGFRa, PDGFRb, PDK1, PDHK1, PDHK2, PDHK3, PDHK4, PEK, PFTAIRE1, PHKg1, PHKg2, PIM1, PIM2, CDK10, CDK9, PITSLRE, MELK, MRCKa, PKACa, PKACb, PKACg, PKCa, PKCb, PKCd, PKCe, PKCg, PKCi, PKD1, PKCt, PKCz, PRKX, HIPK3, PLK1, PLK3, PKN1, PKN2, PRKY, PRP4, PSKH1, RAF1, RET, RHOK, RIPK1, RIPK2, RIPK3, ROCK1, RON, ROR1, ROR2, ROS, RSK3, RSK2, RSK1, RYK, PLK4, p38b, p38g, p38d, MAST1, SGK1, SLK, PLK2, MLK3, SRC, SRPK1, SRPK2, CDKL5, TAO2, SYK, TAK1, BMPR2, TEC, TIE2, TESK1, TGFbR2, TIE1, TTN, TLK1, TLK2, TNK1, Trio, TRKA, TRKB, TRKC, TRRAP, TTK, TXK, TYK2, TYRO3, ULK1, ULK2, VRK1, VRK2, Wee1, YES, YSK1, ZAP70, LZK, DDR1, ADCK1, KDR, ALK7, AurB, AurA, Erk5, BUB1, DDR2, CCK4, - 72 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT LIMK1, LMR1, LMR2, LMR3, EphA7, BMX, CTK, FRK, NEK6, NEK7, AAK1, ChaK1, PYK2, SRM, LOK, KHS2, OSR1, PAK6, PAK4, MST4, STLK3, STLK5, STLK6, TAO3, TAO1, HGK, TNIK, MINK, NRK, LATS1, LATS2, CDK11, NIM1, ULK3, CLIK1L, TTBK2, SCYL1, MASTL, PINK1, ULK4, MLKL, DCAMKL3, SgK493, PFTAIRE2, STK33, PRPK, Erk7, CDKL4, SCYL3, YANK3, NEK9, TSSK3, NuaK2, RSKL2, TSSK2, SCYL2, NEK8, BARK2, NRBP1, PKD2, YANK2, CaMKK2, CCRK, CLK4, CRK7, DRAK1, DRAK2, DYRK3, PKD3, GCN2, SgK494, SgK495, CLIK1, HH498, HIPK2, HRI, ICK, IRE2, PASK, NDR2, QSK, HUNK, MAP3K6, ZAK, MOK, MPSK1, MSSK1, Wnk1, CDKL3, PAK5, PKN3, QIK, MARK4, SgK496, RSKL1, RSK4, NRBP2, SgK071, SGK2, SSTK, SGK3, TTBK1, DCAMKL2, Slob, PBK, SuRTK106, TBK1, TESK2, Trad, TSSK4, VRK3, caMLCK, SPEG, CK1a2, ANKRD3, NEK5, CaMK1d, MAP3K19, NEK11, GPRK7, SgK069, HIPK4, MYO3B, Wnk4, SgK110, BRSK1, Obscn, PSKH2, SIK, KSR2, RIOK3, ADCK3, RIOK1, YANK1, SNRK, EphA10, SgK196, MYO3A, Wnk3, SgK223, NEK10, EphA6, CK1g1, SgK269, SBK, SgK396, SgK288, KIS, CaMK1b, TBCK, SMG1, skMLCK, MAP3K7, LRRK2, MLK4, Haspin, Trb3, CRIK, CaMKK1, LRRK1, SgK307, MAST4, CaMK2d, BIKE, TSSK1, SgK424, SgK085, ADCK2, DAPK3, Wee1B, RNAseL, ChaK2, RIOK2, AlphaK2, AlphaK3, BRD2, BRD3, BRD4, BRDT, AlphaK1, ADCK5, TIF1a, TIF1b, TIF1g, JAK1_b, JAK2_b, JAK3_b, MSK1_b, MSK2_b, RSK3_b, RSK2_b, RSK1_b, TYK2_b, GCN2_b, RSK4_b, SPEG_b, Obscn_b, PAN3, FASTK, G11, TAF1, TAF1L, BCR, ABR, TIF1D, GTF2F1, Col4A3BP, BLVRA, BAZ1A, and BAZ1B. In some embodiments, the target protein is tyrosine-protein kinase (ITK / TSK). In some embodiments, the target protein is bromodomain-containing protein 4 (BRD4). In some embodiments, the target protein is FMS-like tyrosine kinase 3 (FLT-3). In some embodiments, the target protein is Brg / Brahma-associated factors (BAF complex). In some embodiments, the target protein is induced myeloid leukemia cell differentiation protein (MCL-1). In some embodiments, the target protein is signal transducer and activator of transcription 3 (STAT3). In some embodiments, the target protein is barrier-to-autointegration factor (BAF). In some embodiments, the target protein is BCR-ABL. In some embodiments, the disease is cancer. In some embodiments, the disease is an autoimmune disease. In certain embodiments, the target protein is selected from the group consisting of CDK4, CDK6, SHP- 2, FGFR1, FGFR3, FGFR1 fusions, FGFR3 fusions, MDM2, TRIM24, SARS-COV2 proteins (e.g. Mpro, or nsp5), PI3K, PI3K delta, MEK, BCR-ABL, MLL, MALT1, IRAK1, IRAK4, and kinases (e.g., broad spectrum). In some embodiments, the disease is an autoimmune - 73 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT disease. In certain embodiments, the target protein is selected from the group consisting of CDK4, CDK6, SHP-2, FGFR1, FGFR3, FGFR1 fusions, FGFR3 fusions, MDM2, TRIM24, SARS-COV2 proteins (e.g. Mpro, or nsp5), PI3K, PI3K delta, MEK, BCR-ABL, MLL, and MALT1. In certain embodiments, the target protein is SH2 domain-containing protein tyrosine phosphatase-2 (SHP-2). In certain embodiments, the target protein is fibroblast growth factor receptor (FGFR). In certain embodiments, the target protein is FGFR1 fusion. In certain embodiments, the target protein is FGFR3 fusion. In certain embodiments, the target protein is mouse double minute 2 homolog (MDM2). In certain embodiments, the target protein is tripartite motif containing 24 (TRIM24). In certain embodiments, the target protein is SARS- COV2 main protease (Mpro). In certain embodiments, the target protein is phosphoinositide 3- kinase (PI3K) delta. In certain embodiments, the target protein is mitogen-activated protein kinase kinase (MEK). In certain embodiments, the target protein is histone-lysine N- methyltransferase 2A (MLL). In certain embodiments, the target protein is mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1). In certain embodiments, the target protein is Interleukin 1 Receptor Associated Kinase 1 (IRAK1). In certain embodiments, the target protein is one or more kinases. In certain embodiments, the target proteins are a plurality of kinases. Other target proteins that may be degraded using the KLHDC1 / 2-binding compounds described herein (for any of the reasons enumerated elsewhere herein) include, but are not limited to, IKZF1, IKZF3, IRAK4, FOXP3, T-bet (TBX21), BTK, IRF4, IRF5, GATA3, NF-κB (RELA), LCK, ZAP70, ITK, BRD4, BRD2, BRD3, MYC, BTK, AKT1, KRAS, CDK4, CDK6, WEE1, EZH2, SRSF1, RBM39, FOXM1, E2F1, BCL6, AURKA / B.C, BRAF, AR, ER, STAT6, and STAT3. For example, KLHDC1 / 2-binding compounds may be used to degrade intracellular targets implicated in autoimmune and inflammatory diseases. These targets include, for example, IKZF1, IKZF3, IRAK4, BTK, FOXP3, T-bet (TBX21), IRF4, IRF5, STAT6, STAT3, SOCS1, GATA3, NF-κB (RELA), LCK, ZAP70, ITK, JAK1, and JAK3. These proteins regulate pathways associated with immune cell development, T cell polarization, cytokine signaling, Jak-STAT signaling, and negative regulation of inflammation. Degradation of these proteins using KLHDC1 / 2-based bifunctional degraders, such as the compounds described herein, may be therapeutically relevant to treat a variety of conditions, including systemic lupus erythematosus, dermatomyositis, multiple sclerosis, hidradenitis suppurativa, rheumatoid arthritis, lupus nephritis, transplant rejection, graft-versus-host - 74 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT disease, type 1 diabetes, ulcerative colitis, Crohn’s disease, inflammatory bowel disease, allergic dermatitis, eosinophilic esophagitis, asthma, severe asthma, atopic dermatitis, psoriasis, and other chronic immune disorders. KLHDC1 / 2-binding compounds, such as the ones described herein, may also be used to degrade oncogenic drivers and cancer-associated intracellular proteins. Targets of interest include, for example, BRD4, BRD2, BRD3, MYC, c-MYC, MCL1, BCL2, BTK, AKT1, KRAS, CDK4, CDK6, WEE1, EZH2, SRSF1, RBM39, FOXM1, E2F1, BCL6, ITK, AURKA / B / C, BRAF, AR, ER, and STAT3. These proteins play essential roles in chromatin remodeling, transcriptional amplification, apoptosis regulation, oncogenic signaling, hormone receptor activity, splicing, and mitotic checkpoint control. KLHDC1 / 2-based degraders directed against these targets may be used in a range of solid and hematologic tumor indications, including acute myeloid leukemia, diffuse large B cell lymphoma, chronic lymphocytic leukemia, follicular lymphoma, Burkitt lymphoma, multiple myeloma, triple- negative breast cancer, hormone receptor-positive breast cancer, prostate cancer, endometrial carcinoma, ovarian cancer, hepatocellular carcinoma, glioblastoma, medulloblastoma, melanoma, colorectal cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma, bladder cancer, small cell lung cancer, hairy cell leukemia, and thyroid cancer. KLHDC1 / 2-based degradation may also be used to target intracellular proteins relevant to non-oncology and non-immune indications. These may include, without limitation (i) neurodegeneration-associated proteins such as tau (MAPT), TDP-43 (TARDBP), FUS, α- synuclein (SNCA), and huntingtin (HTT), relevant to Alzheimer’s disease, frontotemporal dementia, ALS, Parkinson’s disease, and Huntington’s disease; (ii) metabolic regulators such as PCSK9, GCGR, FXR, and PPARγ, which may be relevant in obesity, non-alcoholic steatohepatitis (NASH), type 2 diabetes, or dyslipidemia; (iii) fibrosis-associated factors such as YAP1, TAZ, SMAD2 / 3, and MRTF-A in IPF, liver, and kidney fibrosis; and (iv) viral proteins and host factors such as HBc, Tat, eIF4A, and NPC1 in chronic viral infection or antiviral defense. In such embodiments, degradation via KLHDC1 / 2 recruitment with the compounds described herein may be used for indications covering neurodegenerative disorders, and metabolic, fibrotic, or infectious diseases. The KLHDC1 / 2-binding compounds, linkers, and target-binding domains described herein could be used in any PROTACs for all the targets described herein. In certain embodiments, an E3-recruiting ligand from a known PROTAC may be replaced with the - 75 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT KLHDC1 / 2 binding compounds described herein, while retaining the target-binding domain and linker. For example, the target binding domains from the validated degraders with known structures such as BRD4 – dBET1 (see, e.g., Winter^et^al., Science,^348(6241):1376- 1381,^2015); known degraders against such as BGB-16673, NRX-5948 or bexobrutideg, ABBV-101; IRAK4 – KT-474 (SAR444656), CR (see, e.g., Ackerman^et^al., Nat^Med,^29:3127-3136,^2023); STAT3-SD36 (see, e.g., Bai^et^al. Cancer^Cell,^36(5):498- 511.e17,^2019); SMARC2 / 4 (see, e.g., Farnaby et al., Nat Chem Biol. 2019;15:672-680). In each case, the person of ordinary skill in the art would recognize how to adapt the E3-recruiting ligand for KLHDC1 / 2 compatibility by applying standard medicinal chemistry, linker engineering, and ternary complex modeling tools. The resulting KLHDC1 / 2-based degrader may retain or improve degradation potency, pharmacologic selectivity, and tissue-specific activity relative to the parent or reference compound. In certain embodiments, a bifunctional compound described herein comprises any known protein target binder residue. The bifunctional compound can be prepared according to standard techniques known to those of ordinary skill in the art. In certain embodiments, the bifunctional compound is prepared according to techniques described herein. For instance, when the known protein target binder comprises a reactive chemical moiety, it can be reacted with the linker (L) and KTM, described elsewhere herein, to form the bifunctional compound. In certain embodiments, the PTM is a small molecule moiety that is configured to bind to or binds to a target protein, target polypeptide, or fragment thereof. In certain embodiments, the target protein, target polypeptide, or fragment thereof is a mediator of abnormal cellular proliferation. In certain embodiments, the PTM is configured to bind to or binds to a target protein selected from the group consisting of structural proteins, receptors, enzymes, cell surface proteins, aromatases, helicases, proteases, kinases, oxidoreductases transferases, hydrolases, lyases, isomerases, ligases, enzyme regulators, signal transducers, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport including protein transporters, nuclear transporters, ion transporters, channel transporters, carriers, permeases, secretases, electron transporters, pathogenesis, chaperones, nucleic acid binders, transcription regulators, and translation regulators. In certain embodiments, the PTM is configured to bind to or binds a target protein selected from the group consisting of Bruton’s tyrosine kinase (BTK); tyrosine-protein kinase (ITK / TSK); bromodomain-containing protein 4 (BRD4); FMS-like tyrosine kinase 3 (FLT-3); Brg / Brahma-associated factors (BAF complex); induced myeloid leukemia cell differentiation - 76 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT protein (MCL-1); signal transducer and activator of transcription 3 (STAT3); barrier-to- autointegration factor (BAF); and BCR-ABL. In certain embodiments, the PTM moiety is configured to bind to or binds to a target protein selected from the group consisting of FLT3, SHP-2, GLD06, CDK4, CDK6, CDK4 / 6, MALT1, BRAF, BCR-ABL, MEK, FGFR1, FGFR3, FGFR1 fusions, FGFR3 fusions, RET, RET fusions, BCL-2, PI3K, PI3K alpha, PI3K Delta, MLL, Aurora A, KRAS, KRAS G12D, KRAS G12C, MDM2, MCL-1, eIF4e, KSR, TRIM24, SHP-2, SARS-COV2 proteins, and MEK. In certain embodiments, the target protein is Bruton’s tyrosine kinase (BTK), and the protein target binder is ibrutinib, sold under the brand name Imbruvica. Ibrutinib is used to treat B cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia. As can be seen from the chemical structure below , ibrutinib comprises at least three chemical reactive groups, an amino group, a piperidine group, and a terminal olefin, each of which can be used to make bifunctional compounds described herein. Based on the crystal structure of ibrutinib bound to BTK, the terminal olefin or piperidine group allows the ibrutinib residue to maintain most of its binding interactions with BTK undisturbed. Accordingly, provided herein are bifunctional compounds comprising an ibrutinib residue as the PTM. In further embodiments, the PTMs binds to BTK and is selected from , the piperidine nitrogen bonds to L in the bifunctional compound. - 77 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, the target protein BCR-ABL, and the protein target binder is dasatinib, sold under the brand name Sprycel. Dasatinib is used to treat chronic myeloid leukemia. The chemical structure of dasatinib is shown below. . Dasatinib comprises a terminal hydroxyl group that can be bonded to L. Accordingly, provided herein are bifunctional compounds comprising a dasatinib residue as the PTM. In certain embodiments, a known protein target binder might not present an apparent reactive group. In such embodiments, the protein target binder can be modified with a reactive group, for instance, in a place where it would not significantly interfere with the binding to its target. In an illustrative example, the small molecule gefitinib inhibits EGFR and is sold under the brand name Iressa. The structure of gefitinib is as follows . Based on the binding of gefitinib to EGFR, in one embodiment, the morpholine is substituted with piperazine to provide a -NH- reactive group . The piperazine residue can be bonded to L. Accordingly, provided herein are bifunctional compounds comprising a gefitinib residue as the PTM. In another illustrative embodiment, ZM447439 is an Aurora kinase inhibitor whose structure is shown below - 78 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT . In one embodiment, the morpholine can be substituted with a piperazine to provide a reactive group . The piperazine residue can be bonded to L. Accordingly, provided herein are bifunctional compounds comprising a ZM447439 residue as the PTM. Other examples of Aurora PTMs include, but are not limited to, . In certain embodiments, either Aurora PTM is bonded to L via the piperidine or piperazine nitrogen, respectively. In another illustrative embodiment, the PTM is the pan kinase inhibitor CTX- 0294885 (CAS Number 1439934-41-4) whose chemical structure is shown below . Because CTX-0294885 is a pan kinase inhibitor, it provides bifunctional compounds that target multiple kinases. Accordingly, provided herein are bifunctional compounds comprising a CTX-0294885 residue as the PTM. - 79 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds wherein PTM is selected from the group consisting of wherein each R100a, R100b, and R100care independently selected from hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, acyl, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, arylalkyl, or - 80 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT heteroaryl; and each X100is independently a halogen selected from the group consisting of bromo, chloro, fluoro, and iodo. In certain embodiments, provided herein are compounds wherein PTM , provided herein are compounds wherein PTM . In certain embodiments, provided herein are compounds - 81 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT compounds wherein embodiments, provided herein are compounds wherein is . In certain embodiments, provided herein are compounds embodiments, provided herein are compounds wherein PTM . In certain - 82 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT embodiments, provided herein are compounds wherein PTM . In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the PTM (X) is selected from the group consisting of - 83 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the PTM (X) is - 84 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT , - 85 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, haloalkyl, heteroaryl, cyano, –C(O)alkyl, –C(O)aryl, or –C(O)heteroaryl. In certain embodiments, R22is hydrogen or halogen. In certain embodiments, A1is absent,–O–, –C(O)–, –C(O)–NH–, –C(O)–N(CH3)–, –C(O)–NH–R4a–, –CH(A2a)–, –N(alkyl)–, or –alkyl–. In certain embodiments, A2is absent or –C(H)(A2a)–. In certain embodiments, A2ais hydrogen, alkyl, aryl, heterocycle, or heteroaryl. In certain embodiments, A3is a bond. In certain embodiments, R23is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, haloalkyl, heteroaryl, cyano, –C(O)alkyl, –C(O)aryl, or –C(O)heteroaryl. In certain embodiments, R24is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, haloalkyl, heteroaryl, cyano, –C(O)alkyl, –C(O)aryl, –C(O)heteroaryl, or an alkylene bound to R25to form a substituted cycloalkyl. In certain embodiments, R25is hydrogen, or an alkylene bound to R4to form a substituted cycloalkyl. In certain embodiments, R25and R24form the substituted cycloalkyl. In certain embodiments, the cycloalkyl is substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, haloalkyl, heteroaryl, cyano, –C(O)alkyl, –C(O)aryl, –C(O)heteroaryl, and halogen. In certain embodiments, R26is hydrogen, or alkyl. In certain embodiments, R21is hydrogen. In certain embodiments, R22is hydrogen. In certain embodiments, A1is –C(O)–. In certain embodiments, A1is –C(O)–NH–. In certain embodiments, A1is –CH2–. In certain embodiments, A1is –N(CH3)–. In certain embodiments, A1is –O–. In certain embodiments, A1is –C(O)–N(CH3)–. In certain - 86 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT embodiments, A1is –C(O)–NH–phenol–. In certain embodiments, . certain embodiments, A2is –CH2–. In certain embodiments, A2is –CH2CH3–. In certain embodiments, A2is –CH(CH3)–. In certain embodiments, A2is –CH(phenyl)–. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the PTM (X) is , . embodiments, each of R21, R22, and R25is hydrogen. In certain embodiments, each of R23, R24, and R26is –CH3. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the - 87 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the In certain embodiments, provided herein are compounds of Formula (I)-(Vb), In certain embodiments, provided herein are compounds of Formula (I)-(Vb), - 88 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the - 89 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (I)-(Vb), embodiments, the target is B-Raf. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), certain embodiments, the target is B-Raf. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is B-Raf. - 90 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is B-Raf. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), the target is B-Raf. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), certain embodiments, the target is B-Raf. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is B- Raf. - 91 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is B-Raf. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), , , , - 92 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT , . certain embodiments, the target is FLT3. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is CDK4. In certain embodiments, the target is CDK6. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is CDK4. In certain embodiments, the target is CDK6. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is CDK4. In certain embodiments, the target is CDK6. - 93 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the PTM (X) is target is SHP-2. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the target is SHP-2. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is SHP-2. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), embodiments, the target is FGFR1 fusion. In certain embodiments, the target is FGFR3 fusion. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is MDM2. - 94 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is MDM2. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is MDM2. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), certain embodiments, the target is TRIM24. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is SARS-COV2. In certain embodiments, the protein is SARS-COV2 Mpro or nsp5. - 95 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the PTM (X) is . In certain embodiments, the target is SARS-COV2. In certain embodiments, the protein is SARS-COV2 Mpro or nsp5. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the PTM (X) is . In certain embodiments, the target is SARS-COV2. In certain embodiments, the protein is SARS-COV2 Mpro or nsp5. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is SARS-COV2. In certain embodiments, the protein is SARS-COV2 Mpro or nsp5. - 96 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is SARS-COV2. In certain embodiments, the protein is SARS-COV2 Mpro or nsp5. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is PI3K delta. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is MEK. - 97 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is MEK. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is MEK. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is MEK. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is BCR-ABL. - 98 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the target is BCR-ABL. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the target is BCR-ABL. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is MLL. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is MALT1. - 99 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is MALT1. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is IRAK1. In certain embodiments, provided herein are compounds of Formula (I)-(Vb), wherein the certain embodiments, the target is a kinase. In certain embodiments, the target is one or more kinases. In certain embodiments, the target is a plurality of kinases. In certain embodiments, provided herein are compounds according to Formula D1, and stereoisomers and pharmaceutically acceptable salts thereof - 100 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT , wherein R1, R2, R3b, R3c, L, and L1are as described in Formula (I) above. In certain embodiments, provided herein are compounds according to Formula D2, and stereoisomers and pharmaceutically acceptable salts thereof , wherein R1, R2, R4, R3c, L, and L1are as described in Formula (I) above. In certain embodiments, provided herein are compounds according to Formula D3, and stereoisomers and pharmaceutically acceptable salts thereof - 101 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT , wherein R1, R2, R3b, R3c, L, and L1are as described in Formula (I) above. In certain embodiments, provided herein are compounds according to Formula D4, and stereoisomers and pharmaceutically acceptable salts thereof , wherein R1, R2, R4, R3c, L, and L1are as described in Formula (I) above. In certain embodiments, provided herein are compounds according to Formula D5, and stereoisomers and pharmaceutically acceptable salts thereof - 102 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT described in Formula (I) above. In certain embodiments, provided herein are compounds according to Formula D6, and stereoisomers and pharmaceutically acceptable salts thereof , wherein R1, R2, R4, R3c, L, and L1are as described in Formula (I) above. In certain embodiments, provided herein are compounds according to Formula D7, and stereoisomers and pharmaceutically acceptable salts thereof , wherein R1, R2, R3b, R3c, L, and L1are as described in Formula (I) above. - 103 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds according to Formula D8, and stereoisomers and pharmaceutically acceptable salts thereof , wherein R1, R2, R4, R3c, L, and L1are as described in Formula (I) above. In certain embodiments, provided herein are compounds according to Formula D9, and stereoisomers and pharmaceutically acceptable salts thereof , wherein R1, R2, R3b, R3c, L, and L1are as described in Formula (I) above. In certain embodiments, provided herein are compounds according to Formula D10, and stereoisomers and pharmaceutically acceptable salts thereof - 104 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT wherein R1, R2, R4, R3c, L, and L1are as described in Formula (I) above. In certain embodiments, provided herein are compounds according to Formula D11, and stereoisomers and pharmaceutically acceptable salts thereof , wherein R1, R2, R3b, R3c, L, and L1are as described in Formula (I) above. In certain embodiments, provided herein are compounds according to Formula D12, and stereoisomers and pharmaceutically acceptable salts thereof wherein R1, R2, R4, R3c, L, and L1are as described in Formula (I) above. - 105 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, provided herein are compounds according to Formula D13, and stereoisomers and pharmaceutically acceptable salts thereof are as described in Formula (I) above. In certain embodiments, provided herein are compounds according to Formula D14, and stereoisomers and pharmaceutically acceptable salts thereof In certain embodiments, provided herein are compounds according to Formula D15, and stereoisomers and pharmaceutically acceptable salts thereof - 106 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT wherein R1, R2, R3b, R3c, L, and L1are as described in Formula (I) above. In certain embodiments, provided herein are compounds according to Formula D16, and stereoisomers and pharmaceutically acceptable salts thereof L1are as described in Formula (I) above. Linkers In any of Formulas I-Vb, L is a linker. The linker can be any linker suitable for linking the right and left portions of a compound herein. In certain embodiments, the linker does not interfere with the PTM or KTM functions of a compound described herein. In certain embodiments, the linker provides useful solubility, flexibility, and / or distance between the portions of a compound described herein. In certain embodiments, linker L includes three to forty carbon atoms, including one or more acyclic and / or cyclic moieties, wherein one or more carbon atoms can be replaced optionally by a heteroatom selected from oxygen (O), nitrogen (N), sulfur (S), and phosphorous (P), or wherein the linker group comprises one, two, three, four, five, six, seven, eight, nine, or ten ethylene glycol units; wherein the linker group is optionally substituted. In certain embodiments, L is a linker according to –L1-L2-L3-L4-L5-L6-L7– or –L7-L6-L5-L4-L3-L2-L1–. In certain embodiments, –L1– is absent; -N(R21)-; -C(R22)2-; - 107 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT C1-8 alkylene; C2-8 alkynylene; -C(O)-Q1-; Q1; or Q2. In certain embodiments, each –L2–, –L3–, –L4–, and –L5– is, independently, absent; -N(R21)-; -C(R22)2-; -C(O)-; -O-; -(CH2-CH2-O)1-8-; -(CH2-CH2-O)1-10-; -(CH2-CH2-O)1-15-; -(CH2-CH2-O)1-20-; C1-8 alkylene; C1-20 alkylene; C2-8 alkynylene; -C(O)-C1-20 alkylene-C(O)-; Q1; Q2; or Q3. In certain embodiments, each –L6– and –L7– is, independently, absent; -N(R21)-; -C(R22)2-; -C(O)-; -C(O)-N(R21)-; -N(R21)-C(O); -C(R22)2-Q1-C(R22)2-; -C(R22)2-C(O)-N(R21)-; -C(O)-C1-20 alkylene-C(O)-; or Q1;. In certain embodiments, each Q1is a three- to seven- membered heterocycloalkylene comprising at least one nitrogen. In certain embodiments, each Q2is a five- to thirteen-membered spiro bicyclic heterocycloalkylene comprising at least one nitrogen. In certain embodiments, each Q3is a three- to six-membered cycloalkylene. In certain embodiments, each R21is, independently, hydrogen or methyl; and each R22is, independently, hydrogen, methyl, aryl, or heteroaryl. In certain embodiments, L is a linker according to –L1-L2-L3-L4-L5-L6-L7– or –L7-L6-L5-L4-L3-L2-L1–. In certain embodiments, L is a linker according to –L1-L2-L3-L4-L5-L6– or –L6-L5-L4-L3-L2-L1–. In certain embodiments, L is a linker according to –L1-L2-L3-L4-L5– or –L5-L4-L3-L2-L1–. In certain embodiments, L is a linker according to –L1-L2-L3-L4– or –L4-L3-L2-L1–. In certain embodiments, L is a linker according to –L1-L2-L3– or –L3-L2-L1–. In certain embodiments, L is a linker according to –L1-L2– or –L2-L1–. In certain embodiments, L is a linker according to –L1–, –L2–, –L3–, –L4–, –L5–, –L6–, –L7–, or other combinations as would be appreciated by a person of ordinary skill in the art. For example, in certain embodiments, L is a linker according to –L1-L3-L6–, –L7-L5-L1–, or –L1-L3-L6-L2–. Each group Lxis described in detail below. In certain embodiments, the linker L comprises at least one heterocyclic group. In certain embodiments, the linker L comprises one heterocyclic group. In certain embodiments, the linker L comprises two heterocyclic groups. In certain embodiments, the linker L comprises three heterocyclic groups. In certain embodiments, the linker L comprises at least one spiro bicyclic heterocycloalkylene group. In certain embodiments, the linker L comprises one spiro bicyclic heterocycloalkylene group. In certain embodiments, the linker L comprises two spiro bicyclic heterocycloalkylene groups. In certain embodiments, the linker L comprises three spiro bicyclic heterocycloalkylene groups. In certain embodiments, the linker L comprises at least one heterocycloalkylene group and at least one spiro bicyclic heterocycloalkylene. The remaining groups of or within the linker are selected for chemical compatibility with adjacent groups, as will be recognized by those of skill in the art. - 108 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, L is a linker according to . In certain embodiments, L is a linker according to –L7-L6-L5-L4-L3-L2-L1–. In certain embodiments, –L1– is absent, -N(R10)-, -C(R11)2-, -C(O)-, -C1-8 alkylene-, -C2-8 alkynylene-, -C6-C10 aryl-, -heteroaryl-, -C4-C10 heteroaryl-, -Q1-, or -Q2-; each –L2–, –L3–, –L4–, and –L5– is independently, absent, -N(R10)-, -C(R11)2-, -C(O)-, -O-, -(CH2-CH2-O)1-8-, C1-8 alkylene-, -C2-8 alkynylene-, -C6-C10 aryl-, substituted -C6-C10 aryl-, -heteroaryl-, -C4-C10 heteroaryl-, -Q1-, -Q2-, or -Q3-; each –L6– and –L7– is independently, absent, -N(R10)-, -C(R10)2-, -C(O)-, -C(O)-N(R10)-, -N(R10)-C(O)-, -heteroaryl-, -C4-C10heteroaryl-, or -C(R11)2-C(O)-N(R10)-. In certain embodiments, L comprises at least one -Q1-. In certain embodiments, L comprises one -Q1-. In certain embodiments, L comprises two -Q1-. In certain embodiments, L comprises three -Q1-. In certain embodiments, L comprises at least one -Q2-. In certain embodiments, L comprises one -Q2-. In certain embodiments, L comprises two -Q2-. In certain embodiments, L comprises three -Q2-. In certain embodiments, L comprises at least one -Q1- and at least one -Q2-. In certain embodiments, L comprises one -Q1- and one -Q2-. In certain embodiments, each -Q1- is an unsubstituted or substituted three- to seven-membered heterocycloalkylene comprising at least one nitrogen; each -Q2- is a five- to thirteen-membered bicyclic heterocycloalkylene comprising at least one nitrogen, wherein the five- to thirteen-membered bicyclic heterocycloalkylene is optionally a spiro bicyclic heterocycloalkylene ring; each -Q3- is a three- to six-membered cycloalkylene; each R10is hydrogen or methyl; and each R11is independently, hydrogen, methyl, aryl, substituted aryl, or heteroaryl. In certain embodiments, R10is hydrogen. In certain embodiments, R10is methyl. In certain embodiments, one R11is hydrogen. In certain embodiments, both R11are hydrogen. In certain embodiments, one R11is methyl. In certain embodiments, one R11is hydrogen and the other is methyl. In certain embodiments, both R11are methyl. In certain embodiments, one R11is aryl. In certain embodiments, one R11is hydrogen or methyl and the other is aryl. In certain embodiments, both R11are aryl. In certain embodiments, R11is a substituted aryl. In certain embodiments, one R11is heteroaryl. In certain embodiments, one R11is hydrogen or methyl and the other is heteroaryl. In certain embodiments, both R11are heteroaryl. - 109 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments of Formulae I-Vb, L comprises at least one -Q1- according t , wherein n1is one or two, and n2is one or two. In certain embodiments of Formulae I-Vb, L comprises at least one -Q1-. In certain embodiments of Formulae I-Vb, L is selected from –Q1-N(Me)-CH2-Q1-C(O)–; –N(Me)-Q1-CH2-Q1-C(O)–; –Q2-CH2-Q1-C(O)–; –Q1-CH2-Q1-C(O)–; –Q1-Q1-C(O)–; –Q1-CH2-N(Me)-Q1-C(O)–; –Q1-CH2-Q1-CH2-C(O)-N(Me)–; –Q1-CH2-Q1–; –Q1-CH2-Q2–; –Q1-CH2-CH2-Q1–; –Q1-CH2-CH2-Q2–; –Q1-C(O)-Q1–; –Q1-C(O)-Q2–; –Q1-CH2-Q1-N(Me)-C(O)–; –CH2-CH2-CH2-CH2-Q1-C(O)–; –Q1-C(O)–; –Q1-C(O)-Q1-CH(C6H5)–; –C≡CCH2-Q1-C(O)–; –Q1-CH2-Q1-NH-C(O)–; –CH2-CH2-CH2-Q1-C(O)–; –Q1-CH2-Q1-C(Me)-C(O)-N(Me)–; –CH2-Q1–; –Q1-C(O)-Q1-CH2–; –N(H)-(CH2)5-C(O)-Q1-CH(C6H5)–; –N(H)-(CH2)2-O-(CH2)2-C(O)-Q1-CH(C6H5)–; –Q1-(CH2)3-C(O)-Q1-CH(C6H5)–; - 110 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT –Q2-C(O)-Q1-CH(C6H5)–; –Q2-CH2-C(O)-Q1-CH(C6H5)–; –Q2-(CH2)3-C(O)-Q1-CH(C6H5)–; –Q2-(CH2)2-C(O)-Q1-CH(C6H5)–; –(CH2)6-Q1-CH(C6H5)–; –Q1-Q1-C(O)-Q1-CH(C6H5)–; –Q1-CH2-C(O)-Q1-CH(C6H5)–; –Q1-(CH2)2-C(O)-Q1-CH(C6H5)–; –(CH2)3-C(O)-Q1-CH(C6H5)–; –(CH2)4-C(O)-Q1-CH(C6H5)–; –(CH2)5-C(O)-Q1-CH(C6H5)–; –(CH2)6-C(O)-Q1-CH(C6H5)–; –(CH2)3-Q1-CH2-C(O)-Q1-CH(C6H5)–; –(CH2)3-O-Q3-C(O)-Q1-CH(C6H5)–; –(CH2)3-O-(CH2)2-C(O)-Q1-CH(C6H5)–; –(CH2)3-O-(CH2)2-C(O)-Q1-CH(pyrid-2-yl)–; –(CH2)4-Q1-CH(C6H5)–; –(CH2)5-Q1-CH(C6H5)–; –(CH2)6-Q1-CH(pyrid-2-yl)–; –(CH2)7-Q1-CH(C6H5)–; –(CH2)7-Q1-CH(Me)-C(O)-N(Me)–; –N(H)-(CH2)2-O-(CH2)2-Q1-CH(Me)-C(O)-N(Me)–; –(CH2)3-O-(CH2)2-C(O)-Q1- CH(Me)-C(O)-N(Me)–; –N(H)-(CH2)2-O-(CH2)2-Q1-CH(C6H5)–; –N(H)-(CH2)2-[O-(CH2)2]2-C(O)-Q1-CH(C6H5)–; –N(H)-(CH2)2-[O-(CH2)2]3-C(O)-Q1-CH(C6H5)–; –N(H)-(CH2)2-[O-(CH2)2]4-C(O)-Q1-CH(C6H5)–; –N(H)-(CH2)2-[O-(CH2)2]5-C(O)-Q1-CH(C6H5)–; –N(H)-(CH2)2-[O-(CH2)2]6-C(O)-Q1-CH(C6H5)–; –N(H)-(CH2)2-[O-(CH2)2]7-C(O)-Q1-CH(C6H5)–; –N(H)-(CH2)2-[O-(CH2)2]8-C(O)-Q1-CH(C6H5)–; –N(H)–Q3–O–(CH2)2–CH2–; –N(H)–(CH2)3-Q1–(CH2)2–; - 111 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT –C(O)–N(H)–[(CH2)3–O]3–(CH2)2–NH–; –C(O)–N(H)–[(CH2)3–O]3–(CH2)2–; –Q1–C(O)–[(CH2)2–O]3–(CH2)2–NH–; –Q1–(CH2)3–O–CH2–; –Q1–C(O)–(C6H6)–CH2–; –Q1–(2-pyridyl)– –N(H)–Q3–X–(2-pyridyl)– –N(H)–Q3–X–(4-pyridyl) –CH C–(CH2)2–Q1–;–Q1–; –C(O)–(CH2-CH2-O)–(CH2)2–C(O)–Q1–CH(C6H5)–; –N(H)-C(O)–(CH2-CH2-O)4–(CH2)2–C(O)–Q1–CH(C6H5)–; –N(H)-C(O)–(CH2-CH2-O)5–(CH2)2–C(O)–Q1–CH(C6H5)–; –(CH2-CH2-O)5–(CH2)2–C(O)–Q1–CH(C6H5)–; –(CH2-CH2-O)–(CH2)2–C(O)–Q1–CH(C6H5)–; –(CH2-CH2-O)4–(CH2)2–C(O)–Q1–CH(C6H5)–; –(CH2)4–Q1–CH(C6H5)–; –(CH2)3–Q1–CH(C6H5)–; –(CH2)6–Q1–CH(C6H5)–; –(CH2)5–Q1–CH(C6H5)–; –(CH2-CH2-O)–(CH2)2–Q1–CH(C6H5)–; - 112 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT –C(O)–(CH2-CH2-O)4–(CH2)2–Q1–CH(C6H5)–; –C(O)–(CH2-CH2-O)5–(CH2)2–C(O)–Q1–CH(C6H5)–; –C(O)–(CH2-CH2-O)6–(CH2)2–C(O)–Q1–CH(C6H5)–; –C(O)–(CH2-CH2-O)3–(CH2)2–C(O)–Q1–CH(C6H5)–; –(CH2)5–C(O)–Q1–CH(C6H5)–; –(CH2-CH2-O)3–(CH2)2–C(O)–Q1–CH(C6H5)–; –(CH2)7–C(O)–Q1–CH(C6H5)–; –C(O)–pyrimidine– –C(O)–(CH2)–Q1–CH2–C(O)–Q1–CH(C6H5)–; –(CH2)2–C(O)–Q1–CH(C6H5)–; –C(O)–(CH2)2–Q1–(CH2)2–C(O)–Q1–CH(C6H5)–; –C(O)–(CH2)9–C(O)–Q1–CH(C6H5)–; –C(O)–(CH2)7–C(O)–Q1–CH(C6H5)–; –C(O)–(CH2)5–C(O)–Q1–CH(C6H5)–; –C(O)–(CH2-CH2-O)2–(CH2)2–C(O)–Q1–CH(C6H5)–; - 113 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT –CH2–C(O)–Q1–CH(C6H5)–; –(CH2)3–C(O)–Q1–CH(C6H5)–; –(CH2)4–C(O)–Q1–CH(C6H5)–; and –Q1–4-pyridyl–Q1–CH(C6H5)–, , or . In some embodiments, X is oxygen or sulfur. In certain embodiments of Formulae I-Vb, L comprises at least one -Q1- selected from the group consisting , , , , . Formulae I-Vb, L comprises at least one certain embodiments of Formulae I-Vb, L comprises at least one certain embodiments of Formulae I-Vb, L comprises at least one certain embodiments of Formulae I-Vb, L comprises at least one certain embodiments of - 114 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT Formulae I-Vb, L comprises at least one certain embodiments of Formulae I-Vb, L comprises at least one -Q1- as . In certain embodiments of Formulas I-Vb, L comprises at least one - In certain embodiments of Formulae I-Vb, L comprises at least one -Q2- according t , wherein n3is one or two. In certain embodiments of Formulae I-Vb, L comprises at least one -Q2- according t . In certain embodiments of Formulae I-Vb, L comprises at least one -Q2- according t , wherein n4is one or two, n5is one or two, and n6is one or two. In certain embodiments of Formulae I-Vb, L comprises at least one -Q2- according . In certain embodiments of Formulae I-Vb, L comprises at least one -Q2- according to wherein n8is one or two. - 115 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments of Formulae I-Vb, L comprises at least one -Q2- according t . In certain embodiments of Formulae I-Vb, L comprises at least one -Q2- according to , wherein n18and n19is two, or n18is two and n19is three, or n18is three and n19is two. In certain embodiments of Formula (I) or Formula (II), L comprises at least one -Q2- according . In certain embodiments of Formulae I-Vb, L comprises at least one -Q2- according to , wherein n22is zero to two; n23is zero to two, and n24is one or two, or wherein n22is two and each n23and n24is one; or n22is two and each n23and n24is two. In certain embodiments of Formulae I-Vb, L comprises at least one -Q2- according In certain embodiments of Formulae I-Vb, L comprises at least one -Q2- according t . In certain embodiments of Formulae I-Vb, L comprises at least one -Q3- according t , wherein n1is one or two, and n2is one or two. - 116 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments of Formulae I-Vb, L comprises at least one -Q3- selected from the group consisting certain embodiments of Formulae I-Vb, L comprises at least one . In certain embodiments of Formulae I-Vb, L is a linker according to the formula –L1-L2-L3-L4-L5-L6-L7–. Each group Lxis described in detail below. In certain embodiments, the linker comprises at least one heterocyclic group. In certain embodiments, the linker comprises two heterocyclic groups. In certain embodiments, the linker comprises three heterocyclic groups. In certain embodiments, the linker comprises at least one spiro bicyclic heterocycloalkylene group. In certain embodiments, the linker comprises at least two spiro bicyclic heterocycloalkylene groups. In certain embodiments, the linker comprises at least three spiro bicyclic heterocycloalkylene groups. In certain embodiments, the linker comprises at least one heterocycloalkylene group and at least one spiro bicyclic heterocycloalkylene. The remaining groups of the linker are selected for chemical compatibility with adjacent groups, as will be recognized by those of ordinary skill in the art. In certain embodiments, L is a linker according to the formula –L1-L2-L3-L4-L5-L6-L7–. In certain embodiments, –L1– is absent, -N(R21)-; -C(R22)2-; C1-8 alkylene; C2-8 alkynylene; Q1; or Q2. In certain embodiments, each –L2–, –L3–, –L4–, and –L5– is independently, absent; -N(R21)-; -C(R22)2-; -C(O)-; -O-; -(CH2-CH2-O)1-8-; C1-8alkylene; C2-8 alkynylene; Q1; Q2; or Q3. In certain embodiments, each –L6– and –L7–, is independently, absent; -N(R21)-; -C(R22)2-; -C(O)-; -C(O)-N(R21)-; -N(R21)-C(O)-; or -C(R22)2-C(O)-N(R21)-. In certain embodiments, L comprises at least one Q1. In certain - 117 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT embodiments, L comprises one Q1. In certain embodiments, L comprises two Q1. In certain embodiments, L comprises three Q1. In certain embodiments, L comprises at least one Q2. In certain embodiments, L comprises one Q2. In certain embodiments, L comprises two Q2. In certain embodiments, L comprises three Q2. In certain embodiments, L comprises at least one Q1and at least one Q2. In certain embodiments, L comprises one Q1and one Q2. In certain embodiments, each Q1is a three- to seven-membered heterocycloalkylene comprising at least one nitrogen. In certain embodiments, each Q2is a five- to thirteen-membered spiro bicyclic heterocycloalkylene comprising at least one nitrogen. In certain embodiments, each Q3is a three- to six-membered cycloalkylene. In certain embodiments, each R21is hydrogen, or methyl. In certain embodiments, each R22is hydrogen, methyl, aryl, or heteroaryl. In certain embodiments, L comprises at least one -Q1- according to , wherein n1is one or two, and n2is one or two. In certain embodiments, L comprises at least one -Q1- selected from the group consisting In certain embodiments, L comprises at least one -Q2- according to , wherein n3is one or two. In certain embodiments, L comprises at least one -Q2- according to . - 118 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, L comprises at least one -Q2- according to , wherein n4is one or two, n5is one or two, and n6is one or two. In certain embodiments, L comprises at least one -Q2- according to . In certain embodiments, L comprises at least one -Q2- according to wherein n8is one or two. In certain embodiments, L comprises at least one -Q2- according to . In certain embodiments, L comprises at least one -Q2- according to , wherein n18and n19is two, or piperidinyl; or when n18is two, then n19is three, or azepanyl; or when n18is three, then n19is two, or azepanyl. In certain embodiments, L comprises at least one -Q2- according to . In certain embodiments, L comprises at least one -Q2- according to , wherein n22is zero to two; n23is zero to two, and n24is one, or two. In certain embodiments, when n22is two, then n23and n24are one; or when n22is two, then n23and n24are two. - 119 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, L comprises at least one -Q2- according to . In certain embodiments, L comprises at least one –Q3- according to , wherein n1is one or two, and n2is one or two. In certain embodiments, L comprises at least one –Q3- selected from the group consisting In certain embodiments of Formulae I-Vb, L is selected from –Q1-N(Me)-CH2-Q1-C(O)–; –N(Me)-Q1-CH2-Q1-C(O)–; –Q2-CH2-Q1-C(O)–; –Q1-CH2-Q1-C(O)–; –Q1-Q1-C(O)–; –Q1-CH2-N(Me)-Q1-C(O)–; –Q1-CH2-Q1-CH2-C(O)-N(Me)–; –Q1-N(Me)-CH2-Q1-C(O)–; –Q1-CH2-Q1–; –Q1-CH2-Q2–; - 120 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT –Q1-CH2-Q1–N(H)–; –Q1-CH2-Q2–N(H)–; –Q1-CH2-Q1–CH2-Q1–; –Q1-CH2-CH2-Q1–; –Q1-CH2-CH2-Q2–; –Q1-C(O)-Q1–; –Q1-C(O)-Q2–; –Q1-CH2-Q1-N(Me)-C(O)–; –CH2-CH2-CH2-CH2-Q1-C(O)–; –Q1-CH2-Q1-C(O)–; –Q1-C(O)–; –Q1-C(O)-Q1-C(C6H5)–; –C≡CCH2-Q1-C(O)–; –Q1-C(O)-Q2–; –Q1-CH2-CH2-Q2–; –Q1-CH2-Q1-N-C(O)–; –CH2-CH2-CH2-Q1-C(O)–; –Q1-CH2-Q1-C(Me)-C(O)-N(Me)–; –Q1-Q1-C(O)–; –CH2-Q1–; –Q1-C(O)-Q1-CH2–; - 121 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT –N(H)-(CH2)5-C(O)-Q1-C(C6H5)–; –N(H)-(CH2)2-O-(CH2)2-C(O)-Q1-C(C6H5)–; –Q1-(CH2)3-C(O)-Q1-C(C6H5)–; –Q2-C(O)-Q1-C(C6H5)–; –Q2-CH2-C(O)-Q1-C(C6H5)–; –Q2-(CH2)3-C(O)-Q1-C(C6H5)–; –Q2-(CH2)2-C(O)-Q1-C(C6H5)–; –(CH2)6-Q1-C(C6H5)–; –Q1-Q1-C(O)-Q1-C(C6H5)–; –Q1-CH2-C(O)-Q1-C(C6H5)–; –Q1-(CH2)2-C(O)-Q1-C(C6H5)–; –Q1-(CH2)3-C(O)-Q1-C(C6H5)–; –(CH2)3-C(O)-Q1-C(C6H5)–; –(CH2)4-C(O)-Q1-C(C6H5)–; –(CH2)5-C(O)-Q1-C(C6H5)–; –(CH2)6-C(O)-Q1-C(C6H5)–; –(CH2)3-Q1-CH2-C(O)-Q1-C(C6H5)–; –(CH2)6-Q1-C(C6H5)–; –(CH2)6-Q1-C(thiazolyl)–; –(CH2)3-O-Q3-C(O)-Q1-C(C6H5)–; –(CH2)3-O-(CH2)2-C(O)-Q1-C(C6H5)–; - 122 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT –(CH2)3-O-(CH2)2-C(O)-Q1-C(thiazolyl)–; –(CH2)3-O-(CH2)2-C(O)-Q1-C(pyrid-2-yl)–; –(CH2)4-Q1-C(C6H5)–; –(CH2)5-Q1-C(C6H5)–; –(CH2)6-Q1-C(C6H5)–; –(CH2)6-Q1-C(thiazolyl)–; –(CH2)6-Q1-C(pyrid-2-yl)–; –(CH2)7-Q1-C(C6H5)–; –(CH2)7-Q1-C(Me)-C(O)-N(Me)–; –N(H)-(CH2)2-O-(CH2)2-Q1-C(Me)-C(O)-N(Me)–; –(CH2)3-O-(CH2)2-C(O)-Q1- C(Me)-C(O)-N(Me)–; –N(H)-(CH2)2-O-(CH2)2-Q1-C(C6H5)–; –N(H)-(CH2)2-O-(CH2)2-C(O)-Q1-C(C6H5)–; –N(H)-(CH2)2-[O-(CH2)2]2-C(O)-Q1-C(C6H5)–; –N(H)-(CH2)2-[O-(CH2)2]3-C(O)-Q1-C(C6H5)–; –N(H)-(CH2)2-[O-(CH2)2]4-C(O)-Q1-C(C6H5)–; –N(H)-(CH2)2-[O-(CH2)2]5-C(O)-Q1-C(C6H5)–; –N(H)-(CH2)2-[O-(CH2)2]6-C(O)-Q1-C(C6H5)–; –N(H)-(CH2)2-[O-(CH2)2]7-C(O)-Q1-C(C6H5)–; –N(H)-(CH2)2-[O-(CH2)2]8-C(O)-Q1-C(C6H5)–; –N(H)–Q3–O–(CH2)2–CH2–; - 123 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT –N(H)–(CH2)3-Q1–(CH2)2–; –C(O)–N(H) –[(CH2)3–O]3–(CH2)2–NH–; –C(O)–N(H) –[(CH2)3–O]3–(CH2)2–; –Q1–C(O)–[(CH2)2–O]3–(CH2)2–NH–; –Q1–(CH2)3–O–CH2–; –Q1–C(O)–(C6H6)–CH2–; –Q1–(2-pyridyl)–O–CH2–; –N(H)–Q3–X1–(2-pyridyl)–O–; –N(H)–Q3–X1–(4-pyridyl)–; –N(H)–(CH2)2–Q3–X1–(2-pyridyl)–O–CH2–;–CH C–(CH2)2Q1–; and–Q1–, wherein X1is oxygen or sulfur. In certain embodiments of Formulae I-Vb, the linker is selected from , , , , , , - 124 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 125 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT , –C(O)(CH2CH2O)n4(CH2)n5NR12C(O)(CH2)n2C(O)–, - 126 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT , - 127 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT , , - 128 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT , , –C(O)(CH2)n5NR12–, , wherein X6is oxygen or NR5; each n1, n2, n4, and n5 is independently an integer from one to ten; each R12is independently hydrogen or alkyl; each n3 and n11 is independently one or two; n6, n7, n9, and n12 are independently one, two, or three; n8 and n10 are zero, one, two, or three; each n13 is independently one, two, three, or four; each n14 is zero, one, two, or three; each n15 is independently one, two, or three; each n16 is independently an integer from one to six; and n17 is one, two, three, four, or five. In certain embodiments, L is a bond. In certain embodiments, the compound is (S)-(S)-(2-(3-(1-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4- tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (27) or (S)-(S)-(2-(3-(1-(2-(4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- - 129 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (91). In certain embodiments, L is –C(O)(CH2)n1NR12C(O)(CH2)n2C(O)– wherein n1 and n2 are independently an integer from one to ten; and R12is hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of (R)-(R)-(2-(3-(1-(4-((4- (3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-4- oxobutyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycine (1); (R)-(R)-(2-(3-(1-(4-((6-(3-(4-amino-3-(4-phenoxyphenyl)-1H- pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-6-oxohexyl)amino)-4-oxobutanoyl)piperidin- 4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (3); (R)-(R)-(2-(3- (1-(4-((8-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1- yl)-8-oxooctyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (5); methyl (R)-(R)-(2-(3-(1-(4-((6-(3-(4-amino-3-(4- phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-6-oxohexyl)amino)-4- oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycinate (50); methyl (R)-(R)-(2-(3-(1-(4-((8-(3-(4-amino-3-(4- phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-8-oxooctyl)amino)-4- oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycinate (52); methyl (R)-(R)-(2-(3-(1-(4-((4-(3-(4-amino-3-(4- phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-4-oxobutyl)amino)-4- oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycinate (55); methyl 2-[2-(2-{1'-[3-({8-[4-(4-{[3-carbamoyl-6-(piperidin-1- yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-8-oxooctyl}carbamoyl)propanoyl]-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (145); ethyl 2- {2-[2-(3-{1-[3-({8-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-8-oxooctyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (146); propan-2-yl 2-{2- [2-(3-{1-[3-({8-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin- 1-yl]-8-oxooctyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1' '- biindazol]-1-yl)acetamido]acetamido}acetate (147); methyl 2-[2-(2-{1'-[3-({6-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-6- oxohexyl}carbamoyl)propanoyl]-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (206); ethyl 2-{2-[2-(3-{1-[3-({6-[4-(4-{[3-carbamoyl-6- - 130 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-6- oxohexyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetamido]acetamido}acetate (207); propan-2-yl 2-{2-[2-(3-{1-[3-({6-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-6- oxohexyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetamido]acetamido}acetate (208); methyl 2-[2-(2-{1'-[3-({4-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-4- oxobutyl}carbamoyl)propanoyl]-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (215); ethyl 2-{2-[2-(3-{1-[3-({4-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-4- oxobutyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetamido]acetamido}acetate (216); propan-2-yl 2-{2-[2-(3-{1-[3-({4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-4- oxobutyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetamido]acetamido}acetate (217); methyl 2-{2-[2-(1'-{3-[(6-{4-[4-({3-carbamoyl-6- [(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-6-oxohexyl)carbamoyl]propanoyl}-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (219); ethyl 2-(2- {2-[3-(1-{3-[(6-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin- 1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-6-oxohexyl)carbamoyl]propanoyl}piperidin- 4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (220); methyl 2-[4-({2-[3-(1-{3-[(6-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-6- oxohexyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (221); propan-2-yl 2-(2-{2-[3-(1-{3- [(6-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin- 2-yl}amino)phenyl]piperidin-1-yl}-6-oxohexyl)carbamoyl]propanoyl}piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (222); methyl 2- {2-[2-(1'-{3-[(8-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin- 1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]propanoyl}-5'-fluoro- 3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (224); ethyl 2- (2-{2-[3-(1-{3-[(8-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-8- - 131 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT oxooctyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (225); propan-2-yl 2-(2-{2-[3-(1-{3-[(8-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (227); methyl 2-(2-{2- [1'-(3-{[12-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H- cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-12- oxododecyl]carbamoyl}propanoyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (235); methyl 2-[2-(2-{3-[1-(3-{[12-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidin-1-yl)-12-oxododecyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (236); methyl 2-(2-{2-[1'-(3-{[9- (4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3- amido]-1H-pyrazol-1-yl}piperidin-1-yl)-9-oxononyl]carbamoyl}propanoyl)-5'-fluoro-3- methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (237); methyl 2-[2-(2-{3- [1-(3-{[9-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H- cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-9- oxononyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl}-N-methylacetamido)acetamido]acetate (238); methyl 2-{2-[2-(1'-{3-[(12-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-12-oxododecyl)carbamoyl]propanoyl}-5'-fluoro-3-(trifluoromethyl)- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (240); methyl 2-{2-[2-(1'-{3-[(12- {4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-12-oxododecyl)carbamoyl]propanoyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (243); methyl 2-(2-{2-[3-(1-{3-[(12-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-12-oxododecyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (245); methyl 2-(2-{2-[1'-(3-{[12- (4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3- amido]-1H-pyrazol-1-yl}piperidin-1-yl)-12-oxododecyl]carbamoyl}propanoyl)-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (246); methyl 2- {2-[2-(1'-{3-[(9-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-9-oxononyl)carbamoyl]propanoyl}-5'- - 132 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (249); methyl 2-{2-[2-(1'-{3-[(9-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-9-oxononyl)carbamoyl]propanoyl}-5'- fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (252); methyl 2- (2-{2-[3-(1-{3-[(9-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-9- oxononyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl]acetamido}acetamido)acetate (254); methyl 2-(2-{2-[1'-(3-{[9-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidin-1-yl)-9-oxononyl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H- [4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (255); methyl 2-[2-(2-{3-[1-(3-{[9-(4-{4- [(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]- 1H-pyrazol-1-yl}piperidin-1-yl)-9-oxononyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (258); methyl 2-[2-(2- {1'-[3-({8-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]- 8-oxooctyl}carbamoyl)propanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (341); rac-methyl 2-{2-[2-(1'-{3-[(8-{4-[4-({3-carbamoyl-6- [(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]propanoyl}-5'-fluoro-3-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (343); rac-methyl 2-{2-[2-(1'-{3- [(6-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin- 2-yl}amino)phenyl]piperidin-1-yl}-6-oxohexyl)carbamoyl]propanoyl}-5'-fluoro-3-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (344); methyl 2-[2-(2-{1'-[3-({4- [4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-4- oxobutyl}carbamoyl)propanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (345); methyl 2-[2-(2-{1'-[3-({6-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-6- oxohexyl}carbamoyl)propanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (347); methyl 2-{2-[2-(3-{1-[3-({8-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-8- oxooctyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-chloro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetamido]acetamido}acetate (386); rac-methyl 2-(2-{2-[3-(1-{3-[(8-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- - 133 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-chloro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (388); rac-methyl 2-(2- {2-[3-(1-{3-[(6-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin- 1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-6-oxohexyl)carbamoyl]propanoyl}piperidin- 4-yl)-5'-chloro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (389); methyl 2-{2-[2-(3-{1-[3-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-4-oxobutyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-chloro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (390); and methyl 2-{2- [2-(3-{1-[3-({6-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin- 1-yl]-6-oxohexyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-chloro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (392). In certain embodiments, L is wherein n1 and n2 are independently an integer from one to ten; n3 is one or two; and R12is hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of (2-(3- (1-(4-((5-(4-(4-((5-chloro-4-((2-(methylcarbamoyl)phenyl)amino)pyrimidin-2- yl)amino)phenyl)piperazin-1-yl)pentyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (6); methyl (2-(3-(1-(4-((3-(4-(4- ((5-chloro-4-((2-(methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1- yl)propyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycinate (8); methyl (2-(3-(1-(4-((5-(4-(4-((5-chloro-4-((2- (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1- yl)pentyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycinate (10); methyl (2-(3-(1-(4-((3-(4-(4-((5-chloro-4-((2- (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1- yl)propyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycinate (12); methyl (2-(3-(1-(4-((7-(4-(4-((5-chloro-4-((2- (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1- yl)heptyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycinate (13); (2-(3-(1-(4-((7-(4-(4-((5-chloro-4-((2- (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1- yl)heptyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycine (14); (2-(3-(1-(4-((3-(4-(4-((5-chloro-4-((2- - 134 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1- yl)propyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycine (16); methyl 2-(2-{2-[1'-(3-{[3-(4-{4-[(5-chloro-4-{[2- (methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)propyl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (127); propan-2-yl 2-[2-(2-{3-[1-(3-{[3-(4-{4-[(5-chloro-4- {[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)propyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl}acetamido)acetamido]acetate (128); methyl 2-(2-{2-[1'-(3-{[5-(4-{4-[(5-chloro-4-{[2- (methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)pentyl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (130); propan-2-yl 2-[2-(2-{3-[1-(3-{[5-(4-{4-[(5-chloro-4- {[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)pentyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl}acetamido)acetamido]acetate (131); methyl 2-(2-{2-[1'-(3-{[7-(4-{4-[(5-chloro-4-{[2- (methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)heptyl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (139); and propan-2-yl 2-[2-(2-{3-[1-(3-{[7-(4-{4-[(5-chloro- 4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)heptyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl}acetamido)acetamido]acetate (140). In certain embodiments, L is –NR12(CH2)n1NR12C(O)(CH2)n2C(O)– wherein n1 and n2 are independently an integer from one to ten; and each R12is independently hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of (S)- (S)-(2-(3-(1-(4-((6-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)hexyl)amino)-4-oxobutanoyl)piperidin- 4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (20); methyl (S)- (S)-(2-(3-(1-(4-((4-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)butyl)amino)-4-oxobutanoyl)piperidin-4- yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (29); methyl (S)- (S)-(2-(3-(1-(4-((2-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)ethyl)amino)-4-oxobutanoyl)piperidin-4- yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (31); (S)-(S)-(2-(3- - 135 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT (1-(4-((4-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)acetamido)butyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (36); (S)-(S)-(2-(3-(1-(4-((2-(2-(4- (4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetamido)ethyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (37); (S)-(S)-(2-(3-(1-(4-((2-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carboxamido)ethyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (43); methyl (S)-(S)-(2-(3-(1-(4-((4- (4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carboxamido)butyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (45); methyl (S)-(S)-(2-(3-(1-(4- ((2-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carboxamido)ethyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (47); methyl (S)-(S)-(2-(3-(1-(4- ((6-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)acetamido)hexyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (111); methyl 2-{2-[2-(1'-{3-[(4- {2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}butyl)carbamoyl]propanoyl}-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (159); ethyl 2-(2-{2-[3-(1-{3-[(4-{2-[(9S)-7-(4- chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca- 2(6),4,7,10,12-pentaen-9-yl]acetamido}butyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (160); propan-2-yl 2-(2- {2-[3-(1-{3-[(4-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}butyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (162); methyl 2-{2-[2-(1'-{3-[(2-{2-[(9S)-7-(4- chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca- 2(6),4,7,10,12-pentaen-9-yl]acetamido}ethyl)carbamoyl]propanoyl}-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (164); ethyl 2-(2- {2-[3-(1-{3-[(2-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- - 136 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (165); propan-2-yl 2-(2-{2-[3-(1-{3-[(2-{2- [(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (167); methyl 2-{2-[2-(1'-{3-[(6-{2-[(9S)-7-(4- chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca- 2(6),4,7,10,12-pentaen-9-yl]acetamido}hexyl)carbamoyl]propanoyl}-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (169); ethyl 2-(2- {2-[3-(1-{3-[(6-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}hexyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (170); and propan-2-yl 2-(2-{2-[3-(1-{3-[(6-{2- [(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}hexyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (172). In certain embodiments, L is wherein n2, n4, and n5 are independently an integer from one to ten; n3 is one or two; and R12is hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of (2-(3-(1-(1-(4-(4- ((5-chloro-4-((2-(methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1- yl)-13-oxo-3,6,9-trioxa-12-azahexadecan-16-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetyl)glycylglycine (2); methyl (2-(3-(1-(1-(4-(4-((5-chloro-4-((2- (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)-13-oxo-3,6,9- trioxa-12-azahexadecan-16-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycinate (7); (2-(3-(1-(1-(4-(4-((5-chloro-4-((2- (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)-19-oxo- 3,6,9,12,15-pentaoxa-18-azadocosan-22-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (11); methyl (2-(3-(1-(1-(4-(4-((5-chloro-4-((2- (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)-19-oxo- - 137 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT 3,6,9,12,15-pentaoxa-18-azadocosan-22-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycinate (15); methyl (2-(3-(1-(1-(4-(4-((5-chloro-4-((2- (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)-25-oxo- 3,6,9,12,15,18,21-heptaoxa-24-azaoctacosan-28-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (17); (2-(3-(1-(1-(4-(4-((5-chloro-4-((2- (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)-25-oxo- 3,6,9,12,15,18,21-heptaoxa-24-azaoctacosan-28-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (19); methyl 2-(2-{2-[1'-(3-{[2-(2-{2-[2-(4- {4-[(5-chloro-4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2- yl)amino]phenyl}piperazin-1-yl)ethoxy]ethoxy}ethoxy)ethyl]carbamoyl}propanoyl)-5'- fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (133); propan-2-yl 2-[2-(2-{3-[1-(3-{[2-(2-{2-[2-(4-{4-[(5-chloro-4-{[2- (methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)ethoxy]ethoxy}ethoxy)ethyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (134); methyl 2-(2-{2-[1'-(3-{[17- (4-{4-[(5-chloro-4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2- yl)amino]phenyl}piperazin-1-yl)-3,6,9,12,15-pentaoxaheptadecan-1- yl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (136); propan-2-yl 2-[2-(2-{3-[1-(3-{[17-(4-{4-[(5-chloro-4- {[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1-yl)- 3,6,9,12,15-pentaoxaheptadecan-1-yl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (137); methyl 2-(2-{2-[1'- (3-{[23-(4-{4-[(5-chloro-4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2- yl)amino]phenyl}piperazin-1-yl)-3,6,9,12,15,18,21-heptaoxatricosan-1- yl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (142); and propan-2-yl 2-[2-(2-{3-[1-(3-{[23-(4-{4-[(5- chloro-4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)-3,6,9,12,15,18,21-heptaoxatricosan-1-yl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (143). In certain embodiments, L is –C(O)(CH2CH2O)n4(CH2)n5NR12C(O)(CH2)n2C(O)– wherein n2, n4, and n5 are independently an integer from one to ten; and R12is hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of (R)-(R)-(2-(3-(1-(1-(3-(4-amino-3-(4-phenoxyphenyl)- - 138 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT 1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-1,14-dioxo-4,7,10-trioxa-13- azaheptadecan-17-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (4); (R)-(R)-(2-(3-(1-(1-(3-(4-amino-3-(4-phenoxyphenyl)-1H- pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-1,26-dioxo-4,7,10,13,16,19,22-heptaoxa-25- azanonacosan-29-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (9); (R)-(R)-(2-(3-(1-(1-(3-(4-amino-3-(4-phenoxyphenyl)-1H- pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-1,20-dioxo-4,7,10,13,16-pentaoxa-19- azatricosan-23-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (49); methyl (R)-(R)-(2-(3-(1-(1-(3-(4-amino-3-(4-phenoxyphenyl)- 1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-1,26-dioxo-4,7,10,13,16,19,22-heptaoxa- 25-azanonacosan-29-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycinate (51); methyl (R)-(R)-(2-(3-(1-(1-(3-(4-amino-3-(4-phenoxyphenyl)- 1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-1,20-dioxo-4,7,10,13,16-pentaoxa-19- azatricosan-23-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycinate (53); methyl (R)-(R)-(2-(3-(1-(1-(3-(4-amino-3-(4-phenoxyphenyl)- 1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-1,14-dioxo-4,7,10-trioxa-13- azaheptadecan-17-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycinate (56); methyl 2-{2-[2-(1'-{3-[(2-{2-[2-(3-{4-[4-({3-carbamoyl-6- [(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}- 5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (149); ethyl 2-(2-{2-[3-(1-{3-[(2-{2-[2-(3-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2- oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (150); methyl 2-[4-({2-[3-(1-{3- [(2-{2-[2-(3-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1- yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (151); propan- 2-yl 2-(2-{2-[3-(1-{3-[(2-{2-[2-(3-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2- oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (152); methyl 2-{2-[2-(1'-{3-[(27- - 139 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT {4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (154); ethyl 2-(2-{2-[3-(1-{3-[(27-{4-[4-({3-carbamoyl-6- [(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (155); propan-2-yl 2-(2-{2-[3-(1-{3-[(27-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (157); ethyl 2-{2-[2-(3-{1-[3-({2-[2-(2-{3-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-3- oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (191); propan-2-yl 2-{2-[2-(3-{1- [3-({2-[2-(2-{3-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin- 1-yl]-3-oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (192); methyl 2-[2-(2-{1'- [3-({18-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]- 18-oxo-3,6,9,12,15-pentaoxaoctadecan-1-yl}carbamoyl)propanoyl]-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (194); ethyl 2- {2-[2-(3-{1-[3-({18-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (195); propan-2-yl 2-{2-[2-(3-{1-[3-({18-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (196); methyl 2-[2-(2-{1'-[3-({27-[4-(4- {[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-27-oxo- 3,6,9,12,15,18,21,24-octaoxaheptacosan-1-yl}carbamoyl)propanoyl]-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (198); ethyl 2- {2-[2-(3-{1-[3-({27-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- - 140 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT yl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (199); propan-2-yl 2-{2-[2-(3-{1-[3-({27-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-27-oxo- 3,6,9,12,15,18,21,24-octaoxaheptacosan-1-yl}carbamoyl)propanoyl]piperidin-4-yl}-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (200); methyl 2- {2-[2-(1'-{3-[(18-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl)carbamoyl]propanoyl}-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (229); ethyl 2-(2-{2-[3-(1-{3-[(18-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (230); propan-2-yl 2-(2-{2-[3-(1-{3-[(18-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (232); methyl 2-{2-[2-(1'-{3-[(27-{4-[5-(2-aminopyrimidin- 4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-27-oxo- 3,6,9,12,15,18,21,24-octaoxaheptacosan-1-yl)carbamoyl]propanoyl}-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (259); methyl 2- {2-[2-(1'-{3-[(27-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl)carbamoyl]propanoyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (262); methyl 2-(2-{2-[3-(1-{3-[(27-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (264); methyl 2-(2-{2-[1'-(3-{[27-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidin-1-yl)-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (265); methyl 2-(2-{2-[1'-(3-{[27-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- - 141 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT yl}piperidin-1-yl)-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl]carbamoyl}propanoyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (268); methyl 2-[2-(2-{3-[1-(3-{[27-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidin-1-yl)-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (270); methyl 2-{2-[2-(1'-{3-[(2-{2-[2-(3-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (294); methyl 2- {2-[2-(1'-{3-[(2-{2-[2-(3-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (297); methyl 2-(2-{2-[3-(1-{3-[(2-{2-[2-(3-{4- [5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (299); methyl 2-(2-{2-[1'-(3-{[2-(2-{2-[3-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H- cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-3- oxopropoxy]ethoxy}ethoxy)ethyl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)- 1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (300); methyl 2-(2-{2-[1'-(3-{[2- (2-{2-[3-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H- cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-3- oxopropoxy]ethoxy}ethoxy)ethyl]carbamoyl}propanoyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (303); methyl 2-[2-(2-{3-[1-(3-{[2-(2-{2-[3-(4- {4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3- amido]-1H-pyrazol-1-yl}piperidin-1-yl)-3- oxopropoxy]ethoxy}ethoxy)ethyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (305); methyl 2-{2-[2-(1'-{3-[(18- {4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1-yl)carbamoyl]propanoyl}-5'- fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (306); methyl 2-{2-[2-(1'-{3-[(18-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- - 142 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan- 1-yl)carbamoyl]propanoyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (309); methyl 2-(2-{2-[3-(1-{3-[(18-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (311); methyl 2-(2-{2-[1'-(3-{[18-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1-yl]carbamoyl}propanoyl)-5'- fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (312); methyl 2-(2-{2-[1'-(3-{[18-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H- cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl]carbamoyl}propanoyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (315); methyl 2-[2-(2-{3-[1-(3-{[18-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (317); methyl 2-[2-(2-{1'-[3-({27-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl}carbamoyl)propanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (319); methyl 2-{2-[2-(3-{1-[3-({27-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl}carbamoyl)propanoyl]piperidin-4-yl}-5'-chloro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (322); rac-methyl 2-{2-[2-(1'-{3-[(27-{4- [4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (339); rac-methyl 2-{2-[2-(1'-{3-[(2-{2-[2-(3-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}- 5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (340); rac- methyl 2-{2-[2-(1'-{3-[(18-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15- - 143 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT pentaoxaoctadecan-1-yl)carbamoyl]propanoyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (342); methyl 2-[2-(2-{1'-[3-({18-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl}carbamoyl)propanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (349); methyl 2-[2-(2-{1'-[3-({2-[2-(2-{3-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-3- oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)propanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)acetamido]acetate (350); rac-methyl 2-(2-{2-[3-(1-{3-[(27-{4-[4- ({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-chloro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (384); rac-methyl 2-(2-{2-[3-(1-{3-[(2-{2-[2-(3-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-chloro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (385); rac-methyl 2-(2-{2-[3-(1- {3-[(18-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1- yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-chloro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (387); methyl 2-{2-[2-(3-{1-[3-({18-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl}carbamoyl)propanoyl]piperidin-4-yl}-5'-chloro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (394); and methyl 2-{2-[2-(3-{1-[3-({2-[2- (2-{3-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-3- oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-chloro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (395). In certain embodiments, L is –NR12(CH2CH2O)n4(CH2)n5NR12C(O)(CH2)n2C(O)– wherein n2, n4, and n5 are independently an integer from one to ten; and each R12is independently hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of methyl 2-{2-[2-(1'-{3- [(23-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamido}- 3,6,9,12,15,18,21-heptaoxatricosan-1-yl)carbamoyl]propanoyl}-5'-fluoro-3-(trifluoromethyl)- - 144 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (12); methyl (S)-(S)-(2-(3-(1-(1-(4- (4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)- 2,28-dioxo-6,9,12,15,18,21,24-heptaoxa-3,27-diazahentriacontan-31-oyl)piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (28); methyl (S)-(S)-(2- (3-(1-(1-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)-2,16-dioxo-6,9,12-trioxa-3,15-diazanonadecan-19-oyl)piperidin-4-yl)- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (30); methyl (S)-(S)- (2-(3-(1-(1-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)-2,22-dioxo-6,9,12,15,18-pentaoxa-3,21-diazapentacosan-25- oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (32); (S)-(S)-(2-(3-(1-(1-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-2,28-dioxo-6,9,12,15,18,21,24-heptaoxa-3,27- diazahentriacontan-31-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (33); (S)-(S)-(2-(3-(1-(1-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-2,22-dioxo-6,9,12,15,18-pentaoxa-3,21- diazapentacosan-25-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (34); (S)-(S)-(2-(3-(1-(1-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-2,16-dioxo-6,9,12-trioxa-3,15- diazanonadecan-19-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (35); methyl (S)-(S)-(2-(3-(1-(1-(4-(2-(7-chlorobenzo[d]thiazol-2- yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidin-4-yl)-1,21-dioxo- 5,8,11,14,17-pentaoxa-2,20-diazatetracosan-24-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (44); ethyl 2-(2-{2-[3-(1-{3-[(23-{2- [(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamido}- 3,6,9,12,15,18,21-heptaoxatricosan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (65) and ethyl (S)-(S)-(2-(3- (1-(1-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)- 2,22-dioxo-6,9,12,15,18-pentaoxa-3,21-diazapentacosan-25-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (120); propan-2-yl 2-(2-{2-[3-(1-{3-[(23-{2- [(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamido}- 3,6,9,12,15,18,21-heptaoxatricosan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'- - 145 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (122); propan-2-yl 2-(2-{2- [3-(1-{3-[(2-{2-[2-(2-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}ethoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (125); methyl 2-{2-[2-(1'- {3-[(17-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamido}-3,6,9,12,15- pentaoxaheptadecan-1-yl)carbamoyl]propanoyl}-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (174); ethyl 2-(2-{2-[3-(1-{3-[(17-{2-[(9S)-7- (4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca- 2(6),4,7,10,12-pentaen-9-yl]acetamido}-3,6,9,12,15-pentaoxaheptadecan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (175); and propan-2-yl 2-(2-{2-[3-(1-{3-[(17-{2-[(9S)-7-(4- chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca- 2(6),4,7,10,12-pentaen-9-yl]acetamido}-3,6,9,12,15-pentaoxaheptadecan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (177). In certain embodiments, L is wherein n4 and n5 are independently an integer from one to ten; each n15 is independently one, two, or three; and each R12is independently hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of methyl 2-[2-(2-{1'-[(1-{[(23-{2-[(9S)-7-(4-chlorophenyl)-4,5,13- trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}-3,6,9,12,15,18,21-heptaoxatricosan-1-yl)carbamoyl]methyl}piperidin-4- yl)methyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (123); methyl 2-[2-(2-{1'-[(1-{[(2-{2-[2-(2-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3- thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}ethoxy)ethoxy]ethoxy}ethyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'- fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (126); and methyl 2-[2-(2-{1'-[(1-{[(17-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamido}-3,6,9,12,15- - 146 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT pentaoxaheptadecan-1-yl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (178). In certain embodiments, L is wherein n1 and each n5 are independently an integer from one to ten; n3 is one or two; each n15 is independently one, two, or three; and each R12is independently hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of methyl 2-{2-[2-(1'-{[1-({[3-(4-{4-[(5- chloro-4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)propyl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (129); methyl 2-{2-[2-(1'-{[1-({[5-(4-{4-[(5- chloro-4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)pentyl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (132); and methyl 2-{2-[2-(1'-{[1-({[7-(4-{4- [(5-chloro-4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin- 1-yl)heptyl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (141). In certain embodiments, L is wherein n4 and each n5 are independently an integer from one to ten; n3 is one or two; each n15 is independently one, two, or three; and R12is independently hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of methyl 2-{2-[2-(1'-{[1-({[2-(2-{2-[2-(4-{4-[(5-chloro- 4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)ethoxy]ethoxy}ethoxy)ethyl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (135); methyl 2-{2-[2-(1'- {[1-({[17-(4-{4-[(5-chloro-4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2- yl)amino]phenyl}piperazin-1-yl)-3,6,9,12,15-pentaoxaheptadecan-1- yl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (138); and methyl 2-{2-[2-(1'-{[1-({[23-(4-{4-[(5-chloro-4- {[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1-yl)- - 147 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT 3,6,9,12,15,18,21-heptaoxatricosan-1-yl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro- 3-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (144). In certain embodiments, wherein each n5 are independently an integer from one to ten; each n15 is independently one, two, or three; and R12is independently hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of methyl 2-(2-{2-[1'-({1-[({8-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-8- oxooctyl}carbamoyl)methyl]piperidin-4-yl}methyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (148); methyl 2-(2-{2-[1'-({1-[({6-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-6- oxohexyl}carbamoyl)methyl]piperidin-4-yl}methyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (209); methyl 2-(2-{2-[1'-({1-[({4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-4- oxobutyl}carbamoyl)methyl]piperidin-4-yl}methyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (218); methyl 2-[2-(2-{1'-[(1-{[(6-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-6-oxohexyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'- fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (223); methyl 2- [2-(2-{1'-[(1-{[(8-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-8- oxooctyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)acetamido]acetate (228); methyl 2-[2-(2-{1'-[(1-{[(12-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-12-oxododecyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3- methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (241); methyl 2-{2-[2-(1'- {[1-({[12-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H- cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-12- oxododecyl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (247); methyl 2-[2-(2-{1'-[(1-{[(9-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-9-oxononyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl- - 148 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT 1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (250); and methyl 2-{2-[2-(1'-{[1- ({[9-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole- 3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-9-oxononyl]carbamoyl}methyl)piperidin-4- yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (256). In certain embodiments, L is wherein n4 and each n5 are independently an integer from one to ten; each n15 is independently one, two, or three; and R12is independently hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of methyl 2-[2-(2-{1'-[(1-{[(2-{2-[2-(3-{4-[4-({3-carbamoyl-6-[(3R)-3- (3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}- 3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3- methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (153); methyl 2-[2-(2-{1'- [(1-{[(27-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1- yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (158); methyl 2-(2-{2-[1'-({1-[({2- [2-(2-{3-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-3- oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)methyl]piperidin-4-yl}methyl)-5'-fluoro-3- methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (193); methyl 2-(2-{2-[1'- ({1-[({18-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]- 18-oxo-3,6,9,12,15-pentaoxaoctadecan-1-yl}carbamoyl)methyl]piperidin-4-yl}methyl)-5'- fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (197); methyl 2- (2-{2-[1'-({1-[({27-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl}carbamoyl)methyl]piperidin-4-yl}methyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (201); methyl 2-[2-(2-{1'-[(1-{[(18-{4-[4-({3-carbamoyl-6- [(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (233); methyl 2-[2-(2-{1'-[(1-{[(27-{4-[5-(2- - 149 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (260); methyl 2-{2-[2-(1'-{[1-({[27-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidin-1-yl)-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (266); methyl 2-[2-(2-{1'-[(1-{[(2-{2-[2-(3-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]methyl}piperidin-4- yl)methyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (295); methyl 2-{2-[2-(1'-{[1-({[2-(2-{2-[3-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-3- oxopropoxy]ethoxy}ethoxy)ethyl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (301); methyl 2-[2-(2-{1'- [(1-{[(18-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3- thiazol-2-yl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (307); and methyl 2-{2-[2-(1'-{[1-({[18-(4-{4-[(4aR,5aS)- 5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol- 1-yl}piperidin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (313). In certain embodiments, L is –C(O)(CH2CH2O)n4(CH2)n5NR12– wherein n4 and n5 are independently an integer from one to ten; and R12is independently hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of methyl 2-[4- ({2-[3-(1-{3-[(27-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (156); methyl 2-[4-({2- [3-(1-{3-[(18-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1- yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- - 150 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (231); methyl 2-(2-{2-[3-(2-{3-[(27-{4- [5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}-2-azaspiro[3.3]heptan-6-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (261); methyl 2-(2-{2-[3-(1-{3-[(27- {4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N- methylacetamido}acetamido)acetate (263); methyl 2-[2-(2-{3-[2-(3-{[27-(4-{4-[(4aR,5aS)- 5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol- 1-yl}piperidin-1-yl)-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl]carbamoyl}propanoyl)-2-azaspiro[3.3]heptan-6-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (267); methyl 2-[2-(2-{3-[1-(3-{[27- (4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3- amido]-1H-pyrazol-1-yl}piperidin-1-yl)-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N- methylacetamido)acetamido]acetate (269); methyl 2-(2-{2-[3-(2-{3-[(2-{2-[2-(3-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}-2- azaspiro[3.3]heptan-6-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N- methylacetamido}acetamido)acetate (296); methyl 2-(2-{2-[3-(1-{3-[(2-{2-[2-(3-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (298); methyl 2-[2-(2-{3-[2-(3-{[2-(2-{2-[3-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-3- oxopropoxy]ethoxy}ethoxy)ethyl]carbamoyl}propanoyl)-2-azaspiro[3.3]heptan-6-yl]-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (302); methyl 2-[2-(2-{3-[1-(3-{[2-(2-{2-[3-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-3- oxopropoxy]ethoxy}ethoxy)ethyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (304); methyl 2-(2-{2- [3-(2-{3-[(18-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]- - 151 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT 1,3-thiazol-2-yl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]propanoyl}-2-azaspiro[3.3]heptan-6-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (308); methyl 2-(2-{2-[3-(1-{3-[(18- {4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N- methylacetamido}acetamido)acetate (310); methyl 2-[2-(2-{3-[2-(3-{[18-(4-{4-[(4aR,5aS)- 5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol- 1-yl}piperidin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1-yl]carbamoyl}propanoyl)-2- azaspiro[3.3]heptan-6-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N- methylacetamido)acetamido]acetate (314); methyl 2-[2-(2-{3-[1-(3-{[18-(4-{4-[(4aR,5aS)- 5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol- 1-yl}piperidin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N- methylacetamido)acetamido]acetate (316); methyl 2-[2-(2-{1'-[3-({27-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl}carbamoyl)propanoyl]-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)acetamido]acetate (318); methyl 2-{2-[2-(3-{1-[3-({27-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-27-oxo- 3,6,9,12,15,18,21,24-octaoxaheptacosan-1-yl}carbamoyl)propanoyl]piperidin-4-yl}-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (320); methyl 2-(4-{[2-(3-{1-[3-({27-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]methyl}-1H-1,2,3-triazol-1-yl)acetate (321); methyl 2-{2-[2-(3-{2-[3-({27-[4- (4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-27-oxo- 3,6,9,12,15,18,21,24-octaoxaheptacosan-1-yl}carbamoyl)propanoyl]-2-azaspiro[3.3]heptan- 6-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)-N- methylacetamido]acetamido}acetate (323); rac-methyl 2-{2-[2-(1'-{3-[(27-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (324); rac-methyl 2-{2-[2-(1'-{3-[(2-{2-[2-(3-{4-[4-({3- - 152 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}- 5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (325); rac-methyl 2-{2-[2-(1'-{3-[(18-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin- 1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl)carbamoyl]propanoyl}-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (327); methyl 2-[2-(2-{1'-[3-({18-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl}carbamoyl)propanoyl]-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)acetamido]acetate (334); methyl 2-[2-(2-{1'-[3-({2-[2-(2-{3-[4-(4- {[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-3- oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)propanoyl]-5'-fluoro-3-(propan-2-yl)-1H,1'H- [4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (335); rac-methyl 2-(2-{2-[3-(1-{3-[(27- {4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N- methylacetamido}acetamido)acetate (354); rac-methyl 2-(2-{2-[3-(1-{3-[(2-{2-[2-(3-{4-[4- ({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (355); rac-methyl 2-(2- {2-[3-(1-{3-[(18-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (357); methyl 2-{2-[2-(3-{1-[3- ({18-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-18- oxo-3,6,9,12,15-pentaoxaoctadecan-1-yl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (364); methyl 2- {2-[2-(3-{1-[3-({2-[2-(2-{3-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-3- oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (365); rac-methyl 2-[4- ({2-[3-(1-{3-[(27-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- - 153 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (369); rac-methyl 2-[4- ({2-[3-(1-{3-[(2-{2-[2-(3-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (370); rac- methyl 2-[4-({2-[3-(1-{3-[(18-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin- 1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (372); methyl 2-(4-{[2- (3-{1-[3-({18-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1- yl]-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1-yl}carbamoyl)propanoyl]piperidin-4-yl}-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]methyl}-1H-1,2,3-triazol-1- yl)acetate (379); methyl 2-(4-{[2-(3-{1-[3-({2-[2-(2-{3-[4-(4-{[3-carbamoyl-6-(piperidin-1- yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-3- oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]methyl}-1H-1,2,3-triazol-1-yl)acetate (380); rac- methyl 2-(2-{2-[3-(2-{3-[(27-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl)carbamoyl]propanoyl}-2-azaspiro[3.3]heptan-6-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (399); rac- methyl 2-(2-{2-[3-(2-{3-[(2-{2-[2-(3-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2- oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}-2-azaspiro[3.3]heptan-6-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (400); rac-methyl 2-(2-{2-[3-(2-{3-[(18-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2- oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-18-oxo- 3,6,9,12,15-pentaoxaoctadecan-1-yl)carbamoyl]propanoyl}-2-azaspiro[3.3]heptan-6-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (402); methyl 2-{2-[2-(3-{2-[3-({18-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl}carbamoyl)propanoyl]-2-azaspiro[3.3]heptan-6-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'- - 154 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (409); and methyl 2-{2-[2-(3-{2-[3- ({2-[2-(2-{3-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1- yl]-3-oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)propanoyl]-2-azaspiro[3.3]heptan-6-yl}- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (410). In certain embodiments, L is –NR12(CH2)n1NR12– wherein n1 is an integer from one to ten; and each R12is independently hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of methyl 2-[4-({2-[3-(1-{3-[(4-{2-[(9S)-7-(4- chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca- 2(6),4,7,10,12-pentaen-9-yl]acetamido}butyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (161); methyl 2-[4-({2-[3-(1-{3-[(2-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia- 1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (166); and methyl 2-[4-({2- [3-(1-{3-[(6-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}hexyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (171). In certain embodiments, wherein each n5 is an integer from one to ten; each n15 is independently one, two, or three; and each R12is independently hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of methyl 2-[2-(2-{1'-[(1-{[(4-{2-[(9S)-7-(4-chlorophenyl)- 4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12- pentaen-9-yl]acetamido}butyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (163); methyl 2-[2-(2-{1'-[(1-{[(2- {2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}ethyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H- [4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (168); and methyl 2-[2-(2-{1'-[(1-{[(6-{2- [(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- - 155 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}hexyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H- [4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (173). In certain embodiments, L is –NR12(CH2CH2O)n4(CH2)n5NR12–, wherein n4 and n5 are an integer from one to ten; and each R12is independently hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of methyl 2-[4-({2-[3-(1-{3-[(23-{2-[(9S)-7-(4-chlorophenyl)-4,5,13- trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}-3,6,9,12,15,18,21-heptaoxatricosan-1-yl)carbamoyl]propanoyl}piperidin-4- yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1- yl]acetate (121); methyl 2-{2-[2-(1'-{3-[(2-{2-[2-(2-{2-[(9S)-7-(4-chlorophenyl)-4,5,13- trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}ethoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (124); and methyl 2-[4-({2-[3-(1-{3-[(17-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamido}-3,6,9,12,15- pentaoxaheptadecan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (176). In certain embodiments, wherein n8 is zero, one, two, or three; and each n15 is independently one, two, or three. In certain embodiments, the compound is selected from the group consisting of methyl 2-[2-(2-{1'-[4-(4-{4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidin-1-yl)-4-oxobutanoyl]-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)acetamido]acetate (179); methyl 2-[2-(2-{1'-[4-(4-{4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidin-1-yl)-4-oxobutanoyl]-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (338); methyl 2-{2-[2-(3-{1-[4-(4-{4-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidin-1-yl)-4-oxobutanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (368); methyl 2-(4-{[2-(3-{1-[4-(4- - 156 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT {4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidin-1-yl)-4-oxobutanoyl]piperidin-4-yl}-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]methyl}-1H-1,2,3-triazol-1-yl)acetate (383); and methyl 2-{2-[2-(3-{2-[4-(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidin-1-yl)-4- oxobutanoyl]-2-azaspiro[3.3]heptan-6-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)- N-methylacetamido]acetamido}acetate (413). In certain embodiments, wherein n1 is an integer from one to ten; and each n15 is independently one, two, or three. In certain embodiments, the compound is selected from the group consisting of ethyl 2-{2-[2-(3-{1-[4- (4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidin-1-yl)-4-oxobutanoyl]piperidin-4-yl}-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (180); propan-2-yl 2-{2-[2- (3-{1-[4-(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine- 1-carbonyl]piperidine-1-carbonyl}piperidin-1-yl)-4-oxobutanoyl]piperidin-4-yl}-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (181); methyl 2-[2-(2-{1'- [4-(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidin-1-yl)-4-oxobutanoyl]-5'-fluoro-3-methyl-1H,1'H- [4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (353); and methyl 2-{2-[2-(3-{1-[4-(4-{4- [4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidin-1-yl)-4-oxobutanoyl]piperidin-4-yl}-5'-chloro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (398). In certain embodiments, wherein each n5 is an integer from one to ten; and each n15 is independently one, two, or three. In certain embodiments, the compound is methyl 2-(2-{2-[1'-({1-[2-(4-{4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- - 157 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT carbonyl}piperidin-1-yl)-2-oxoethyl]piperidin-4-yl}methyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (182). In certain embodiments, wherein each n15 is independently one, two, or three. In certain embodiments, the compound is selected from the group consisting of methyl 2-{2-[2-(1'-{4-[4-(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1- yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidine-1- carbonyl)piperidin-1-yl]-4-oxobutanoyl}-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (183); methyl 2-{4-[(2-{3-[1-(4-{4-[4-(4-{4-[4- ({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)methyl]-1H-1,2,3-triazol-1-yl}acetate (212); rac-methyl 2-(2-{2- [1'-(4-{4-[4-(4-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin- 1-yl]pyrazin-2-yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (331); methyl 2-{2-[2-(1'-{4-[4-(4-{4-[4-(4-{[3-carbamoyl- 6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidine-1-carbonyl)piperidin-1-yl]-4-oxobutanoyl}-5'-fluoro-3-(propan-2-yl)- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (337); rac-methyl 2-[2-(2-{3-[1-(4- {4-[4-(4-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1- yl]pyrazin-2-yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (361); methyl 2-(2-{2-[3-(1-{4-[4-(4- {4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]-4- oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N- methylacetamido}acetamido)acetate (367); rac-methyl 2-{4-[(2-{3-[1-(4-{4-[4-(4-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'- - 158 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT biindazol]-1-yl}acetamido)methyl]-1H-1,2,3-triazol-1-yl}acetate (376); methyl 2-[4-({2-[3- (1-{4-[4-(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine- 1-carbonyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]-4- oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (382); rac-methyl 2-[2-(2-{3-[2-(4-{4-[4- (4-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin- 2-yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)-2-azaspiro[3.3]heptan-6-yl]-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (406); and methyl 2-(2- {2-[3-(2-{4-[4-(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidine-1- carbonyl)piperidin-1-yl]-4-oxobutanoyl}-2-azaspiro[3.3]heptan-6-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (412). In certain embodiments, is an integer from one to ten; and each n15 is independently one, two, or three. In certain embodiments, the compound is selected from the group consisting of ethyl 2-(2-{2-[3-(1-{4- [4-(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]-4- oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (184); propan-2-yl 2-(2-{2-[3-(1-{4-[4-(4-{4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidine-1-carbonyl)piperidin-1-yl]-4-oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (185); methyl 2-(2-{2-[1'- (4-{4-[4-(4-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1- yl]pyrazin-2-yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (210); ethyl 2-[2-(2-{3-[1-(4-{4-[4-(4-{4-[4- ({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'- - 159 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT biindazol]-1-yl}acetamido)acetamido]acetate (211); propan-2-yl 2-[2-(2-{3-[1-(4-{4-[4-(4- {4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)acetamido]acetate (213); rac-methyl 2-(2-{2-[1'-(4-{4-[4-(4-{4-[4- ({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (346); methyl 2-{2-[2-(1'-{4-[4-(4-{4-[4-(4-{[3-carbamoyl- 6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidine-1-carbonyl)piperidin-1-yl]-4-oxobutanoyl}-5'-fluoro-3-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (352); rac-methyl 2-[2-(2-{3-[1-(4-{4-[4- (4-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin- 2-yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-chloro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)acetamido]acetate (391); and methyl 2-(2-{2-[3-(1-{4-[4-(4-{4-[4- (4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]-4- oxobutanoyl}piperidin-4-yl)-5'-chloro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (397). In certain embodiments, L is wherein each n5 is an integer from one to ten; and each n15 is independently one, two, or three. In certain embodiments, the compound is selected from the group consisting of methyl 2-[2-(2-{1'-[(1-{2-[4-(4-{4-[4-(4- {[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]-2-oxoethyl}piperidin- 4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (186); and methyl 2-{2-[2-(1'-{[1-(2-{4-[4-(4-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2- oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidine-1- carbonyl}piperidine-1-carbonyl)piperidine-1-carbonyl]piperidin-1-yl}-2-oxoethyl)piperidin- - 160 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT 4-yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (214). In certain embodiments, wherein n1 is an integer from one to ten; and each n15 is independently one, two, or three. In certain embodiments, the compound is selected from the group consisting of methyl 2-(2-{2-[1'-(4-{4- [(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4-oxobutanoyl)-5'- fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (187); methyl 2-{2-[2-(3-{2-[4-(4-{[4-(4-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin- 1-yl]methyl}piperidin-1-yl)-4-oxobutanoyl]-2-azaspiro[3.3]heptan-6-yl}-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (285); methyl 2-{2-[2- (3-{1-[4-(4-{[4-(4-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin- 1-yl]methyl}piperidin-1-yl)-4-oxobutanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1' biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (286); methyl 2-(2-{2-[3-(2-{4-[4- ({4-[4-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H- cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4-oxobutanoyl}-2-azaspiro[3.3]heptan-6-yl)- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (290); methyl 2-(2-{2-[3-(1-{4-[4-({4-[4-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidine-1- carbonyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N- methylacetamido}acetamido)acetate (292); methyl 2-(2-{2-[1'-(4-{4-[(4-{4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4-oxobutanoyl)-5'-fluoro-3-(propan-2-yl)- 1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (336); methyl 2-[2-(2-{3-[1-(4-{4- [(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4- - 161 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N- methylacetamido)acetamido]acetate (366); methyl 2-{4-[(2-{3-[1-(4-{4-[(4-{4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)methyl]-1H-1,2,3-triazol-1-yl}acetate (381); and methyl 2-[2-(2-{3-[2-(4-{4-[(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidin-1- yl)methyl]piperidin-1-yl}-4-oxobutanoyl)-2-azaspiro[3.3]heptan-6-yl]-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (411). In certain embodiments, each n1 is an integer from one to ten; and each n15 is independently one, two, or three. In certain embodiments, the compound is selected from the group consisting of ethyl 2-[2-(2-{3- [1-(4-{4-[(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidin-1- yl)methyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1' biindazol]-1-yl}acetamido)acetamido]acetate (188); propan-2-yl 2-[2-(2-{3-[1-(4-{4-[(4-{4- [4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4- oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (189); methyl 2-[2-(2-{1'-[4-(4-{[4-(4-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-4- oxobutanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (239); methyl 2-[2-(2-{1'-[4-(4-{[4-(4-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane- 1-sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidine-1-carbonyl}piperidine-1- carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-4-oxobutanoyl]-5'-fluoro-3-(trifluoromethyl)- 1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (283); methyl 2-{2-[2-(3-{1-[4-(4- {[4-(4-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3- thiazol-2-yl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]methyl}piperidin-1- yl)-4-oxobutanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- - 162 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT yl)acetamido]acetamido}acetate (287); methyl 2-{2-[2-(1'-{4-[4-({4-[4-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidine-1-carbonyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- oxobutanoyl}-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (288); methyl 2-{2-[2-(1'-{4-[4-({4-[4-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidine-1-carbonyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- oxobutanoyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (291); methyl 2-(2-{2-[3-(1-{4-[4-({4-[4-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidine-1- carbonyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (293); methyl 2-(2-{2-[1'-(4-{4-[(4-{4-[4-(4-{[3-carbamoyl- 6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4-oxobutanoyl)-5'-fluoro-3-methyl-1H,1'H- [4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (351); and methyl 2-[2-(2-{3-[1-(4-{4-[(4- {4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4- oxobutanoyl)piperidin-4-yl]-5'-chloro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (396). In certain embodiments, L is wherein n1 and each n5 are independently an integer from one to ten; and each n15 is independently one, two, or three. In certain embodiments, the compound is selected from the group consisting of methyl 2-{2-[2- (1'-{[1-(2-{4-[(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidin-1- yl)methyl]piperidin-1-yl}-2-oxoethyl)piperidin-4-yl]methyl}-5'-fluoro-3-methyl-1 [4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (190); methyl 2-(2-{2-[1'-({1-[2-(4-{[4-(4- {4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-2- - 163 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT oxoethyl]piperidin-4-yl}methyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (284); and methyl 2-[2-(2-{1'-[(1-{2-[4-({4-[4-(4-{4- [(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]- 1H-pyrazol-1-yl}piperidine-1-carbonyl)piperidine-1-carbonyl]piperidin-1- yl}methyl)piperidin-1-yl]-2-oxoethyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H- [4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (289). In certain embodiments, wherein n1 is an integer from one to ten; and each n15 is independently one, two, or three. In certain embodiments, the compound is methyl 2-{2-[2-(1'-{4-[4-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- oxobutanoyl}-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (202). In certain embodiments, wherein each n1 is independently an integer from one to ten; and each n15 is independently one, two, or three. In certain embodiments, the compound is selected from the group consisting of ethyl 2-(2-{2-[3- (1-{4-[4-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4-oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (203); propan-2-yl 2-(2-{2- [3-(1-{4-[4-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (204); methyl 2-(2-{2-[1'-(4-{4-[(4-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4-oxobutanoyl)-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (271); methyl 2- (2-{2-[1'-(4-{4-[(4-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin- 1-yl}-4-oxobutanoyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- - 164 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT yl]acetamido}acetamido)acetate (274); methyl 2-[2-(2-{3-[1-(4-{4-[(4-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4- yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (276); methyl 2-[2-(2-{1'-[4-(4-{[4-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidine-1- carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-4-oxobutanoyl]-5'-fluoro-3-(trifluoromethyl)- 1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (277); methyl 2-[2-(2-{1'-[4-(4- {[4-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole- 3-amido]-1H-pyrazol-1-yl}piperidine-1-carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-4- oxobutanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (280); methyl 2-{2-[2-(3-{1-[4-(4-{[4-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidine-1- carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-4-oxobutanoyl]piperidin-4-yl}-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (281); methyl 2- {2-[2-(1'-{4-[4-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- oxobutanoyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (348); and methyl 2-(2-{2-[3-(1-{4-[4-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- oxobutanoyl}piperidin-4-yl)-5'-chloro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (393). In certain embodiments, wherein n1 and each n5 are independently an integer from one to ten; and each n15 is independently one, two, or three. In certain embodiments, the compound is selected from the group consisting of methyl 2-[2-(2-{1'-[(1-{2-[4-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1- yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]- 2-oxoethyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (205); methyl 2-{2-[2-(1'-{[1-(2-{4-[(4-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-2-oxoethyl)piperidin-4- - 165 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (272); and methyl 2-(2-{2-[1'-({1-[2-(4-{[4-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidine-1- carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-2-oxoethyl]piperidin-4-yl}methyl)-5'-fluoro- 3-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (278). In certain embodiments, L is –C(O)(CH2)n5NR12– wherein n5 is an integer from one to ten; and R12is hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of methyl 2-[4-({2-[3-(1-{3-[(8-{4-[4-({3-carbamoyl-6-[(3R)-3-(3- methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-8- oxooctyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (226); methyl 2-[2-(2-{3-[2-(3-{[12-(4- {4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3- amido]-1H-pyrazol-1-yl}piperidin-1-yl)-12-oxododecyl]carbamoyl}propanoyl)-2- azaspiro[3.3]heptan-6-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N- methylacetamido)acetamido]acetate (234); methyl 2-(2-{2-[3-(2-{3-[(12-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-12-oxododecyl)carbamoyl]propanoyl}-2-azaspiro[3.3]heptan-6-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (242); methyl 2-(2-{2-[3-(1-{3-[(12-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-12- oxododecyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (244); methyl 2-[2-(2-{3-[1-(3-{[12- (4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3- amido]-1H-pyrazol-1-yl}piperidin-1-yl)-12-oxododecyl]carbamoyl}propanoyl)piperidin-4- yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (248); methyl 2-(2-{2-[3-(2-{3-[(9-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-9-oxononyl)carbamoyl]propanoyl}-2- azaspiro[3.3]heptan-6-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N- methylacetamido}acetamido)acetate (251); methyl 2-(2-{2-[3-(1-{3-[(9-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-9-oxononyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (253); methyl 2-[2-(2- {3-[2-(3-{[9-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H- - 166 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-9- oxononyl]carbamoyl}propanoyl)-2-azaspiro[3.3]heptan-6-yl]-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (257); methyl 2-[2-(2-{1'-[3-({8- [4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-8- oxooctyl}carbamoyl)propanoyl]-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (326); rac-methyl 2-{2-[2-(1'-{3-[(8-{4-[4-({3-carbamoyl-6- [(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]propanoyl}-5'-fluoro-3-(propan-2- yl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (328); rac-methyl 2-{2-[2-(1'- {3-[(6-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1- yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-6-oxohexyl)carbamoyl]propanoyl}-5'-fluoro- 3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (329); methyl 2- [2-(2-{1'-[3-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin- 1-yl]-4-oxobutyl}carbamoyl)propanoyl]-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (330); methyl 2-[2-(2-{1'-[3-({6-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-6- oxohexyl}carbamoyl)propanoyl]-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (332); methyl 2-{2-[2-(3-{1-[3-({8-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-8- oxooctyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)-N-methylacetamido]acetamido}acetate (356); rac-methyl 2-(2-{2-[3-(1-{3-[(8-{4-[4- ({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (358); rac- methyl 2-(2-{2-[3-(1-{3-[(6-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-6- oxohexyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl]-N-methylacetamido}acetamido)acetate (359); methyl 2-{2-[2-(3-{1-[3-({4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-4- oxobutyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)-N-methylacetamido]acetamido}acetate (360); methyl 2-{2-[2-(3-{1-[3-({6-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-6- oxohexyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- - 167 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT 1-yl)-N-methylacetamido]acetamido}acetate (362); methyl 2-(4-{[2-(3-{1-[3-({8-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-8- oxooctyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetamido]methyl}-1H-1,2,3-triazol-1-yl)acetate (371); rac-methyl 2-[4-({2-[3-(1-{3-[(8- {4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (373); rac-methyl 2-[4-({2-[3-(1-{3-[(6-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2- oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-6- oxohexyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (374); methyl 2-(4-{[2-(3-{1-[3-({4-[4- (4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-4- oxobutyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetamido]methyl}-1H-1,2,3-triazol-1-yl)acetate (375); methyl 2-(4-{[2-(3-{1-[3-({6-[4- (4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-6- oxohexyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetamido]methyl}-1H-1,2,3-triazol-1-yl)acetate (377); methyl 2-{2-[2-(3-{2-[3-({8-[4- (4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-8- oxooctyl}carbamoyl)propanoyl]-2-azaspiro[3.3]heptan-6-yl}-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (401); rac-methyl 2-(2-{2-[3-(2- {3-[(8-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1- yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]propanoyl}-2- azaspiro[3.3]heptan-6-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N- methylacetamido}acetamido)acetate (403); rac-methyl 2-(2-{2-[3-(2-{3-[(6-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-6-oxohexyl)carbamoyl]propanoyl}-2-azaspiro[3.3]heptan- 6-yl)-5'-fluoro-1'-methyl-1H ,1'H-[4,6'-biindazol]-1-yl]-N- methylacetamido}acetamido)acetate (404); methyl 2-{2-[2-(3-{2-[3-({4-[4-(4-{[3-carbamoyl- 6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-4- oxobutyl}carbamoyl)propanoyl]-2-azaspiro[3.3]heptan-6-yl}-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (405); and methyl 2-{2-[2-(3-{2- [3-({6-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-6- - 168 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT oxohexyl}carbamoyl)propanoyl]-2-azaspiro[3.3]heptan-6-yl}-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (407). In certain embodiments, wherein n1 is an integer from one to ten; and each n15 is independently one, two, or three. In certain embodiments, the compound is selected from the group consisting of methyl 2-[2-(2-{3-[2-(4-{4-[(4-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4-oxobutanoyl)-2- azaspiro[3.3]heptan-6-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N- methylacetamido)acetamido]acetate (273); methyl 2-[2-(2-{3-[1-(4-{4-[(4-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4- yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (275); methyl 2-{2-[2-(3-{2-[4-(4-{[4-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidine-1- carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-4-oxobutanoyl]-2-azaspiro[3.3]heptan-6-yl}- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (279); methyl 2-{2-[2-(3-{1-[4-(4-{[4-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidine-1- carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-4-oxobutanoyl]piperidin-4-yl}-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (282); methyl 2-{2-[2-(1'- {4-[4-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4-oxobutanoyl}-5'-fluoro-3-(propan-2-yl)- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (333); methyl 2-(2-{2-[3-(1-{4-[4- ({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4-oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (363); methyl 2- [4-({2-[3-(1-{4-[4-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (378); and methyl 2-(2-{2-[3-(2-{4-[4- ({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- - 169 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4-oxobutanoyl}-2-azaspiro[3.3]heptan-6-yl)- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (408). In certain embodiments, L is wherein n6 and n7 are independently one, two, or three; and n8 is zero, one, two, or three. In certain embodiments, the compound is selected from the group consisting of (S)-(S)-(2-(3-(1-(2-(1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidin-4-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (18); (2-(3-(1-(3-(1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)pyrrolidin-3-yl)propanoyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (41); (2-(3-(1-(2-(1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)azepan-4-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (42); (S)-(S)-(2-(3-(1-(1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (48); (S)-(S)-(2-(3-(1-(1-(2-(4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)piperidine-4-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (57); (2-(3-(1-(3-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)pyrrolidin-3- yl)propanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (59); (2-(3-(1-(2-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)azepan-4-yl)acetyl)piperidin-4- yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (60); and (S)-(S)-(2- (3-(1-(2-(1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetyl)glycylglycine (92). - 170 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, L is wherein n3 is one or two; and n9 is one, two, or three. In certain embodiments, the compound is (S)-(S)-(2-(3-(1-(2- (4-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperazin-1-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (25). In certain embodiments, L is wherein n3 is one or two; n10 is zero, one, two, or three; X6is oxygen or NR5; and R5is independently hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of (2-(3-(1- (4-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)-1-methylpiperazine-2-carbonyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (21); (2-(3-(1-(2-(4-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)morpholin-2-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (26); (2-(3-(1-(4-(2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)-1-methylpiperazine-2-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (61); and (2-(3-(1-(2-(4-(2-((S)-4-(4-chlorophenyl)-2,3,9- trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)morpholin-2- yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (90). In certain embodiments, wherein n11 is one or two. In certain embodiments, the compound is (2-(3-(1-(2-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)-2-azabicyclo[2.2.2]octane-6-carbonyl)piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (22) or (2-(3-(1-(2-(2-((S)- 4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- - 171 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT yl)acetyl)-2-azabicyclo[2.2.2]octane-6-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetyl)glycylglycine (63). In certain embodiments, wherein n12 is one, two, or three. In certain embodiments, the compound is (2-(3-(1-(1-(4-(2-(7-chlorobenzo[d]thiazol-2- yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4- carbonyl)piperidine-3-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (40) or (2-(3-(1-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidine-3-carbonyl)piperidin- 4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (58). In certain embodiments, wherein each n13 is independently one, two, three, or four. In certain embodiments, the compound is (2-(3-(1-((1S,6R)-2-(2-((S)- 4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)-2-azabicyclo[4.1.0]heptane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetyl)glycylglycine (62). In certain embodiments, wherein n14 is zero, one, two, or three; and R12is hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of (2-(3-(1-((1S,4r)-4-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1- ((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carboxamido)cyclohexane-1- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (23); (2-(3-(1-((1S,4r)-4-((4-(2-(7-chlorobenzo[d]thiazol-2- yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4- carboxamido)methyl)cyclohexane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetyl)glycylglycine (24); (2-(3-(1-((1S,4r)-4-((2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetamido)methyl)cyclohexane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- - 172 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT [4,6'-biindazol]-1-yl)acetyl)glycylglycine (54); and (2-(3-(1-((1S,4r)-4-(2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetamido)cyclohexane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (64). In certain embodiments, independently one, two, or three; and R12is hydrogen or alkyl. In certain embodiments, the compound is (S)-(S)-(2-(3-(1-(1-(2-(1-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2- oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)-N-methylpiperidine-4- carboxamido)ethyl)piperidine-4-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (38) or (S)-(S)-(2-(3-(1-(1-(2-(1-(2-(4-(4-chlorophenyl)- 2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)-N- methylpiperidine-4-carboxamido)ethyl)piperidine-4-carbonyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (110). In certain embodiments, wherein each n15 is independently one, two, or three; n16 is an integer from one to six; and R12is independently hydrogen or alkyl. In certain embodiments, the compound is (2-(3-(1-(1-(2-(1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)-N-methylpyrrolidine-2-carboxamido)ethyl)piperidine-4- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (77) or (2-(3-(1-(1-(2-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl- 6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)-N-methylpyrrolidine-2- carboxamido)ethyl)piperidine-4-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (104). - 173 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, wherein n8 is zero, one, two, or three; and each n15 is independently one, two, or three. In certain embodiments, the compound is selected from the group consisting of (S)-(S)-(2-(3-(1-(2-(1-(1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)acetyl)piperidin-4-yl)- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (39); (S)-(S)-(2-(3-(1- (1-(1-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)- 5'-fluoro-1'-methyl-1H ,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (79); (2-(3-(1-(1-(1-(4- (2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidine-3-carbonyl)piperidin-4-yl)- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (80); (2-(3-(1-(3-(1-(1- (4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)pyrrolidin-3-yl)propanoyl)piperidin-4- yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (81); (2-(3-(1-(2-(1- (1-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)azepan-4-yl)acetyl)piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (82); (S)-(S)-(2-(3-(1-(1- (1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)acetyl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (107); (2-(3-(1-(1-(1-(2- ((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin- 6-yl)acetyl)piperidine-4-carbonyl)piperidine-3-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (108); (2-(3-(1-(3-(1-(1-(2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)piperidine-4-carbonyl)pyrrolidin-3-yl)propanoyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (112); (2-(3-(1-(2-(1-(1-(2-((S)-4- (4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- - 174 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT yl)acetyl)piperidine-4-carbonyl)azepan-4-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (113); and (S)-(S)-(2-(3-(1-(2-(1-(1-(2-(4- (4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)piperidine-4-carbonyl)piperidin-4-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (119). In certain embodiments, wherein n3 is one or two; and each n15 is independently one, two, or three. In certain embodiments, the compound is methyl (S)-(S)-(2-(3-(1-(4-(4-(4-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo- 1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)piperazine-1- carbonyl)piperidin-1-yl)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycinate (46). In certain embodiments, L is wherein each n15 is independently one, two, or three; and n16 is an integer from one to six. In certain embodiments, the compound is (2-(3-(1-(1-((4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo- 1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)prolyl)piperidine-4- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (66) or (2-(3-(1-(1-((2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)prolyl)piperidine-4- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (93). In certain embodiments, wherein n16 is an integer from one to six; and n17 is one, two, three, four, or five. In certain embodiments, the compound is - 175 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT (2-(3-(1-(1-((4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4- tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)prolyl)piperidine-3- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (67) or (2-(3-(1-(1-((2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)prolyl)piperidine-3- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (94). In certain embodiments, wherein n3 is one or two; n13 is one, two, three, or four; n15 is one, two, or three; and n16 is an integer from one to six. In certain embodiments, the compound is selected from the group consisting of (2-(3-(1-(3-(1- ((4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)prolyl)pyrrolidin-3-yl)propanoyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (68); (2-(3-(1-(2-(1-((4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)prolyl)azepan-4-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (69); (2-(3-(1-(2-(1-((4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)prolyl)piperidin-4-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (78); (2-(3-(1-(3-(1-((2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)prolyl)pyrrolidin-3-yl)propanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (95); (2-(3-(1-(2-(1-((2-((S)-4-(4-chlorophenyl)-2,3,9- trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)prolyl)azepan-4- yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (96); and (2-(3-(1-(2-(1-((2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl- 6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)prolyl)piperidin-4- yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (106). - 176 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, wherein n13 is one, two, three, or four; n14 is zero, one, two, or three; n16 is an integer from one to six; X6is oxygen or NR5; and R5is hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of (2-(3-(1-(4-((4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1- ((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)prolyl)-1- methylpiperazine-2-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (70); (2-(3-(1-(2-(4-((4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1- ((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)prolyl)morpholin-2- yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (76); (2-(3-(1-(4-((2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)prolyl)-1-methylpiperazine-2- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (97); and (2-(3-(1-(2-(4-((2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl- 6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)prolyl)morpholin-2- yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (103). In certain embodiments, L is wherein each n13 is independently one, two, three, or four; and n16 is an integer from one to six. In certain embodiments, the compound is (2-(3-(1-((1S,6R)-2-((4-(2-(7-chlorobenzo[d]thiazol-2- yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4- carbonyl)prolyl)-2-azabicyclo[4.1.0]heptane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (71) or (2-(3-(1-((1S,6R)-2-((2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)prolyl)-2-azabicyclo[4.1.0]heptane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (98). - 177 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, wherein each n11 is independently one or two; and each n16 is independently an integer from one to six. In certain embodiments, the compound is (2-(3-(1-(2-((4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)prolyl)-2-azabicyclo[2.2.2]octane-6-carbonyl)piperidin-4-yl)- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (72) or (2-(3-(1-(2-((2- ((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin- 6-yl)acetyl)prolyl)-2-azabicyclo[2.2.2]octane-6-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (99). In certain embodiments, wherein n14 is zero, one, two, or three; n16 is an integer from one to six; and R12is hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of (2-(3-(1-((1S,4r)-4-(1-(4- (2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)pyrrolidine-2-carboxamido)cyclohexane-1- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (73); (2-(3-(1-((1S,4r)-4-((1-(4-(2-(7-chlorobenzo[d]thiazol-2- yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4- carbonyl)pyrrolidine-2-carboxamido)methyl)cyclohexane-1-carbonyl)piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (74); (2-(3-(1-((1S,4r)-4- (1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)acetyl)pyrrolidine-2-carboxamido)cyclohexane-1-carbonyl)piperidin-4- yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (100); and (2-(3-(1- ((1S,4r)-4-((1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)acetyl)pyrrolidine-2-carboxamido)methyl)cyclohexane-1- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (101). - 178 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, wherein n14 is zero, one, two, or three; each n15 is independently one, two, or three; and n16 is independently an integer from one to six. In certain embodiments, the compound is (2-(3-(1-(2-(4-((4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)prolyl)piperazin-1-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (75) or (2-(3-(1-(2-(4-((2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)prolyl)piperazin-1-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (102). In certain embodiments, wherein n13 is one, two, three, or four; n14 is zero, one, two, or three; each n15 is independently one, two, or three; X6is oxygen or NR5; and R5is hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of (2-(3-(1-(4-(1-(4-(2-(7-chlorobenzo[d]thiazol-2- yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4- carbonyl)piperidine-4-carbonyl)-1-methylpiperazine-2-carbonyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (83); (2-(3-(1-(2-(4-(1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)morpholin-2-yl)acetyl)piperidin-4-yl)- 5'-fluoro-1'-methyl-1H ,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (89); (2-(3-(1-(4-(1-(2- ((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin- 6-yl)acetyl)piperidine-4-carbonyl)-1-methylpiperazine-2-carbonyl)piperidin-4-yl)-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (114); and (2-(3-(1-(2-(4-(1-(2- ((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin- 6-yl)acetyl)piperidine-4-carbonyl)morpholin-2-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (118). - 179 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, wherein each n13 is independently one, two, three, or four; and each n15 is independently one, two, or three. In certain embodiments, the compound is (2-(3-(1-((1S,6R)-2-(1-(4-(2-(7-chlorobenzo[d]thiazol- 2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4- carbonyl)piperidine-4-carbonyl)-2-azabicyclo[4.1.0]heptane-1-carbonyl)piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (84) or (2-(3-(1-((1S,6R)- 2-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)acetyl)piperidine-4-carbonyl)-2-azabicyclo[4.1.0]heptane-1- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (115). In certain embodiments, L is wherein each n11 is independently one or two; and each n15 is independently one, two, or three. In certain embodiments, the compound is (2-(3-(1-(2-(1-(4- (2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)-2-azabicyclo[2.2.2]octane-6- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (85) or (2-(3-(1-(2-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidine-4-carbonyl)-2- azabicyclo[2.2.2]octane-6-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (116). - 180 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, L is wherein n14 is zero, one, two, or three; each n15 is independently one, two, or three; and R12is hydrogen or alkyl. In certain embodiments, the compound is selected from the group consisting of (2-(3-(1- ((1r,4r)-4-(1-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4- tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)piperidine-4- carboxamido)cyclohexane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (86); (2-(3-(1-((1r,4r)-4-((1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carboxamido)methyl)cyclohexane-1- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (87); (2-(3-(1-((1S,4r)-4-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9- trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidine-4- carboxamido)cyclohexane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (105); and (2-(3-(1-((1S,4r)-4-((1-(2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)piperidine-4-carboxamido)methyl)cyclohexane-1-carbonyl)piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (117). In certain embodiments, wherein each n15 is independently one, two, or three. In certain embodiments, the compound is (S)-(S)-(2-(3-(1-(2- (4-(1-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperazin-1-yl)acetyl)piperidin-4-yl)- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (88). - 181 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT In certain embodiments, wherein n14 is zero, one, two, or three; and each n15 is independently one, two, or three. In certain embodiments, the compound is (S)-(S)-(2-(3-(1-(2-(4-(1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidine-4-carbonyl)piperazin-1- yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (109). Bifunctional Compounds In certain embodiments, provided herein are compounds of Table 1 below, or a pharmaceutically acceptable salt, stereoisomer, and / or mixture of stereoisomers thereof. In certain embodiments, the compound is selected from the group consisting of the compounds of Table 1, or a pharmaceutically acceptable salt thereof. Table 1 - 182 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 183 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 184 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 185 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 186 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 187 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 188 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 189 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 190 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 191 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 192 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 193 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 194 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT p # 33 - 195 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 196 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 197 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 198 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 199 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 200 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 201 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 202 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 203 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 204 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 205 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 206 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 207 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 208 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 209 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 210 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 211 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 212 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 213 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 214 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 215 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 216 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 217 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 218 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 219 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 220 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 221 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 222 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 223 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 224 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 225 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 226 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 227 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 228 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 229 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 230 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 231 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 232 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 233 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 234 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 235 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 236 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 237 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 238 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 239 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 240 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 241 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 242 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 243 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 244 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 245 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 246 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 247 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 248 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 249 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 250 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 251 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 252 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 253 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 254 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 255 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 256 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 257 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 258 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 259 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 260 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 261 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 262 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 263 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 264 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 265 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 266 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 267 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 268 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 269 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 270 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 271 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 272 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 273 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 274 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 275 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 276 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 277 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 278 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 279 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 280 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 281 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 282 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 283 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 284 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 285 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 286 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 287 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 288 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 289 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 290 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 291 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 292 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 293 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 294 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 295 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 296 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT Cpd # 286 287 - 297 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 298 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 299 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 300 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 301 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 302 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 303 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 304 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 305 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 306 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 307 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 308 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 309 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 310 - 1104806877\8\AMERICAS Attorney Docket No.: 121843.00295 NU-3700 PCT - 311 - 1104806877\8\AMERICAS Atto...

Claims

Attorney Docket No.: 121843.00295 NU-3700 PCT WHAT IS CLAIMED IS:

1. A compound according to Formula (I)whereinis a Kelch Domain Containing Protein (KLHDC) targeting moiety (KTM); L is a bond or a linker; andis a protein targeting moiety (PTM).

2. The compound of claim 1, wherein the KTM binds KLHDC2.

3. The compound of claim 1 or 2, wherein the KTM binds KLHDC1.

4. The compound of any one of the preceding claims, according to Formula (II)or a pharmaceutically acceptable salt thereof, wherein one of R3bor R4is, and the other is hydrogen, C1-5alkyl, or haloalkyl; R1is hydrogen or C1-5 alkyl;each R5is independently hydrogen or alkyl; - 458 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCTeach R7hydrogen or C1-5alkyl; aa is one or two; R3cis hydrogen, halogen, or CN;wherein m is an integer from one to ten; L is a bond or a linker; and is a protein targeting moiety (PTM).

5. The compound of any one of the preceding claims, according to Formula (II)or a pharmaceutically acceptable salt thereof, wherein - 459 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT one of R3band R4is, and the other is hydrogen or C1-5 alkyl; R1is hydrogen or C1-5 alkyl;each R5is independently hydrogen or alkyl;each R7hydrogen or C1-5alkyl; aa is one or two; R3cis hydrogen, halogen, or CN;L is a bond or a linker; andis a protein targeting moiety (PTM).

6. The compound of claim 4 or 5, according to Formula (III)- 460 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT or a pharmaceutically acceptable salt thereof.

7. The compound of claim 4 or 5, according to Formula (IV)or a pharmaceutically acceptable salt thereof.

8. The compound of any one of the preceding claims, wherein each R5is hydrogen.

9. The compound of any one of the preceding claims, wherein R7is hydrogen or methyl.

10. The compound of any one of the preceding claims, wherein aa is one.

11. The compound of any one of the preceding claims, wherein aa is two.

12. The compound of any one of the preceding claims, according to Formula (V)or a pharmaceutically acceptable salt thereof.

13. The compound of any one of the preceding claims, according to Formula (Va) - 461 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCTor a pharmaceutically acceptable salt thereof.

14. The compound of any one of the preceding claims, according to Formula (Vb), (Vc), (Vd), (Ve), (Vf), (Vg), or (Vh)- 462 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCTor a pharmaceutically acceptable salt thereof.

15. The compound of any one of the preceding claims, according to Formula (VIa), (VIb), or (VIc)- 463 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCTor a pharmaceutically acceptable salt thereof.

16. The compound of any one of the preceding claims, according to Formula (VIIa), (VIIb), (VIIc), (VIId), (VIIe), (VIIf), (VIIg), (VIIh), (VIIi), (VIIj), (VIIk), or (VIIl), - 464 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT- 465 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCTor a pharmaceutically acceptable salt thereof.

17. The compound of any one of the preceding claims, according to Formula (VIIIa), (VIIIb), (VIIIc), (VIIId), (VIIIe), or (VIIIf), - 466 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT); or a pharmaceutically acceptable salt thereof.

18. The compound of any one of the preceding claims, according to Formula (IXa), (IXb) or (IXc) - 467 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCTor a pharmaceutically acceptable salt thereof.

19. The compound of any one of the preceding claims, according to Formula (XIIa), (XIIb) or (XIIc)(XIIa), - 468 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCTor a pharmaceutically acceptable salt thereof.

20. The compound of any one of the preceding claims, wherein linker L comprises three to forty carbon atoms, comprising one or more acyclic and / or cyclic moieties, wherein one or more carbon atoms can be replaced optionally by a heteroatom selected from oxygen (O), nitrogen (N), sulfur (S), and phosphorous (P), or wherein the linker group comprises one, two, three, four, five, six, seven, eight, nine, or ten ethylene glycol units; wherein the linker group is optionally substituted.

21. The compound of any one of the preceding claims, wherein L is according to –L1-L2-L3-L4-L5-L6-L7– wherein –L1– is absent; -N(R21)-; -C(R22)2-; -C(O)-; C1-8 alkylene; C2-8 alkynylene; -C(O)-Q1-; Q1; or Q2; each –L2–, –L3–, –L4–, and –L5– is, independently, absent; -N(R21)-; -C(R22)2-; -C(O)-; -O-; -(CH2-CH2-O)1-8-; C1-20 alkylene; C2-8 alkynylene; -C(O)-C1-20 alkylene-C(O)-; Q1; Q2; or Q3; each –L6– and –L7– is, independently, absent; -N(R21)-; -C(R22)2-; -C(O)-; -C(O)-N(R21)-; -N(R21)-C(O)-; -C(R22)2-Q1-C(R22)2-; -C(R22)2-C(O)-N(R21)-; -C(O)-C1-20 alkylene-C(O)-; or Q1; each Q1is a three- to seven-membered heterocycloalkylene comprising at least one nitrogen; - 469 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT each Q2is a five- to thirteen-membered spiro bicyclic heterocycloalkylene comprising at least one nitrogen; each Q3is a three- to six-membered cycloalkylene; wherein each R21is, independently, hydrogen, or methyl; and each R22is, independently, hydrogen, methyl, aryl, or heteroaryl.

22. The compound of any one of the preceding claims, wherein L is a bond, , ,- 470 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT, - 471 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT ,, - 472 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT ,, wherein X6is oxygen or NR5; each n1, n2, n4, and n5 is independently an integer from one to ten; each R12is independently hydrogen or alkyl; each n3 and n11 is independently one or two; n6, n7, n9, and n12 are independently one, two, or three; n8 and n10 are zero, one, two, or three; each n13 is independently one, two, three, or four; each n14 is zero, one, two, or three; - 473 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT each n15 is independently one, two, or three; each n16 is independently an integer from one to six; and n17 is one, two, three, four, or five.

23. The compound of any one of the previous claims, wherein L is a bond.

24. The compound of any one of the preceding claims, wherein PTM is a small molecule moiety that binds to a target protein, target polypeptide, or fragment thereof.

25. The compound of any one of the preceding claims, wherein the target protein, target polypeptide, or fragment thereof is a mediator of abnormal cellular proliferation.

26. The compound of any one of the preceding claims, wherein the PTM binds to a target protein selected from the group consisting of structural proteins, receptors, enzymes, cell surface proteins, aromatases, helicases, proteases, kinases, oxidoreductases transferases, hydrolases, lyases, isomerases, ligases, enzyme regulators, signal transducers, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport including protein transporters, nuclear transporters, ion transporters, channel transporters, carriers, permeases, secretases, electron transporters, pathogenesis, chaperones, nucleic acid binders, transcription regulators. and translation regulators.

27. The compound of any one of the preceding claims, wherein the PTM binds a target protein selected from the group consisting of Bruton’s tyrosine kinase (BTK); tyrosine- protein kinase (ITK / TSK); bromodomain-containing protein 4 (BRD4); FMS-like tyrosine kinase 3 (FLT-3); Brg / Brahma-associated factors (BAF complex); induced myeloid leukemia cell differentiation protein (MCL-1); signal transducer and activator of transcription 3 (STAT3); barrier-to-autointegration factor (BAF); and BCR-ABL.

28. The compound of any one of the preceding claims, wherein the PTM moiety is configured to bind to a target protein selected from the group consisting of FLT3, SHP-2, GLD06, CDK4, CDK6, CDK4 / 6, MALT1, BRAF, BCR-ABL, MEK, FGFR1, FGFR3, FGFR1 fusions, FGFR3 fusions, RET, RET fusions, BCL-2, PI3K, PI3K alpha, PI3K Delta, - 474 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT MLL, Aurora A, KRAS, KRAS G12D, KRAS G12C, MDM2, MCL-1, eIF4e, KSR, TRIM24, SHP-2, SARS-COV2 proteins, and MEK.

29. The compound of any one of the preceding claims, wherein PTM is selected from the group consisting of, - 475 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCTwherein each R100a, R100b, and R100care independently selected from hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, acyl, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, arylalkyl, or heteroaryl; and each X100is independently a halogen selected from the group consisting of bromo, chloro, fluoro, and iodo.

30. The compound of claim 26 or 29, wherein- 476 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT- 477 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT.

31. The compound of claim 29, wherein the compound is (S)-(S)-(2-(3-(1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (27) or (S)-(S)-(2-(3-(1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (91).

32. The compound of claim 24, wherein L is –C(O)(CH2)n1NR12C(O)(CH2)n2C(O)– wherein n1 and n2 are independently an integer from one to ten; and R12is hydrogen or alkyl.

33. The compound of claim 32, wherein the compound is selected from the group consisting of (R)-(R)-(2-(3-(1-(4-((4-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4- d]pyrimidin-1-yl)piperidin-1-yl)-4-oxobutyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (1); (R)-(R)-(2-(3-(1-(4-((6-(3-(4- amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-6- oxohexyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycine (3); (R)-(R)-(2-(3-(1-(4-((8-(3-(4-amino-3-(4-phenoxyphenyl)-1H- pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-8-oxooctyl)amino)-4-oxobutanoyl)piperidin-4- yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (5); methyl (R)-(R)- - 478 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT (2-(3-(1-(4-((6-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1- yl)piperidin-1-yl)-6-oxohexyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (50); methyl (R)-(R)-(2-(3-(1-(4-((8-(3- (4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-8- oxooctyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycinate (52); methyl (R)-(R)-(2-(3-(1-(4-((4-(3-(4-amino-3-(4- phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-4-oxobutyl)amino)-4- oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycinate (55); methyl 2-[2-(2-{1'-[3-({8-[4-(4-{[3-carbamoyl-6-(piperidin-1- yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-8-oxooctyl}carbamoyl)propanoyl]-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (145); ethyl 2- {2-[2-(3-{1-[3-({8-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-8-oxooctyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (146); propan-2-yl 2- {2-[2-(3-{1-[3-({8-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-8-oxooctyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (147); methyl 2-[2-(2- {1'-[3-({6-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]- 6-oxohexyl}carbamoyl)propanoyl]-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (206); ethyl 2-{2-[2-(3-{1-[3-({6-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-6- oxohexyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetamido]acetamido}acetate (207); propan-2-yl 2-{2-[2-(3-{1-[3-({6-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-6- oxohexyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetamido]acetamido}acetate (208); methyl 2-[2-(2-{1'-[3-({4-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-4- oxobutyl}carbamoyl)propanoyl]-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (215); ethyl 2-{2-[2-(3-{1-[3-({4-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-4- oxobutyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetamido]acetamido}acetate (216); propan-2-yl 2-{2-[2-(3-{1-[3-({4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-4- - 479 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT oxobutyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetamido]acetamido}acetate (217); methyl 2-{2-[2-(1'-{3-[(6-{4-[4-({3-carbamoyl-6- [(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-6-oxohexyl)carbamoyl]propanoyl}-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (219); ethyl 2- (2-{2-[3-(1-{3-[(6-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-6- oxohexyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl]acetamido}acetamido)acetate (220); methyl 2-[4-({2-[3-(1-{3-[(6-{4-[4-({3-carbamoyl- 6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-6-oxohexyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (221); propan-2-yl 2-(2-{2-[3-(1-{3-[(6-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2- oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-6- oxohexyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl]acetamido}acetamido)acetate (222); methyl 2-{2-[2-(1'-{3-[(8-{4-[4-({3-carbamoyl-6- [(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]propanoyl}-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (224); ethyl 2- (2-{2-[3-(1-{3-[(8-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-8- oxooctyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (225); propan-2-yl 2-(2-{2-[3-(1-{3-[(8-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (227); methyl 2-(2-{2- [1'-(3-{[12-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H- cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-12- oxododecyl]carbamoyl}propanoyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (235); methyl 2-[2-(2-{3-[1-(3-{[12-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidin-1-yl)-12-oxododecyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (236); methyl 2-(2-{2-[1'-(3-{[9- - 480 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT (4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3- amido]-1H-pyrazol-1-yl}piperidin-1-yl)-9-oxononyl]carbamoyl}propanoyl)-5'-fluoro-3- methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (237); methyl 2-[2-(2-{3- [1-(3-{[9-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H- cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-9- oxononyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl}-N-methylacetamido)acetamido]acetate (238); methyl 2-{2-[2-(1'-{3-[(12-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-12-oxododecyl)carbamoyl]propanoyl}-5'-fluoro-3-(trifluoromethyl)- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (240); methyl 2-{2-[2-(1'-{3-[(12- {4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-12-oxododecyl)carbamoyl]propanoyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (243); methyl 2-(2-{2-[3-(1-{3-[(12-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-12-oxododecyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (245); methyl 2-(2-{2-[1'-(3-{[12- (4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3- amido]-1H-pyrazol-1-yl}piperidin-1-yl)-12-oxododecyl]carbamoyl}propanoyl)-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (246); methyl 2- {2-[2-(1'-{3-[(9-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-9-oxononyl)carbamoyl]propanoyl}-5'- fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (249); methyl 2-{2-[2-(1'-{3-[(9-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-9-oxononyl)carbamoyl]propanoyl}-5'- fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (252); methyl 2- (2-{2-[3-(1-{3-[(9-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-9- oxononyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl]acetamido}acetamido)acetate (254); methyl 2-(2-{2-[1'-(3-{[9-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidin-1-yl)-9-oxononyl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H- [4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (255); methyl 2-[2-(2-{3-[1-(3-{[9-(4-{4- [(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]- - 481 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 1H-pyrazol-1-yl}piperidin-1-yl)-9-oxononyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (258); methyl 2-[2-(2- {1'-[3-({8-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]- 8-oxooctyl}carbamoyl)propanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (341); rac-methyl 2-{2-[2-(1'-{3-[(8-{4-[4-({3-carbamoyl-6- [(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]propanoyl}-5'-fluoro-3-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (343); rac-methyl 2-{2-[2-(1'-{3- [(6-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin- 2-yl}amino)phenyl]piperidin-1-yl}-6-oxohexyl)carbamoyl]propanoyl}-5'-fluoro-3-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (344); methyl 2-[2-(2-{1'-[3-({4- [4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-4- oxobutyl}carbamoyl)propanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (345); methyl 2-[2-(2-{1'-[3-({6-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-6- oxohexyl}carbamoyl)propanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (347); methyl 2-{2-[2-(3-{1-[3-({8-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-8- oxooctyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-chloro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetamido]acetamido}acetate (386); rac-methyl 2-(2-{2-[3-(1-{3-[(8-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-chloro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (388); rac-methyl 2-(2- {2-[3-(1-{3-[(6-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin- 1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-6-oxohexyl)carbamoyl]propanoyl}piperidin- 4-yl)-5'-chloro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (389); methyl 2-{2-[2-(3-{1-[3-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-4-oxobutyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-chloro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (390); and methyl 2-{2- [2-(3-{1-[3-({6-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin- 1-yl]-6-oxohexyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-chloro-1'-methyl-1H,1'biindazol]-1-yl)acetamido]acetamido}acetate (392). - 482 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 34. The compound of claim 24, wherein L iswherein n1 and n2 are independently an integer from one to ten; n3 is one or two; and R12is hydrogen or alkyl.

35. The compound of claim 34, wherein the compound is selected from the group consisting of (2-(3-(1-(4-((5-(4-(4-((5-chloro-4-((2- (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1- yl)pentyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycine (6); methyl (2-(3-(1-(4-((3-(4-(4-((5-chloro-4-((2- (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1- yl)propyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycinate (8); methyl (2-(3-(1-(4-((5-(4-(4-((5-chloro-4-((2- (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1- yl)pentyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycinate (10); methyl (2-(3-(1-(4-((3-(4-(4-((5-chloro-4-((2- (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1- yl)propyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycinate (12); methyl (2-(3-(1-(4-((7-(4-(4-((5-chloro-4-((2- (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1- yl)heptyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycinate (13); (2-(3-(1-(4-((7-(4-(4-((5-chloro-4-((2- (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1- yl)heptyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycine (14); (2-(3-(1-(4-((3-(4-(4-((5-chloro-4-((2- (methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-1- yl)propyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycine (16); methyl 2-(2-{2-[1'-(3-{[3-(4-{4-[(5-chloro-4-{[2- (methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)propyl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (127); propan-2-yl 2-[2-(2-{3-[1-(3-{[3-(4-{4-[(5-chloro-4- {[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)propyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- - 483 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 1-yl}acetamido)acetamido]acetate (128); methyl 2-(2-{2-[1'-(3-{[5-(4-{4-[(5-chloro-4-{[2- (methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)pentyl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (130); propan-2-yl 2-[2-(2-{3-[1-(3-{[5-(4-{4-[(5-chloro-4- {[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)pentyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl}acetamido)acetamido]acetate (131); methyl 2-(2-{2-[1'-(3-{[7-(4-{4-[(5-chloro-4-{[2- (methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)heptyl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (139); and propan-2-yl 2-[2-(2-{3-[1-(3-{[7-(4-{4-[(5- chloro-4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)heptyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl}acetamido)acetamido]acetate (140).

36. The compound of claim 24, wherein L is –NR12(CH2)n1NR12C(O)(CH2)n2C(O)– wherein n1 and n2 are independently an integer from one to ten; and each R12is independently hydrogen or alkyl.

37. The compound of claim 36, wherein the compound is selected from the group consisting of (S)-(S)-(2-(3-(1-(4-((6-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)hexyl)amino)-4-oxobutanoyl)piperidin- 4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (20); methyl (S)- (S)-(2-(3-(1-(4-((4-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)butyl)amino)-4-oxobutanoyl)piperidin-4- yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (29); methyl (S)- (S)-(2-(3-(1-(4-((2-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)ethyl)amino)-4-oxobutanoyl)piperidin-4- yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (31); (S)-(S)-(2- (3-(1-(4-((4-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)acetamido)butyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (36); (S)-(S)-(2-(3-(1-(4-((2-(2-(4- (4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetamido)ethyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- - 484 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT biindazol]-1-yl)acetyl)glycylglycine (37); (S)-(S)-(2-(3-(1-(4-((2-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carboxamido)ethyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (43); methyl (S)-(S)-(2-(3-(1-(4-((4- (4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carboxamido)butyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (45); methyl (S)-(S)-(2-(3-(1-(4- ((2-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carboxamido)ethyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (47); methyl (S)-(S)-(2-(3-(1-(4- ((6-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)acetamido)hexyl)amino)-4-oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (111); methyl 2-{2-[2-(1'-{3-[(4- {2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}butyl)carbamoyl]propanoyl}-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (159); ethyl 2-(2-{2-[3-(1-{3-[(4-{2-[(9S)-7-(4- chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca- 2(6),4,7,10,12-pentaen-9-yl]acetamido}butyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (160); propan-2-yl 2-(2- {2-[3-(1-{3-[(4-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}butyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (162); methyl 2-{2-[2-(1'-{3-[(2-{2-[(9S)-7-(4- chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca- 2(6),4,7,10,12-pentaen-9-yl]acetamido}ethyl)carbamoyl]propanoyl}-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (164); ethyl 2- (2-{2-[3-(1-{3-[(2-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (165); propan-2-yl 2-(2-{2-[3-(1-{3-[(2-{2- [(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- - 485 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT yl]acetamido}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (167); methyl 2-{2-[2-(1'-{3-[(6-{2-[(9S)-7-(4- chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca- 2(6),4,7,10,12-pentaen-9-yl]acetamido}hexyl)carbamoyl]propanoyl}-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (169); ethyl 2- (2-{2-[3-(1-{3-[(6-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}hexyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (170); and propan-2-yl 2-(2-{2-[3-(1-{3-[(6-{2- [(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}hexyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (172).

38. The compound of claim 24, wherein L iswherein n2, n4, and n5 are independently an integer from one to ten; n3 is one or two; and R12is hydrogen or alkyl.

39. The compound of claim 38, wherein the compound is selected from the group consisting of (2-(3-(1-(1-(4-(4-((5-chloro-4-((2-(methylcarbamoyl)phenyl)amino)pyrimidin- 2-yl)amino)phenyl)piperazin-1-yl)-13-oxo-3,6,9-trioxa-12-azahexadecan-16-oyl)piperidin-4- yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (2); methyl (2-(3- (1-(1-(4-(4-((5-chloro-4-((2-(methylcarbamoyl)phenyl)amino)pyrimidin-2- yl)amino)phenyl)piperazin-1-yl)-13-oxo-3,6,9-trioxa-12-azahexadecan-16-oyl)piperidin-4- yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (7); (2-(3-(1-(1- (4-(4-((5-chloro-4-((2-(methylcarbamoyl)phenyl)amino)pyrimidin-2- yl)amino)phenyl)piperazin-1-yl)-19-oxo-3,6,9,12,15-pentaoxa-18-azadocosan-22- oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (11); methyl (2-(3-(1-(1-(4-(4-((5-chloro-4-((2-(methylcarbamoyl)phenyl)amino)pyrimidin-2- yl)amino)phenyl)piperazin-1-yl)-19-oxo-3,6,9,12,15-pentaoxa-18-azadocosan-22- oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (15); methyl (2-(3-(1-(1-(4-(4-((5-chloro-4-((2-(methylcarbamoyl)phenyl)amino)pyrimidin-2- - 486 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT yl)amino)phenyl)piperazin-1-yl)-25-oxo-3,6,9,12,15,18,21-heptaoxa-24-azaoctacosan-28- oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (17); (2-(3-(1-(1-(4-(4-((5-chloro-4-((2-(methylcarbamoyl)phenyl)amino)pyrimidin-2- yl)amino)phenyl)piperazin-1-yl)-25-oxo-3,6,9,12,15,18,21-heptaoxa-24-azaoctacosan-28- oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (19); methyl 2-(2-{2-[1'-(3-{[2-(2-{2-[2-(4-{4-[(5-chloro-4-{[2- (methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)ethoxy]ethoxy}ethoxy)ethyl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H- [4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (133); propan-2-yl 2-[2-(2-{3-[1-(3-{[2- (2-{2-[2-(4-{4-[(5-chloro-4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2- yl)amino]phenyl}piperazin-1- yl)ethoxy]ethoxy}ethoxy)ethyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (134); methyl 2-(2-{2-[1'-(3-{[17- (4-{4-[(5-chloro-4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2- yl)amino]phenyl}piperazin-1-yl)-3,6,9,12,15-pentaoxaheptadecan-1- yl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (136); propan-2-yl 2-[2-(2-{3-[1-(3-{[17-(4-{4-[(5-chloro-4- {[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1-yl)- 3,6,9,12,15-pentaoxaheptadecan-1-yl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (137); methyl 2-(2-{2-[1'- (3-{[23-(4-{4-[(5-chloro-4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2- yl)amino]phenyl}piperazin-1-yl)-3,6,9,12,15,18,21-heptaoxatricosan-1- yl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (142); and propan-2-yl 2-[2-(2-{3-[1-(3-{[23-(4-{4-[(5- chloro-4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)-3,6,9,12,15,18,21-heptaoxatricosan-1-yl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (143).

40. The compound of claim 24, wherein L is –C(O)(CH2CH2O)n4(CH2)n5NR12C(O)(CH2)n2C(O)– wherein n2, n4, and n5 are independently an integer from one to ten; and R12is hydrogen or alkyl. - 487 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 41. The compound of claim 40, wherein the compound is selected from the group consisting of (R)-(R)-(2-(3-(1-(1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4- d]pyrimidin-1-yl)piperidin-1-yl)-1,14-dioxo-4,7,10-trioxa-13-azaheptadecan-17- oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (4); (R)-(R)-(2-(3-(1-(1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1- yl)piperidin-1-yl)-1,26-dioxo-4,7,10,13,16,19,22-heptaoxa-25-azanonacosan-29- oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (9); (R)-(R)-(2-(3-(1-(1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1- yl)piperidin-1-yl)-1,20-dioxo-4,7,10,13,16-pentaoxa-19-azatricosan-23-oyl)piperidin-4-yl)- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (49); methyl (R)-(R)-(2- (3-(1-(1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1- yl)-1,26-dioxo-4,7,10,13,16,19,22-heptaoxa-25-azanonacosan-29-oyl)piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (51); methyl (R)-(R)-(2- (3-(1-(1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1- yl)-1,20-dioxo-4,7,10,13,16-pentaoxa-19-azatricosan-23-oyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (53); methyl (R)-(R)-(2-(3-(1-(1- (3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-1,14- dioxo-4,7,10-trioxa-13-azaheptadecan-17-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetyl)glycylglycinate (56); methyl 2-{2-[2-(1'-{3-[(2-{2-[2-(3-{4-[4- ({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}- 5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (149); ethyl 2-(2-{2-[3-(1-{3-[(2-{2-[2-(3-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2- oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (150); methyl 2-[4-({2-[3-(1-{3- [(2-{2-[2-(3-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1- yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (151); propan- 2-yl 2-(2-{2-[3-(1-{3-[(2-{2-[2-(3-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2- oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl- - 488 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (152); methyl 2-{2-[2-(1'-{3-[(27- {4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (154); ethyl 2-(2-{2-[3-(1-{3-[(27-{4-[4-({3-carbamoyl-6- [(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (155); propan-2-yl 2-(2-{2-[3-(1-{3-[(27-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (157); ethyl 2-{2-[2-(3-{1-[3-({2-[2-(2-{3-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-3- oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (191); propan-2-yl 2-{2-[2-(3-{1- [3-({2-[2-(2-{3-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin- 1-yl]-3-oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (192); methyl 2-[2-(2-{1'- [3-({18-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]- 18-oxo-3,6,9,12,15-pentaoxaoctadecan-1-yl}carbamoyl)propanoyl]-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (194); ethyl 2- {2-[2-(3-{1-[3-({18-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (195); propan-2-yl 2-{2-[2-(3-{1-[3-({18-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (196); methyl 2-[2-(2-{1'-[3-({27-[4-(4- {[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-27-oxo- 3,6,9,12,15,18,21,24-octaoxaheptacosan-1-yl}carbamoyl)propanoyl]-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (198); ethyl 2- {2-[2-(3-{1-[3-({27-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- - 489 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT yl]amino}phenyl)piperidin-1-yl]-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (199); propan-2-yl 2-{2-[2-(3-{1-[3-({27-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-27-oxo- 3,6,9,12,15,18,21,24-octaoxaheptacosan-1-yl}carbamoyl)propanoyl]piperidin-4-yl}-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (200); methyl 2- {2-[2-(1'-{3-[(18-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl)carbamoyl]propanoyl}-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (229); ethyl 2-(2-{2-[3-(1-{3-[(18-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (230); propan-2-yl 2-(2-{2-[3-(1-{3-[(18-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (232); methyl 2-{2-[2-(1'-{3-[(27-{4-[5-(2-aminopyrimidin- 4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-27-oxo- 3,6,9,12,15,18,21,24-octaoxaheptacosan-1-yl)carbamoyl]propanoyl}-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (259); methyl 2- {2-[2-(1'-{3-[(27-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl)carbamoyl]propanoyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (262); methyl 2-(2-{2-[3-(1-{3-[(27-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (264); methyl 2-(2-{2-[1'-(3-{[27-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidin-1-yl)-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (265); methyl 2-(2-{2-[1'-(3-{[27-(4-{4-[(4aR,5aS)-5,5- - 490 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidin-1-yl)-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl]carbamoyl}propanoyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (268); methyl 2-[2-(2-{3-[1-(3-{[27-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidin-1-yl)-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (270); methyl 2-{2-[2-(1'-{3-[(2-{2-[2-(3-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (294); methyl 2- {2-[2-(1'-{3-[(2-{2-[2-(3-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (297); methyl 2-(2-{2-[3-(1-{3-[(2-{2-[2-(3-{4- [5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (299); methyl 2-(2-{2-[1'-(3-{[2-(2-{2-[3-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H- cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-3- oxopropoxy]ethoxy}ethoxy)ethyl]carbamoyl}propanoyl)-5'-fluoro-3-(trifluoromethyl)- 1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (300); methyl 2-(2-{2-[1'-(3-{[2- (2-{2-[3-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H- cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-3- oxopropoxy]ethoxy}ethoxy)ethyl]carbamoyl}propanoyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (303); methyl 2-[2-(2-{3-[1-(3-{[2-(2-{2-[3-(4- {4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3- amido]-1H-pyrazol-1-yl}piperidin-1-yl)-3- oxopropoxy]ethoxy}ethoxy)ethyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (305); methyl 2-{2-[2-(1'-{3-[(18- {4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1-yl)carbamoyl]propanoyl}-5'- fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (306); - 491 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT methyl 2-{2-[2-(1'-{3-[(18-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan- 1-yl)carbamoyl]propanoyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (309); methyl 2-(2-{2-[3-(1-{3-[(18-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (311); methyl 2-(2-{2-[1'-(3-{[18-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1-yl]carbamoyl}propanoyl)-5'- fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (312); methyl 2-(2-{2-[1'-(3-{[18-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H- cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl]carbamoyl}propanoyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (315); methyl 2-[2-(2-{3-[1-(3-{[18-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (317); methyl 2-[2-(2-{1'-[3-({27-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl}carbamoyl)propanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (319); methyl 2-{2-[2-(3-{1-[3-({27-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl}carbamoyl)propanoyl]piperidin-4-yl}-5'-chloro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (322); rac-methyl 2-{2-[2-(1'-{3-[(27-{4- [4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (339); rac-methyl 2-{2-[2-(1'-{3-[(2-{2-[2-(3-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}- 5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (340); rac- methyl 2-{2-[2-(1'-{3-[(18-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- - 492 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl)carbamoyl]propanoyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (342); methyl 2-[2-(2-{1'-[3-({18-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl}carbamoyl)propanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (349); methyl 2-[2-(2-{1'-[3-({2-[2-(2-{3-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-3- oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)propanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)acetamido]acetate (350); rac-methyl 2-(2-{2-[3-(1-{3-[(27-{4-[4- ({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-chloro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (384); rac-methyl 2-(2-{2-[3-(1-{3-[(2-{2-[2-(3-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-chloro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (385); rac-methyl 2-(2-{2-[3-(1- {3-[(18-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1- yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-chloro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (387); methyl 2-{2-[2-(3-{1-[3-({18-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl}carbamoyl)propanoyl]piperidin-4-yl}-5'-chloro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (394); and methyl 2-{2-[2-(3-{1-[3-({2- [2-(2-{3-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-3- oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-chloro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (395).

42. The compound of claim 24, wherein L is –NR12(CH2CH2O)n4(CH2)n5NR12C(O)(CH2)n2C(O)– wherein n2, n4, and n5 are independently an integer from one to ten; and each R12is independently hydrogen or alkyl. - 493 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 43. The compound of claim 42, wherein the compound is selected from the group consisting of methyl 2-{2-[2-(1'-{3-[(23-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia- 1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamido}- 3,6,9,12,15,18,21-heptaoxatricosan-1-yl)carbamoyl]propanoyl}-5'-fluoro-3-(trifluoromethyl)- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (12); methyl (S)-(S)-(2-(3-(1-(1- (4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)- 2,28-dioxo-6,9,12,15,18,21,24-heptaoxa-3,27-diazahentriacontan-31-oyl)piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (28); methyl (S)-(S)-(2- (3-(1-(1-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)-2,16-dioxo-6,9,12-trioxa-3,15-diazanonadecan-19-oyl)piperidin-4-yl)- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (30); methyl (S)-(S)- (2-(3-(1-(1-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)-2,22-dioxo-6,9,12,15,18-pentaoxa-3,21-diazapentacosan-25- oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (32); (S)-(S)-(2-(3-(1-(1-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-2,28-dioxo-6,9,12,15,18,21,24-heptaoxa-3,27- diazahentriacontan-31-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (33); (S)-(S)-(2-(3-(1-(1-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-2,22-dioxo-6,9,12,15,18-pentaoxa-3,21- diazapentacosan-25-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (34); (S)-(S)-(2-(3-(1-(1-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-2,16-dioxo-6,9,12-trioxa-3,15- diazanonadecan-19-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (35); methyl (S)-(S)-(2-(3-(1-(1-(4-(2-(7-chlorobenzo[d]thiazol-2- yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidin-4-yl)-1,21-dioxo- 5,8,11,14,17-pentaoxa-2,20-diazatetracosan-24-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (44); ethyl 2-(2-{2-[3-(1-{3-[(23-{2- [(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamido}- 3,6,9,12,15,18,21-heptaoxatricosan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (65) and ethyl (S)-(S)-(2-(3- (1-(1-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)- 2,22-dioxo-6,9,12,15,18-pentaoxa-3,21-diazapentacosan-25-oyl)piperidin-4-yl)-5'-fluoro-1'-methyl- - 494 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycinate (120); propan-2-yl 2-(2-{2-[3-(1-{3-[(23-{2- [(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamido}- 3,6,9,12,15,18,21-heptaoxatricosan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (122); propan-2-yl 2-(2-{2-[3-(1-{3-[(2-{2-[2-(2-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3- thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}ethoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (125); methyl 2-{2-[2-(1'- {3-[(17-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamido}-3,6,9,12,15- pentaoxaheptadecan-1-yl)carbamoyl]propanoyl}-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (174); ethyl 2-(2-{2-[3-(1-{3-[(17-{2-[(9S)-7- (4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca- 2(6),4,7,10,12-pentaen-9-yl]acetamido}-3,6,9,12,15-pentaoxaheptadecan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (175); and propan-2-yl 2-(2-{2-[3-(1-{3-[(17-{2-[(9S)-7-(4- chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca- 2(6),4,7,10,12-pentaen-9-yl]acetamido}-3,6,9,12,15-pentaoxaheptadecan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (177).

44. The compound of claim 24, wherein L iswherein n4 and n5 are independently an integer from one to ten; each n15 is independently one, two, or three; and each R12is independently hydrogen or alkyl.

45. The compound of claim 44, wherein the compound is selected from the group consisting of methyl 2-[2-(2-{1'-[(1-{[(23-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3- thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamido}- 3,6,9,12,15,18,21-heptaoxatricosan-1-yl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro- - 495 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 3-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (123); methyl 2-[2-(2- {1'-[(1-{[(2-{2-[2-(2-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}ethoxy)ethoxy]ethoxy}ethyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'- fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (126); and methyl 2-[2-(2-{1'-[(1-{[(17-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamido}-3,6,9,12,15- pentaoxaheptadecan-1-yl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (178).

46. The compound of claim 24, wherein L iswherein n1 and each n5 are independently an integer from one to ten; n3 is one or two; each n15 is independently one, two, or three; and each R12is independently hydrogen or alkyl.

47. The compound of claim 46, wherein the compound is selected from the group consisting of methyl 2-{2-[2-(1'-{[1-({[3-(4-{4-[(5-chloro-4-{[2- (methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)propyl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (129); methyl 2-{2-[2-(1'-{[1-({[5-(4-{4-[(5- chloro-4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)pentyl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (132); and methyl 2-{2-[2-(1'-{[1-({[7-(4-{4- [(5-chloro-4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin- 1-yl)heptyl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (141).

48. The compound of claim 24, wherein L iswherein n4 and each n5 are - 496 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT independently an integer from one to ten; n3 is one or two; each n15 is independently one, two, or three; and R12is independently hydrogen or alkyl.

49. The compound of claim 48, wherein the compound is selected from the group consisting of methyl 2-{2-[2-(1'-{[1-({[2-(2-{2-[2-(4-{4-[(5-chloro-4-{[2- (methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1- yl)ethoxy]ethoxy}ethoxy)ethyl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (135); methyl 2-{2-[2-(1'- {[1-({[17-(4-{4-[(5-chloro-4-{[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2- yl)amino]phenyl}piperazin-1-yl)-3,6,9,12,15-pentaoxaheptadecan-1- yl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (138); and methyl 2-{2-[2-(1'-{[1-({[23-(4-{4-[(5-chloro-4- {[2-(methylcarbamoyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}piperazin-1-yl)- 3,6,9,12,15,18,21-heptaoxatricosan-1-yl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro- 3-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (144).

50. The compound of claim 24, wherein L iswherein each n5 are independently an integer from one to ten; each n15 is independently one, two, or three; and R12is independently hydrogen or alkyl.

51. The compound of claim 50, wherein the compound is selected from the group consisting of methyl 2-(2-{2-[1'-({1-[({8-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-8-oxooctyl}carbamoyl)methyl]piperidin-4-yl}methyl)-5'- fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (148); methyl 2- (2-{2-[1'-({1-[({6-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-6-oxohexyl}carbamoyl)methyl]piperidin-4-yl}methyl)-5'- fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (209); methyl 2- (2-{2-[1'-({1-[({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-4-oxobutyl}carbamoyl)methyl]piperidin-4-yl}methyl)-5'- fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (218); methyl 2- - 497 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT [2-(2-{1'-[(1-{[(6-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-6- oxohexyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1biindazol]-1-yl}acetamido)acetamido]acetate (223); methyl 2-[2-(2-{1'-[(1-{[(8-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'- fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (228); methyl 2- [2-(2-{1'-[(1-{[(12-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-12- oxododecyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)acetamido]acetate (241); methyl 2-{2-[2-(1'-{[1-({[12-(4-{4- [(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]- 1H-pyrazol-1-yl}piperidin-1-yl)-12-oxododecyl]carbamoyl}methyl)piperidin-4-yl]methyl}- 5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (247); methyl 2-[2-(2-{1'-[(1-{[(9-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-9- oxononyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)acetamido]acetate (250); and methyl 2-{2-[2-(1'-{[1-({[9-(4-{4- [(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]- 1H-pyrazol-1-yl}piperidin-1-yl)-9-oxononyl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'- fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (256).

52. The compound of claim 24, wherein L iswherein n4 and each n5 are independently an integer from one to ten; each n15 is independently one, two, or three; and R12is independently hydrogen or alkyl.

53. The compound of claim 52, wherein the compound is selected from the group consisting of methyl 2-[2-(2-{1'-[(1-{[(2-{2-[2-(3-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl- 2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3- - 498 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (153); methyl 2-[2-(2-{1'- [(1-{[(27-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1- yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (158); methyl 2-(2-{2-[1'-({1- [({2-[2-(2-{3-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1- yl]-3-oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)methyl]piperidin-4-yl}methyl)-5'-fluoro- 3-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (193); methyl 2-(2-{2- [1'-({1-[({18-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1- yl]-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1-yl}carbamoyl)methyl]piperidin-4-yl}methyl)- 5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (197); methyl 2-(2-{2-[1'-({1-[({27-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl}carbamoyl)methyl]piperidin-4-yl}methyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (201); methyl 2-[2-(2-{1'-[(1-{[(18-{4-[4-({3-carbamoyl-6- [(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (233); methyl 2-[2-(2-{1'-[(1-{[(27-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (260); methyl 2-{2-[2-(1'-{[1-({[27-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidin-1-yl)-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (266); methyl 2-[2-(2-{1'-[(1-{[(2-{2-[2-(3-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]methyl}piperidin-4- yl)methyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (295); methyl 2-{2-[2-(1'-{[1-({[2-(2-{2-[3-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-3- oxopropoxy]ethoxy}ethoxy)ethyl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3- - 499 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (301); methyl 2-[2-(2-{1'- [(1-{[(18-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3- thiazol-2-yl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (307); and methyl 2-{2-[2-(1'-{[1-({[18-(4-{4-[(4aR,5aS)- 5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol- 1-yl}piperidin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl]carbamoyl}methyl)piperidin-4-yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (313).

54. The compound of claim 24, wherein L is –C(O)(CH2CH2O)n4(CH2)n5NR12– wherein n4 and n5 are independently an integer from one to ten; and R12is independently hydrogen or alkyl.

55. The compound of claim 54, wherein the compound is selected from the group consisting of methyl 2-[4-({2-[3-(1-{3-[(27-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2- oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-27-oxo- 3,6,9,12,15,18,21,24-octaoxaheptacosan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (156); methyl 2-[4-({2-[3-(1-{3-[(18-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2- oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-18-oxo- 3,6,9,12,15-pentaoxaoctadecan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (231); methyl 2-(2-{2-[3-(2-{3-[(27-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl)carbamoyl]propanoyl}-2-azaspiro[3.3]heptan-6-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (261); methyl 2- (2-{2-[3-(1-{3-[(27-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (263); methyl 2-[2-(2-{3-[2-(3- {[27-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H- cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-27-oxo- - 500 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 3,6,9,12,15,18,21,24-octaoxaheptacosan-1-yl]carbamoyl}propanoyl)-2-azaspiro[3.3]heptan- 6-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N- methylacetamido)acetamido]acetate (267); methyl 2-[2-(2-{3-[1-(3-{[27-(4-{4-[(4aR,5aS)- 5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol- 1-yl}piperidin-1-yl)-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N- methylacetamido)acetamido]acetate (269); methyl 2-(2-{2-[3-(2-{3-[(2-{2-[2-(3-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}-2- azaspiro[3.3]heptan-6-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N- methylacetamido}acetamido)acetate (296); methyl 2-(2-{2-[3-(1-{3-[(2-{2-[2-(3-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (298); methyl 2-[2-(2-{3-[2-(3-{[2-(2-{2-[3-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-3- oxopropoxy]ethoxy}ethoxy)ethyl]carbamoyl}propanoyl)-2-azaspiro[3.3]heptan-6-yl]-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (302); methyl 2-[2-(2-{3-[1-(3-{[2-(2-{2-[3-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-3- oxopropoxy]ethoxy}ethoxy)ethyl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (304); methyl 2-(2-{2- [3-(2-{3-[(18-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]- 1,3-thiazol-2-yl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]propanoyl}-2-azaspiro[3.3]heptan-6-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (308); methyl 2-(2-{2-[3-(1-{3-[(18- {4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N- methylacetamido}acetamido)acetate (310); methyl 2-[2-(2-{3-[2-(3-{[18-(4-{4-[(4aR,5aS)- 5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol- 1-yl}piperidin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1-yl]carbamoyl}propanoyl)-2- azaspiro[3.3]heptan-6-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N- - 501 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT methylacetamido)acetamido]acetate (314); methyl 2-[2-(2-{3-[1-(3-{[18-(4-{4-[(4aR,5aS)- 5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol- 1-yl}piperidin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl]carbamoyl}propanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N- methylacetamido)acetamido]acetate (316); methyl 2-[2-(2-{1'-[3-({27-[4-(4-{[3-carbamoyl- 6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl}carbamoyl)propanoyl]-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)acetamido]acetate (318); methyl 2-{2-[2-(3-{1-[3-({27-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-27-oxo- 3,6,9,12,15,18,21,24-octaoxaheptacosan-1-yl}carbamoyl)propanoyl]piperidin-4-yl}-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (320); methyl 2-(4-{[2-(3-{1-[3-({27-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]methyl}-1H-1,2,3-triazol-1-yl)acetate (321); methyl 2-{2-[2-(3-{2-[3-({27-[4- (4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-27-oxo- 3,6,9,12,15,18,21,24-octaoxaheptacosan-1-yl}carbamoyl)propanoyl]-2-azaspiro[3.3]heptan- 6-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)-N- methylacetamido]acetamido}acetate (323); rac-methyl 2-{2-[2-(1'-{3-[(27-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (324); rac-methyl 2-{2-[2-(1'-{3-[(2-{2-[2-(3-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}- 5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (325); rac-methyl 2-{2-[2-(1'-{3-[(18-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin- 1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl)carbamoyl]propanoyl}-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (327); methyl 2-[2-(2-{1'-[3-({18-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl}carbamoyl)propanoyl]-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)acetamido]acetate (334); methyl 2-[2-(2-{1'-[3-({2-[2-(2-{3-[4-(4- - 502 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT {[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-3- oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)propanoyl]-5'-fluoro-3-(propan-2-yl)-1H,1'H- [4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (335); rac-methyl 2-(2-{2-[3-(1-{3-[(27- {4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24-octaoxaheptacosan-1- yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N- methylacetamido}acetamido)acetate (354); rac-methyl 2-(2-{2-[3-(1-{3-[(2-{2-[2-(3-{4-[4- ({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (355); rac-methyl 2-(2- {2-[3-(1-{3-[(18-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (357); methyl 2-{2-[2-(3-{1-[3- ({18-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-18- oxo-3,6,9,12,15-pentaoxaoctadecan-1-yl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (364); methyl 2- {2-[2-(3-{1-[3-({2-[2-(2-{3-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-3- oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (365); rac-methyl 2-[4- ({2-[3-(1-{3-[(27-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (369); rac-methyl 2-[4- ({2-[3-(1-{3-[(2-{2-[2-(3-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (370); rac- methyl 2-[4-({2-[3-(1-{3-[(18-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin- 1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-18-oxo-3,6,9,12,15- pentaoxaoctadecan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- - 503 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT [4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (372); methyl 2-(4-{[2- (3-{1-[3-({18-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1- yl]-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1-yl}carbamoyl)propanoyl]piperidin-4-yl}-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]methyl}-1H-1,2,3-triazol-1- yl)acetate (379); methyl 2-(4-{[2-(3-{1-[3-({2-[2-(2-{3-[4-(4-{[3-carbamoyl-6-(piperidin-1- yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-3- oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]methyl}-1H-1,2,3-triazol-1-yl)acetate (380); rac- methyl 2-(2-{2-[3-(2-{3-[(27-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-27-oxo-3,6,9,12,15,18,21,24- octaoxaheptacosan-1-yl)carbamoyl]propanoyl}-2-azaspiro[3.3]heptan-6-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (399); rac- methyl 2-(2-{2-[3-(2-{3-[(2-{2-[2-(3-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2- oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-3- oxopropoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}-2-azaspiro[3.3]heptan-6-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (400); rac-methyl 2-(2-{2-[3-(2-{3-[(18-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2- oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-18-oxo- 3,6,9,12,15-pentaoxaoctadecan-1-yl)carbamoyl]propanoyl}-2-azaspiro[3.3]heptan-6-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (402); methyl 2-{2-[2-(3-{2-[3-({18-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidin-1-yl]-18-oxo-3,6,9,12,15-pentaoxaoctadecan-1- yl}carbamoyl)propanoyl]-2-azaspiro[3.3]heptan-6-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (409); and methyl 2-{2-[2-(3-{2-[3- ({2-[2-(2-{3-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1- yl]-3-oxopropoxy}ethoxy)ethoxy]ethyl}carbamoyl)propanoyl]-2-azaspiro[3.3]heptan-6-yl}- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (410).

56. The compound of claim 24, wherein L is –NR12(CH2)n1NR12– wherein n1 is an integer from one to ten; and each R12is independently hydrogen or alkyl. - 504 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 57. The compound of claim 56, wherein the compound is selected from the group consisting of methyl 2-[4-({2-[3-(1-{3-[(4-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3- thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}butyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (161); methyl 2-[4-({2-[3- (1-{3-[(2-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}ethyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (166); and methyl 2-[4-({2- [3-(1-{3-[(6-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}hexyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (171).

58. The compound of claim 24, wherein L iswherein each n5 is an integer from one to ten; each n15 is independently one, two, or three; and each R12is independently hydrogen or alkyl.

59. The compound of claim 58, wherein the compound is selected from the group consisting of methyl 2-[2-(2-{1'-[(1-{[(4-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3- thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}butyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H- [4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (163); methyl 2-[2-(2-{1'-[(1-{[(2-{2- [(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}ethyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H- [4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (168); and methyl 2-[2-(2-{1'-[(1-{[(6-{2- [(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- - 505 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT yl]acetamido}hexyl)carbamoyl]methyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H- [4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (173).

60. The compound of claim 24, wherein L is –NR12(CH2CH2O)n4(CH2)n5NR12–, wherein n4 and n5 are an integer from one to ten; and each R12is independently hydrogen or alkyl.

61. The compound of claim 60, wherein the compound is selected from the group consisting of methyl 2-[4-({2-[3-(1-{3-[(23-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3- thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamido}- 3,6,9,12,15,18,21-heptaoxatricosan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (121); methyl 2-{2-[2-(1'-{3-[(2-{2-[2-(2-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia- 1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- yl]acetamido}ethoxy)ethoxy]ethoxy}ethyl)carbamoyl]propanoyl}-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (124); and methyl 2-[4-({2-[3-(1-{3-[(17-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12- tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamido}-3,6,9,12,15- pentaoxaheptadecan-1-yl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (176).

62. The compound of claim 24, whereinwherein n8 is zero, one, two, or three; and each n15 is independently one, two, or three.

63. The compound of claim 62, wherein the compound is selected from the group consisting of methyl 2-[2-(2-{1'-[4-(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidin-1-yl)-4- oxobutanoyl]-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (179); methyl 2-[2-(2-{1'-[4-(4-{4-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidin-1-yl)-4-oxobutanoyl]-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1- - 506 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT yl}acetamido)acetamido]acetate (338); methyl 2-{2-[2-(3-{1-[4-(4-{4-[4-(4-{[3-carbamoyl- 6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidin-1-yl)-4-oxobutanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (368); methyl 2-(4-{[2-(3-{1-[4-(4- {4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidin-1-yl)-4-oxobutanoyl]piperidin-4-yl}-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]methyl}-1H-1,2,3-triazol-1-yl)acetate (383); and methyl 2-{2-[2-(3-{2-[4-(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidin-1-yl)-4- oxobutanoyl]-2-azaspiro[3.3]heptan-6-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)- N-methylacetamido]acetamido}acetate (413).

64. The compound of claim 24, whereinwherein n1 is an integer from one to ten; and each n15 is independently one, two, or three.

65. The compound of claim 64, wherein the compound is selected from the group consisting of ethyl 2-{2-[2-(3-{1-[4-(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidin-1-yl)-4- oxobutanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (180); propan-2-yl 2-{2-[2-(3-{1-[4-(4-{4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidin-1-yl)-4-oxobutanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (181); methyl 2-[2-(2-{1'-[4-(4-{4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidin-1-yl)-4-oxobutanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (353); and methyl 2-{2-[2-(3-{1-[4-(4-{4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidin-1-yl)-4-oxobutanoyl]piperidin-4-yl}-5'-chloro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (398). - 507 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 66. The compound of claim 24, wherein L iswherein each n5 is an integer from one to ten; and each n15 is independently one, two, or three.

67. The compound of claim 66, wherein the compound is methyl 2-(2-{2-[1'-({1-[2-(4- {4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidin-1-yl)-2-oxoethyl]piperidin-4-yl}methyl)-5'-fluoro- 3-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (182).

68. The compound of claim 24, whereinwherein each n15 is independently one, two, or three.

69. The compound of claim 68, wherein the compound is selected from the group consisting of methyl 2-{2-[2-(1'-{4-[4-(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin- 2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidine-1- carbonyl)piperidin-1-yl]-4-oxobutanoyl}-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (183); methyl 2-{4-[(2-{3-[1-(4-{4-[4-(4-{4-[4- ({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)methyl]-1H-1,2,3-triazol-1-yl}acetate (212); rac-methyl 2-(2-{2- [1'-(4-{4-[4-(4-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin- 1-yl]pyrazin-2-yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (331); methyl 2-{2-[2-(1'-{4-[4-(4-{4-[4-(4-{[3-carbamoyl- 6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidine-1-carbonyl)piperidin-1-yl]-4-oxobutanoyl}-5'-fluoro-3-(propan-2-yl)- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (337); rac-methyl 2-[2-(2-{3-[1- - 508 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT (4-{4-[4-(4-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1- yl]pyrazin-2-yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (361); methyl 2-(2-{2-[3-(1-{4-[4-(4- {4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]-4- oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N- methylacetamido}acetamido)acetate (367); rac-methyl 2-{4-[(2-{3-[1-(4-{4-[4-(4-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)methyl]-1H-1,2,3-triazol-1-yl}acetate (376); methyl 2-[4-({2-[3- (1-{4-[4-(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine- 1-carbonyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]-4- oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (382); rac-methyl 2-[2-(2-{3-[2-(4-{4-[4- (4-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin- 2-yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)-2-azaspiro[3.3]heptan-6-yl]-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (406); and methyl 2-(2- {2-[3-(2-{4-[4-(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidine-1- carbonyl)piperidin-1-yl]-4-oxobutanoyl}-2-azaspiro[3.3]heptan-6-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (412).

70. The compound of claim 24, whereinwherein n1 is an integer from one to ten; and each n15 is independently one, two, or three.

71. The compound of claim 70, wherein the compound is selected from the group consisting of ethyl 2-(2-{2-[3-(1-{4-[4-(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin- 2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidine-1- - 509 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT carbonyl)piperidin-1-yl]-4-oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (184); propan-2-yl 2-(2-{2-[3-(1-{4-[4-(4-{4- [4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]-4- oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (185); methyl 2-(2-{2-[1'-(4-{4-[4-(4-{4-[4-({3-carbamoyl- 6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (210); ethyl 2-[2-(2-{3-[1-(4-{4-[4-(4-{4-[4- ({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)acetamido]acetate (211); propan-2-yl 2-[2-(2-{3-[1-(4-{4-[4-(4- {4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)acetamido]acetate (213); rac-methyl 2-(2-{2-[1'-(4-{4-[4-(4-{4- [4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (346); methyl 2-{2-[2-(1'-{4-[4-(4-{4-[4-(4-{[3-carbamoyl- 6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidine-1-carbonyl)piperidin-1-yl]-4-oxobutanoyl}-5'-fluoro-3-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (352); rac-methyl 2-[2-(2-{3-[1-(4-{4-[4- (4-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin- 2-yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-chloro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)acetamido]acetate (391); and methyl 2-(2-{2-[3-(1-{4-[4-(4-{4-[4- (4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]-4- oxobutanoyl}piperidin-4-yl)-5'-chloro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (397). - 510 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 72. The compound of claim 24, wherein L iswherein each n5 is an integer from one to ten; and each n15 is independently one, two, or three.

73. The compound of claim 72, wherein the compound is selected from the group consisting of methyl 2-[2-(2-{1'-[(1-{2-[4-(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1- yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidine-1- carbonyl)piperidin-1-yl]-2-oxoethyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl}acetamido)acetamido]acetate (186); and methyl 2-{2-[2-(1'-{[1-(2-{4-[4-(4- {4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}-2-oxoethyl)piperidin-4-yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetamido]acetamido}acetate (214).

74. The compound of claim 24, whereinwherein n1 is an integer from one to ten; and each n15 is independently one, two, or three.

75. The compound of claim 74, wherein the compound is selected from the group consisting of methyl 2-(2-{2-[1'-(4-{4-[(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin- 2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidin-1- yl)methyl]piperidin-1-yl}-4-oxobutanoyl)-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (187); methyl 2-{2-[2-(3-{2-[4-(4-{[4-(4-{4-[5- (2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-4- oxobutanoyl]-2-azaspiro[3.3]heptan-6-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)- N-methylacetamido]acetamido}acetate (285); methyl 2-{2-[2-(3-{1-[4-(4-{[4-(4-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- - 511 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT yl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-4- oxobutanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)-N- methylacetamido]acetamido}acetate (286); methyl 2-(2-{2-[3-(2-{4-[4-({4-[4-(4-{4- [(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]- 1H-pyrazol-1-yl}piperidine-1-carbonyl)piperidine-1-carbonyl]piperidin-1- yl}methyl)piperidin-1-yl]-4-oxobutanoyl}-2-azaspiro[3.3]heptan-6-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (290); methyl 2-(2-{2- [3-(1-{4-[4-({4-[4-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H- cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidine-1-carbonyl)piperidine-1- carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4-oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (292); methyl 2- (2-{2-[1'-(4-{4-[(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidin-1- yl)methyl]piperidin-1-yl}-4-oxobutanoyl)-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]- 1-yl]acetamido}acetamido)acetate (336); methyl 2-[2-(2-{3-[1-(4-{4-[(4-{4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (366); methyl 2- {4-[(2-{3-[1-(4-{4-[(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidin-1- yl)methyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'biindazol]-1-yl}acetamido)methyl]-1H-1,2,3-triazol-1-yl}acetate (381); and methyl 2-[2-(2- {3-[2-(4-{4-[(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidin-1- yl)methyl]piperidin-1-yl}-4-oxobutanoyl)-2-azaspiro[3.3]heptan-6-yl]-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (411).

76. The compound of claim 24, whereinwherein each n1 is an integer from one to ten; and each n15 is independently one, two, or three. - 512 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 77. The compound of claim 76, wherein the compound is selected from the group consisting of ethyl 2-[2-(2-{3-[1-(4-{4-[(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin- 2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidin-1- yl)methyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'biindazol]-1-yl}acetamido)acetamido]acetate (188); propan-2-yl 2-[2-(2-{3-[1-(4-{4-[(4-{4- [4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4- oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (189); methyl 2-[2-(2-{1'-[4-(4-{[4-(4-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-4- oxobutanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (239); methyl 2-[2-(2-{1'-[4-(4-{[4-(4-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3- (propane-1-sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidine-1-carbonyl}piperidine-1- carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-4-oxobutanoyl]-5'-fluoro-3-(trifluoromethyl)- 1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (283); methyl 2-{2-[2-(3-{1-[4-(4- {[4-(4-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3- thiazol-2-yl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]methyl}piperidin-1- yl)-4-oxobutanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (287); methyl 2-{2-[2-(1'-{4-[4-({4-[4-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidine-1-carbonyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- oxobutanoyl}-5'-fluoro-3-(trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (288); methyl 2-{2-[2-(1'-{4-[4-({4-[4-(4-{4-[(4aR,5aS)-5,5- difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1- yl}piperidine-1-carbonyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- oxobutanoyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (291); methyl 2-(2-{2-[3-(1-{4-[4-({4-[4-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidine-1- carbonyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (293); methyl 2-(2-{2-[1'-(4-{4-[(4-{4-[4-(4-{[3-carbamoyl- 6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1- - 513 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4-oxobutanoyl)-5'-fluoro-3-methyl-1H,1'H- [4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (351); and methyl 2-[2-(2-{3-[1-(4-{4-[(4- {4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4- oxobutanoyl)piperidin-4-yl]-5'-chloro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (396).

78. The compound of claim 24, wherein L iswherein n1 and each n5 are independently an integer from one to ten; and each n15 is independently one, two, or three.

79. The compound of claim 78, wherein the compound is selected from the group consisting of methyl 2-{2-[2-(1'-{[1-(2-{4-[(4-{4-[4-(4-{[3-carbamoyl-6-(piperidin-1- yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidine-1-carbonyl}piperidin-1- yl)methyl]piperidin-1-yl}-2-oxoethyl)piperidin-4-yl]methyl}-5'-fluoro-3-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (190); methyl 2-(2-{2-[1'-({1-[2-(4-{[4- (4-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol- 2-yl]piperidine-1-carbonyl}piperidine-1-carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-2- oxoethyl]piperidin-4-yl}methyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (284); and methyl 2-[2-(2-{1'-[(1-{2-[4-({4-[4-(4-{4- [(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]- 1H-pyrazol-1-yl}piperidine-1-carbonyl)piperidine-1-carbonyl]piperidin-1- yl}methyl)piperidin-1-yl]-2-oxoethyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H- [4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (289).

80. The compound of claim 24, whereinwherein n1 is an integer from one to ten; and each n15 is independently one, two, or three. - 514 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 81. The compoudn of claim 80, wherein the compound is methyl 2-{2-[2-(1'-{4-[4-({4- [4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4-oxobutanoyl}-5'-fluoro-3-(trifluoromethyl)- 1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (202).

82. The compound of claim 24, whereinwherein each n1 is independently an integer from one to ten; and each n15 is independently one, two, or three.

83. The compound of claim 82, wherein the compound is selected from the group consisting of ethyl 2-(2-{2-[3-(1-{4-[4-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (203); propan-2-yl 2-(2-{2-[3-(1-{4-[4-({4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidin-1- yl}methyl)piperidin-1-yl]-4-oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]acetamido}acetamido)acetate (204); methyl 2-(2-{2-[1'-(4-{4-[(4-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4-oxobutanoyl)-5'-fluoro-3- (trifluoromethyl)-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (271); methyl 2- (2-{2-[1'-(4-{4-[(4-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin- 1-yl}-4-oxobutanoyl)-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (274); methyl 2-[2-(2-{3-[1-(4-{4-[(4-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-4-oxobutanoyl)piperidin-4- yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (276); methyl 2-[2-(2-{1'-[4-(4-{[4-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidine-1- carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-4-oxobutanoyl]-5'-fluoro-3-(trifluoromethyl)- 1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (277); methyl 2-[2-(2-{1'-[4-(4- - 515 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT {[4-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole- 3-amido]-1H-pyrazol-1-yl}piperidine-1-carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-4- oxobutanoyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl}acetamido)acetamido]acetate (280); methyl 2-{2-[2-(3-{1-[4-(4-{[4-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidine-1- carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-4-oxobutanoyl]piperidin-4-yl}-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (281); methyl 2- {2-[2-(1'-{4-[4-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- oxobutanoyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (348); and methyl 2-(2-{2-[3-(1-{4-[4-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- oxobutanoyl}piperidin-4-yl)-5'-chloro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}acetamido)acetate (393).

84. The compound of claim 24, wherein L iswherein n1 and each n5 are independently an integer from one to ten; and each n15 is independently one, two, or three.

85. The compound of claim 84, wherein the compound is selected from the group consisting of methyl 2-[2-(2-{1'-[(1-{2-[4-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1- yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]- 2-oxoethyl}piperidin-4-yl)methyl]-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (205); methyl 2-{2-[2-(1'-{[1-(2-{4-[(4-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin-1-yl}-2-oxoethyl)piperidin-4- yl]methyl}-5'-fluoro-3-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (272); and methyl 2-(2-{2-[1'-({1-[2-(4-{[4-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl- 1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidine-1- carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-2-oxoethyl]piperidin-4-yl}methyl)-5'-fluoro- 3-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}acetamido)acetate (278). - 516 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 86. The compound of claim 24, wherein L is –C(O)(CH2)n5NR12– wherein n5 is an integer from one to ten; and R12is hydrogen or alkyl.

87. The compound of claim 86, wherein the compound is selected from the group consisting of methyl 2-[4-({2-[3-(1-{3-[(8-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2- oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-8- oxooctyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (226); methyl 2-[2-(2-{3-[2-(3-{[12-(4- {4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3- amido]-1H-pyrazol-1-yl}piperidin-1-yl)-12-oxododecyl]carbamoyl}propanoyl)-2- azaspiro[3.3]heptan-6-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N- methylacetamido)acetamido]acetate (234); methyl 2-(2-{2-[3-(2-{3-[(12-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-12-oxododecyl)carbamoyl]propanoyl}-2-azaspiro[3.3]heptan-6-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (242); methyl 2-(2-{2-[3-(1-{3-[(12-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-12- oxododecyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (244); methyl 2-[2-(2-{3-[1-(3-{[12- (4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3- amido]-1H-pyrazol-1-yl}piperidin-1-yl)-12-oxododecyl]carbamoyl}propanoyl)piperidin-4- yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (248); methyl 2-(2-{2-[3-(2-{3-[(9-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidin-1-yl}-9-oxononyl)carbamoyl]propanoyl}-2- azaspiro[3.3]heptan-6-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N- methylacetamido}acetamido)acetate (251); methyl 2-(2-{2-[3-(1-{3-[(9-{4-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1-sulfonamido)phenyl]-1,3-thiazol-2- yl]piperidin-1-yl}-9-oxononyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (253); methyl 2-[2-(2- {3-[2-(3-{[9-(4-{4-[(4aR,5aS)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H- cyclopropa[f]indazole-3-amido]-1H-pyrazol-1-yl}piperidin-1-yl)-9- oxononyl]carbamoyl}propanoyl)-2-azaspiro[3.3]heptan-6-yl]-5'-fluoro-1'-methyl-1H,1'H- - 517 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT [4,6'-biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (257); methyl 2-[2-(2-{1'-[3- ({8-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-8- oxooctyl}carbamoyl)propanoyl]-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (326); rac-methyl 2-{2-[2-(1'-{3-[(8-{4-[4-({3-carbamoyl-6- [(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]propanoyl}-5'-fluoro-3-(propan-2- yl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (328); rac-methyl 2-{2-[2-(1'- {3-[(6-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1- yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-6-oxohexyl)carbamoyl]propanoyl}-5'-fluoro- 3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (329); methyl 2- [2-(2-{1'-[3-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin- 1-yl]-4-oxobutyl}carbamoyl)propanoyl]-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (330); methyl 2-[2-(2-{1'-[3-({6-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-6- oxohexyl}carbamoyl)propanoyl]-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1- yl}acetamido)acetamido]acetate (332); methyl 2-{2-[2-(3-{1-[3-({8-[4-(4-{[3-carbamoyl-6- (piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-8- oxooctyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)-N-methylacetamido]acetamido}acetate (356); rac-methyl 2-(2-{2-[3-(1-{3-[(8-{4-[4- ({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro- 1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (358); rac- methyl 2-(2-{2-[3-(1-{3-[(6-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1- yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-6- oxohexyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl]-N-methylacetamido}acetamido)acetate (359); methyl 2-{2-[2-(3-{1-[3-({4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-4- oxobutyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)-N-methylacetamido]acetamido}acetate (360); methyl 2-{2-[2-(3-{1-[3-({6-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-6- oxohexyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)-N-methylacetamido]acetamido}acetate (362); methyl 2-(4-{[2-(3-{1-[3-({8-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-8- - 518 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT oxooctyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetamido]methyl}-1H-1,2,3-triazol-1-yl)acetate (371); rac-methyl 2-[4-({2-[3-(1-{3- [(8-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin- 2-yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]propanoyl}piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1- yl]acetate (373); rac-methyl 2-[4-({2-[3-(1-{3-[(6-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl- 2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-6- oxohexyl)carbamoyl]propanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (374); methyl 2-(4-{[2-(3-{1-[3-({4-[4- (4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-4- oxobutyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetamido]methyl}-1H-1,2,3-triazol-1-yl)acetate (375); methyl 2-(4-{[2-(3-{1-[3-({6-[4- (4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-6- oxohexyl}carbamoyl)propanoyl]piperidin-4-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetamido]methyl}-1H-1,2,3-triazol-1-yl)acetate (377); methyl 2-{2-[2-(3-{2-[3-({8-[4- (4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-8- oxooctyl}carbamoyl)propanoyl]-2-azaspiro[3.3]heptan-6-yl}-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (401); rac-methyl 2-(2-{2-[3-(2- {3-[(8-{4-[4-({3-carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1- yl]pyrazin-2-yl}amino)phenyl]piperidin-1-yl}-8-oxooctyl)carbamoyl]propanoyl}-2- azaspiro[3.3]heptan-6-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N- methylacetamido}acetamido)acetate (403); rac-methyl 2-(2-{2-[3-(2-{3-[(6-{4-[4-({3- carbamoyl-6-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazin-2- yl}amino)phenyl]piperidin-1-yl}-6-oxohexyl)carbamoyl]propanoyl}-2-azaspiro[3.3]heptan- 6-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]-N- methylacetamido}acetamido)acetate (404); methyl 2-{2-[2-(3-{2-[3-({4-[4-(4-{[3- carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]-4- oxobutyl}carbamoyl)propanoyl]-2-azaspiro[3.3]heptan-6-yl}-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (405); and methyl 2-{2-[2-(3- {2-[3-({6-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidin-1-yl]- 6-oxohexyl}carbamoyl)propanoyl]-2-azaspiro[3.3]heptan-6-yl}-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)-N-methylacetamido]acetamido}acetate (407). - 519 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 88. The compound of claim 24, whereinwherein n1 is an integer from one to ten; and each n15 is independently one, two, or three.

89. The compound of claim 88, wherein the compound is selected from the group consisting of methyl 2-[2-(2-{3-[2-(4-{4-[(4-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3- (propane-1-sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidine-1-carbonyl}piperidin-1- yl)methyl]piperidin-1-yl}-4-oxobutanoyl)-2-azaspiro[3.3]heptan-6-yl]-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl}-N-methylacetamido)acetamido]acetate (273); methyl 2-[2-(2- {3-[1-(4-{4-[(4-{4-[5-(2-aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-1- sulfonamido)phenyl]-1,3-thiazol-2-yl]piperidine-1-carbonyl}piperidin-1-yl)methyl]piperidin- 1-yl}-4-oxobutanoyl)piperidin-4-yl]-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl}-N- methylacetamido)acetamido]acetate (275); methyl 2-{2-[2-(3-{2-[4-(4-{[4-(4-{4-[(4aR,5aS)- 5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol- 1-yl}piperidine-1-carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-4-oxobutanoyl]-2- azaspiro[3.3]heptan-6-yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)-N- methylacetamido]acetamido}acetate (279); methyl 2-{2-[2-(3-{1-[4-(4-{[4-(4-{4-[(4aR,5aS)- 5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-amido]-1H-pyrazol- 1-yl}piperidine-1-carbonyl)piperidin-1-yl]methyl}piperidin-1-yl)-4-oxobutanoyl]piperidin-4- yl}-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetamido]acetamido}acetate (282); methyl 2-{2-[2-(1'-{4-[4-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- oxobutanoyl}-5'-fluoro-3-(propan-2-yl)-1H,1'H-[4,6'-biindazol]-1- yl)acetamido]acetamido}acetate (333); methyl 2-(2-{2-[3-(1-{4-[4-({4-[4-(4-{[3-carbamoyl- 6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1-carbonyl]piperidin-1- yl}methyl)piperidin-1-yl]-4-oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl]-N-methylacetamido}acetamido)acetate (363); methyl 2-[4-({2-[3-(1-{4-[4- ({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2-yl]amino}phenyl)piperidine-1- carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4-oxobutanoyl}piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl]acetamido}methyl)-1H-1,2,3-triazol-1-yl]acetate (378); and methyl 2-(2-{2-[3-(2-{4-[4-({4-[4-(4-{[3-carbamoyl-6-(piperidin-1-yl)pyrazin-2- yl]amino}phenyl)piperidine-1-carbonyl]piperidin-1-yl}methyl)piperidin-1-yl]-4- - 520 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT oxobutanoyl}-2-azaspiro[3.3]heptan-6-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl]- N-methylacetamido}acetamido)acetate (408).

90. The compound of claim 24, whereinwherein n6 and n7 are independently one, two, or three; and n8 is zero, one, two, or three.

91. The compound of claim 90, wherein the compound is selected from the group consisting of (S)-(S)-(2-(3-(1-(2-(1-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo- 1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)acetyl)piperidin- 4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (18); (2-(3-(1-(3- (1-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)pyrrolidin-3-yl)propanoyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (41); (2-(3-(1-(2-(1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)azepan-4-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (42); (S)-(S)-(2-(3-(1-(1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (48); (S)-(S)-(2-(3-(1-(1-(2-(4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)piperidine-4-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (57); (2-(3-(1-(3-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)pyrrolidin-3- yl)propanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (59); (2-(3-(1-(2-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)azepan-4-yl)acetyl)piperidin-4- yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (60); and (S)-(S)-(2- (3-(1-(2-(1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetyl)glycylglycine (92). - 521 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 92. The compound of claim 24, wherein L iswherein n3 is one or two; and n9 is one, two, or three.

93. The compound of claim 92, wherein the compound is (S)-(S)-(2-(3-(1-(2-(4-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperazin-1-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (25).

94. The compound of claim 24, whereinwherein n3 is one or two; n10 is zero, one, two, or three; X6is oxygen or NR5; and R5is independently hydrogen or alkyl.

95. The compound of claim 94, wherein the compound is selected from the group consisting of (2-(3-(1-(4-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4- tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)-1-methylpiperazine-2- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (21); (2-(3-(1-(2-(4-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1- ((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)morpholin-2- yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (26); (2-(3-(1-(4-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)-1-methylpiperazine-2- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (61); and (2-(3-(1-(2-(4-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl- 6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)morpholin-2- yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (90). - 522 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 96. The compound of claim 24, whereinwherein n11 is one or two.

97. The compound of claim 96, wherein the compound is (2-(3-(1-(2-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)-2-azabicyclo[2.2.2]octane-6-carbonyl)piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (22) or (2-(3-(1-(2-(2- ((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin- 6-yl)acetyl)-2-azabicyclo[2.2.2]octane-6-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (63).

98. The compound of claim 24, whereinwherein n12 is one, two, or three.

99. The compound of claim 98, wherein the compound is (2-(3-(1-(1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-3-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (40) or (2-(3-(1-(1-(2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)piperidine-3-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (58).

100. The compound of claim 24, whereinwherein each n13 is independently one, two, three, or four.

101. The compound of claim 100, wherein the compound is (2-(3-(1-((1S,6R)-2-(2-((S)-4- (4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- - 523 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT yl)acetyl)-2-azabicyclo[4.1.0]heptane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetyl)glycylglycine (62).

102. The compound of claim 24, whereinwherein n14 is zero, one, two, or three; and R12is hydrogen or alkyl.

103. The compound of claim 102, wherein the compound is selected from the group consisting of (2-(3-(1-((1S,4r)-4-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo- 1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carboxamido)cyclohexane-1- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (23); (2-(3-(1-((1S,4r)-4-((4-(2-(7-chlorobenzo[d]thiazol-2- yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4- carboxamido)methyl)cyclohexane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetyl)glycylglycine (24); (2-(3-(1-((1S,4r)-4-((2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetamido)methyl)cyclohexane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetyl)glycylglycine (54); and (2-(3-(1-((1S,4r)-4-(2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetamido)cyclohexane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (64).

104. The compound of claim 24, whereinwherein each n15 is independently one, two, or three; and R12is hydrogen or alkyl.

105. The compound of claim 104, wherein the compound is (S)-(S)-(2-(3-(1-(1-(2-(1-(4-(2- (7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)-N-methylpiperidine-4-carboxamido)ethyl)piperidine-4- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- - 524 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT yl)acetyl)glycylglycine (38) or (S)-(S)-(2-(3-(1-(1-(2-(1-(2-(4-(4-chlorophenyl)-2,3,9- trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)-N- methylpiperidine-4-carboxamido)ethyl)piperidine-4-carbonyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (110).

106. The compound of claim 24, whereinwherein each n15 is independently one, two, or three; n16 is an integer from one to six; and R12is independently hydrogen or alkyl.

107. The compound of claim 106, wherein the compound is (2-(3-(1-(1-(2-(1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)-N-methylpyrrolidine-2-carboxamido)ethyl)piperidine-4- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (77) or (2-(3-(1-(1-(2-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl- 6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)-N-methylpyrrolidine-2- carboxamido)ethyl)piperidine-4-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (104).

108. The compound of claim 24, whereinwherein n8 is zero, one, two, or three; and each n15 is independently one, two, or three.

109. The compound of claim 108, wherein the compound is selected from the group consisting of (S)-(S)-(2-(3-(1-(2-(1-(1-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2- oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (39); (S)-(S)-(2-(3-(1-(1-(1-(4-(2-(7-chlorobenzo[d]thiazol-2- - 525 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (79); (2-(3-(1-(1-(1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidine-3-carbonyl)piperidin-4-yl)- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (80); (2-(3-(1-(3-(1-(1- (4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)pyrrolidin-3-yl)propanoyl)piperidin-4- yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (81); (2-(3-(1-(2-(1- (1-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)azepan-4-yl)acetyl)piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (82); (S)-(S)-(2-(3-(1-(1- (1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)acetyl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (107); (2-(3-(1-(1-(1-(2- ((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin- 6-yl)acetyl)piperidine-4-carbonyl)piperidine-3-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (108); (2-(3-(1-(3-(1-(1-(2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)piperidine-4-carbonyl)pyrrolidin-3-yl)propanoyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (112); (2-(3-(1-(2-(1-(1-(2-((S)-4- (4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)piperidine-4-carbonyl)azepan-4-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (113); and (S)-(S)-(2-(3-(1-(2-(1-(1-(2-(4- (4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)piperidine-4-carbonyl)piperidin-4-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (119).

110. The compound of claim 24, whereinwherein n3 is one or two; and each n15 is independently one, two, or three. - 526 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 111. The compound of claim 110, wherein the compound is methyl (S)-(S)-(2-(3-(1-(4-(4- (4-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperazine-1-carbonyl)piperidin-1-yl)-4- oxobutanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycinate (46).

112. The compound of claim 24, whereinwherein each n15 is independently one, two, or three; and n16 is an integer from one to six.

113. The compound of claim 112, wherein the compound is (2-(3-(1-(1-((4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)prolyl)piperidine-4-carbonyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (66) or (2-(3-(1-(1-((2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)prolyl)piperidine-4-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (93).

114. The compound of claim 24, whereinwherein n16 is an integer from one to six; and n17 is one, two, three, four, or five.

115. The compound of claim 114, wherein the compound is (2-(3-(1-(1-((4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)prolyl)piperidine-3-carbonyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (67) or (2-(3-(1-(1-((2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- - 527 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT yl)acetyl)prolyl)piperidine-3-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (94).

116. The compound of claim 24, whereinwherein n3 is one or two; n13 is one, two, three, or four; n15 is one, two, or three; and n16 is an integer from one to six.

117. The compound of claim 116, wherein the compound is selected from the group consisting of (2-(3-(1-(3-(1-((4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo- 1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)prolyl)pyrrolidin-3- yl)propanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (68); (2-(3-(1-(2-(1-((4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1- ((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)prolyl)azepan-4- yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (69); (2-(3-(1-(2-(1-((4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1- ((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)prolyl)piperidin-4- yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (78); (2-(3-(1-(3-(1-((2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)prolyl)pyrrolidin-3- yl)propanoyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (95); (2-(3-(1-(2-(1-((2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)prolyl)azepan-4- yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (96); and (2-(3-(1-(2-(1-((2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl- 6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)prolyl)piperidin-4- yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (106). - 528 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 118. The compound of claim 24, wherein L is wherein n13 is one, two, three, or four; n14 is zero, one, two, or three; n16 is an integer from one to six; X6is oxygen or NR5; and R5is hydrogen or alkyl.

119. The compound of claim 118, wherein the compound is selected from the group consisting of (2-(3-(1-(4-((4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4- tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)prolyl)-1-methylpiperazine-2- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (70); (2-(3-(1-(2-(4-((4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1- ((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)prolyl)morpholin-2- yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (76); (2-(3-(1-(4-((2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)prolyl)-1-methylpiperazine-2- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (97); and (2-(3-(1-(2-(4-((2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl- 6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)prolyl)morpholin-2- yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (103).

120. The compound of claim 24, whereinwherein each n13 is independently one, two, three, or four; and n16 is an integer from one to six.

121. The compound of claim 120, wherein the compound is (2-(3-(1-((1S,6R)-2-((4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)prolyl)-2-azabicyclo[4.1.0]heptane-1-carbonyl)piperidin-4- yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (71) or (2-(3-(1- ((1S,6R)-2-((2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- - 529 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT a][1,4]diazepin-6-yl)acetyl)prolyl)-2-azabicyclo[4.1.0]heptane-1-carbonyl)piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (98).

122. The compound of claim 24, whereinwherein each n11 is independently one or two; and each n16 is independently an integer from one to six.

123. The compound of claim 122, wherein the compound is (2-(3-(1-(2-((4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)prolyl)-2-azabicyclo[2.2.2]octane-6-carbonyl)piperidin-4-yl)- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (72) or (2-(3-(1-(2-((2- ((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin- 6-yl)acetyl)prolyl)-2-azabicyclo[2.2.2]octane-6-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (99).

124. The compound of claim 24, whereinwherein n14 is zero, one, two, or three; n16 is an integer from one to six; and R12is hydrogen or alkyl.

125. The compound of claim 124, wherein the compound is selected from the group consisting of (2-(3-(1-((1S,4r)-4-(1-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2- oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)pyrrolidine-2- carboxamido)cyclohexane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (73); (2-(3-(1-((1S,4r)-4-((1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- - 530 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT carbonyl)piperidine-4-carbonyl)pyrrolidine-2-carboxamido)methyl)cyclohexane-1- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (74); (2-(3-(1-((1S,4r)-4-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9- trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)pyrrolidine-2- carboxamido)cyclohexane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (100); and (2-(3-(1-((1S,4r)-4-((1-(2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)pyrrolidine-2-carboxamido)methyl)cyclohexane-1-carbonyl)piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (101).

126. The compound of claim 24, whereinwherein n14 is zero, one, two, or three; each n15 is independently one, two, or three; and n16 is independently an integer from one to six.

127. The compound of claim 126, wherein the compound is (2-(3-(1-(2-(4-((4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)prolyl)piperazin-1-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'- methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (75) or (2-(3-(1-(2-(4-((2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)prolyl)piperazin-1-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (102).one, two, three, or four; n14 is zero, one, two, or three; each n15 is independently one, two, or three; X6is oxygen or NR5; and R5is hydrogen or alkyl. - 531 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 129. The compound of claim 128, wherein the compound is selected from the group consisting of (2-(3-(1-(4-(1-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo- 1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)-1- methylpiperazine-2-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (83); (2-(3-(1-(2-(4-(1-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)- 1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)piperidine-4- carbonyl)morpholin-2-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycine (89); (2-(3-(1-(4-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidine-4-carbonyl)-1- methylpiperazine-2-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (114); and(2-(3-(1-(2-(4-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9- trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidine-4- carbonyl)morpholin-2-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]- 1-yl)acetyl)glycylglycine (118).

130. The compound of claim 24, whereinwherein each n13 is independently one, two, three, or four; and each n15 is independently one, two, or three.

131. The compound of claim 130, wherein the compound is (2-(3-(1-((1S,6R)-2-(1-(4-(2- (7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)-2-azabicyclo[4.1.0]heptane-1- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (84) or (2-(3-(1-((1S,6R)-2-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9- trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidine-4- carbonyl)-2-azabicyclo[4.1.0]heptane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H- [4,6'-biindazol]-1-yl)acetyl)glycylglycine (115). - 532 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 132. The compound of claim 24, whereinwherein each n11 is independently one or two; and each n15 is independently one, two, or three.

133. The compound of claim 132, wherein the compound is (2-(3-(1-(2-(1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)-2-azabicyclo[2.2.2]octane-6- carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (85) or (2-(3-(1-(2-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidine-4-carbonyl)-2- azabicyclo[2.2.2]octane-6-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (116).

134. The compound of claim 24, whereinwherein n14 is zero, one, two, or three; each n15 is independently one, two, or three; and R12is hydrogen or alkyl.

135. The compound of claim 134, wherein the compound is selected from the group consisting of (2-(3-(1-((1r,4r)-4-(1-(4-(2-(7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2- oxo-1,2,3,4-tetrahydroquinoline-4-carbonyl)piperidine-4-carbonyl)piperidine-4- carboxamido)cyclohexane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (86); (2-(3-(1-((1r,4r)-4-((1-(4-(2-(7- chlorobenzo[d]thiazol-2-yl)phenoxy)-1-((S)-2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carboxamido)methyl)cyclohexane-1- - 533 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1- yl)acetyl)glycylglycine (87); (2-(3-(1-((1S,4r)-4-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9- trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidine-4- carboxamido)cyclohexane-1-carbonyl)piperidin-4-yl)-5'-fluoro-1'-methyl-1H,1'H-[4,6'- biindazol]-1-yl)acetyl)glycylglycine (105); and (2-(3-(1-((1S,4r)-4-((1-(2-((S)-4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)piperidine-4-carboxamido)methyl)cyclohexane-1-carbonyl)piperidin-4-yl)-5'- fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (117).

136. The compound of claim 24, whereinwherein each n15 is independently one, two, or three.

137. The compound of claim 136, wherein the compound is (S)-(S)-(2-(3-(1-(2-(4-(1-(4-(2- (7-chlorobenzo[d]thiazol-2-yl)phenoxy)-1-(2-oxo-1,2,3,4-tetrahydroquinoline-4- carbonyl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperazin-1-yl)acetyl)piperidin-4-yl)- 5'-fluoro-1'-methyl-1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (88).

138. The compound of claim 24, whereinwherein n14 is zero, one, two, or three; and each n15 is independently one, two, or three.

139. The compound of claim 138, wherein the compound is (S)-(S)-(2-(3-(1-(2-(4-(1-(2-(4- (4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6- yl)acetyl)piperidine-4-carbonyl)piperazin-1-yl)acetyl)piperidin-4-yl)-5'-fluoro-1'-methyl- 1H,1'H-[4,6'-biindazol]-1-yl)acetyl)glycylglycine (109).

140. The compound of claim 1, selected from the group consisting of - 534 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT- 535 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT- 536 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT- 537 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT- 538 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCTand stereoisomers and pharmaceutically acceptable salts thereof.

141. The compound of claim 1, selected from the group consisting of the compounds of Table 1, or a pharmaceutically acceptable salt thereof.

142. A drug-antibody conjugate comprising an antibody or an antigen binding fragment thereof covalently linked to one or more compounds of any one of claims 1-141.

143. The conjugate of claim 142, wherein the antibody or antigen binding fragment thereof binds to its target with a KD< 30 nM, and the one or more compounds are covalently bound to the antibody or an antigen binding fragment thereof via one or more cleavable linkers. - 539 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 144. The conjugate of claim 142 or 143, wherein the antibody, or antigen binding fragment thereof, comprises three heavy chain CDRs and three light chain CDRs of an antibody seleted from the group consisting of rituximab, inotuzumab, polatuzumab, trastuzumab, gentuzumab, lintuzumab, and loncastuximab.

145. The conjugate of any one of claims 142-144, wherein the antibody or antigen binding fragment thereof comprises the heavy chain variable region and the light chain variable region of an antibody selected from the group consisting of rituximab, inotuzumab, polatuzumab, trastuzumab, gentuzumab, lintuzumab, and loncastuximab.

146. The conjugate of any one of claims 142-145, wherein the antibody or antigen binding fragment thereof is selected from the group consisting of rituximab, inotuzumab, polatuzumab, trastuzumab, gentuzumab, lintuzumab, and loncastuximab.

147. The conjugate of any one of claims 142-146, that comprises the antigen binding fragment, and wherein the antigen binding fragment is selected from Fv, Fab, Fab’, F(ab’)2 Fc, scFv, scFv-Fc, diabodies, triabodies, tetrabodies, minibodies, nanobodies, and combinations thereof.

148. The conjugate of any one of claims 142-147, wherein the antibody or antigen binding fragment thereof is linked to at least one of the compounds of any one of claims 1-89 via one or more linkers.

149. The conjugate of claim 148, wherein at least one of the one or more linkers is hydrolytically stable.

150. The conjugate of claim 148, wherein at least one of the one or more linkers is cleavable.

151. The conjugate of claim 150, wherein at least one of the linkers is a protease cleavable linker, an enzyme cleavable linker, a pH-sensitive linker, or a non-cleavable linker.

152. The conjugate of any one of claims 142-151, wherein at least one of the linkers is selected from alkylene, substituted alkylene, heteroalkylene, substituted heteroalkylene, arylene, substituted arylene, heteroarlyene, and substituted heteroarylene. - 540 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 153. The conjugate of any one of claims 142-151, wherein at least one of the linkers comprises a peptide residue selected from the group consisting of alanine-alanine, valine-citrulline, citrulline-valine, lysine-phenylalanine, phenylalanine-lysine, valine- asparagine, asparagine-valine, threonine-asparagine, asparagine-threonine, serine-asparagine, asparagine-serine, phenylalanine-asparagine, asparagine-phenylalanine, leucine-asparagine, asparagine-leucine, isoleucine-asparagine, asparagine-isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid-asparagine, asparagine-glutamic acid, citrulline-asparagine, asparagine-citrulline, alanine-asparagine, asparagine-alanine, and glycine-glycine-phenylalanine-glycine (GGFG) residues.

154. The conjugate of any one of claims 142-153, wherein at least one of the linkers is conjugated to a native or engineered cysteine residue of the heavy or light chain of the antibody or antigen binding fragment thereof.

155. The conjugate of any one of claims 142-154, wherein the conjugate is represented by the structure of Formula (I) Formula (I) or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof; wherein Ab is the antibody or antigen-binding fragment thereof; LL is a bond or a linker; each PAY is individually one of the compounds of any one of claims 1-89; and n is an integer selected from one to twelve.

156. The conjugate of any one of claims 142-155, represented by Formula (Ia)Formula (Ia) or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof; wherein Ab is the antibody or antigen-binding fragment thereof; each PAY is individually one of the compounds of any one of claims 1-89; - 541 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT RL is the residue of a reactive group linked to an amino acid of Ab; SP1, SP2, and SP3are, independently at each occurrence, absent or a divalent spacer group; W1is, independently at each occurrence, absentW2is, independently at each occurrence, absent, an amino acid residue, or a peptide residue wherein the amino acid residue or peptide residue is optionally substituted or derivatized with one or more of a HP2group, –N(R)C(O)-(CH2CH2O)bCH3, –N(R)- (CH2CH2O)bCH3, or –C(O)N(R)-(CH2CH2O)bCH3 wherein R is hydrogen or –C1-3 alkyl; b is an integer from two to twenty-four; HP1is, independently at each occurrence, absent or a divalent hydrophilic group; HP2, when present, is a monovalent hydrophilic group; RT is, independently at each occurrence, absent or a release trigger group; and n is an integer from zero to twelve.

157. The conjugate of claim 156, wherein HP1is absent.

158. The conjugate of claim 156, wherein HP1is a hydrophilic polymer.

159. The conjugate of claim 158, wherein HP1is polyethylene glycol (PEG).

160. The conjugate of any one of claims 156-159, wherein HP2is absent.

161. The conjugate of any one of claims 156-159, wherein HP2is a hydrophilic polymer.

162. The conjugate of claim 161, wherein HP2is polyethylene glycol (PEG), –N(R)C(O)-(CH2CH2O)bCH3, –N(R)-(CH2CH2O)bCH3, –C(O)N(R)-(CH2CH2O)bCH3, or methoxypolyethylene glycol (mPEG). - 542 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 163. The conjugate of any one of claims 156-162, wherein SP1is selected from PAB, PAB-OH, and PABC; or residues thereof.

164. The conjugate of any one of claims 156-162, wherein SP2and SP3are independently absent or selected from –C(H)(CH2NH2)C(O)NH–, -C(O)-, substituted or unsubstituted alkylene, and substituted or unsubstituted heteroalkylene, wherein the substituents are independently selected from -C(O)- and –N(R)C(O)-(CH2CH2O)nCH3, wherein R is hydrogen or –C1-3 alkyl; and n is an integer from two to twenty-four; or a combination thereof.

165. The conjugate of any one of claims 156-164, wherein SP2is absent, -C(O)-, unsubstituted alkylene, alkylene substituted with –N(R)C(O)-(CH2CH2O)nCH3, or a combination thereof.

166. The conjugate of any one of claims 89o-89x, wherein SP3is absent, –C(H)(CH2NH2)C(O)NH–, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, wherein the substituents are independently selected from -C(O)- and –N(R)C(O)-(CH2CH2O)nCH3, wherein R is hydrogen or –C1-3 alkyl; and n is an integer from two to twenty-four; or a combination thereof.

167. The conjugate of any one of claims 156-165, wherein W2is independently an amino acid residue or a peptide residue wherein the amino acid residue or the peptide residue is optionally substituted or derivatized with a HP2or –N(R)-(CH2CH2O)bCH3, or a combination thereof.

168. The conjugate of claim 167, wherein W2is selected from valine-citrulline, valine- alanine, alanine-alanine, alanine-phenylalanine, phenylalanine-lysine, glycine-valine-citrulline, and glycine-glycine-glycine, glutamic acid-valine-citrulline, aspartic acid-valine-citrulline, glutamic acid-valine-alanine, aspartic acid-valine-alanine, - 543 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT glycine-glycine-phenylalanine-glycine (GGFG), –NH-C(H)(CH2C(O)N(R)-(CH2CH2O)bCH3)C(O)-valine-citrulline, –NH-C(H)(CH2CH2C(O)N(R)-(CH2CH2O)bCH3)C(O)-valine-citrulline, –NH-C(H)(CH2C(O)N(R)-(CH2CH2O)bCH3)C(O)-valine-alanine, and –NH-C(H)(CH2CH2C(O)N(R)-(CH2CH2O)bCH3)C(O)-valine-alanine.

169. The conjugate of any one of claims 156-168, wherein RT is a β-glucuronidase- cleavable β-glucuronide.

170. The conjugate of any one of claims 156-169, wherein RL is linked to the side chain of a residue of Ab selected from cysteine residues, glutamine residues, lysine residues, and amino- terminal residues.

171. The conjugate of any one of claims 156-170, wherein RL is an amide moiety, the residue of a maleimide moiety, or a succinimde moiety.

172. A linker-payload represented by Formula (II) Formula (II) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof; wherein PAY is a compound of any one of claims 1-141; RL is a reactive group; SP1, SP2, and SP3are, independently at each occurrence, absent or a divalent spacer group; W1is, independently at each occurrence, absentW2is, independently at each occurrence, absent, an amino acid residue, or a peptide residue wherein the amino acid residue or peptide residue is optionally substituted or derivatized with one or more of a HP2group, –N(R)C(O)-(CH2CH2O)bCH3, –N(R)-(CH2CH2O)bCH3, or –C(O)N(R)-(CH2CH2O)bCH3 wherein R is hydrogen or –C1-3alkyl; - 544 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT b is an integer from two to twenty-four; HP1is, independently at each occurrence, absent or a divalent hydrophilic group; HP2, when present, is a monovalent hydrophilic group; and RT is independently, at each occurrence, absent or a release trigger group.

173. The linker-payload of claim 172, wherein HP1is absent.

174. The linker-paylaod of claim 172, wherein HP1is a hydrophilic polymer.

175. The linker-payload of claim 174, wherein HP1is polyethylene glycol (PEG).

176. The linker-payload of any one of claims 172-175, wherein HP2is absent.

177. The linker-payload of any one of claims 172-175, wherein HP2is a hydrophilic polymer.

178. The linker-payload of claim 177, wherein HP2is polyethylene glycol (PEG), –N(R)C(O)-(CH2CH2O)bCH3, –N(R)-(CH2CH2O)bCH3, –C(O)N(R)-(CH2CH2O)bCH3, or methoxypolyethylene glycol (mPEG).

179. The linker-payload of any one of claims 172-178, wherein SP1is selected from PAB, PAB-OH, and PABC; or residues thereof.

180. The linker-payload of any one of claims 172-178, wherein SP2and SP3are independently absent or selected from –C(H)(CH2NH2)C(O)NH–, -C(O)-, substituted or unsubstituted alkylene, and substituted or unsubstituted heteroalkylene, wherein the substituents are independently selected from -C(O)- and –N(R)C(O)-(CH2CH2O)nCH3, wherein R is hydrogen or –C1-3alkyl; and n is an integer from two to twenty-four; or a combination thereof.

181. The linker-payload of any one of claims 172-180, wherein SP2is absent, -C(O)-, or unsubstituted alkylene, alkylene substituted with –N(R)C(O)-(CH2CH2O)nCH3, or a combination thereof. - 545 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 89oo. The linker-payload of any one of claims 172-181, wherein SP3is absent, –C(H)(CH2NH2)C(O)NH–, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, wherein the substituents are independently selected from -C(O)- and –N(R)C(O)-(CH2CH2O)nCH3, wherein R is hydrogen or –C1-3alkyl; and n is an integer from two to twenty-four; or a combination thereof.

182. The linker-payload of any one of claims 172-181, wherein W2is independently an amino acid residue or a peptide residue wherein the amino acid residue or the peptide residue is optionally substituted or derivatized with a HP2or –N(R)-(CH2CH2O)bCH3, or a combination thereof.

183. The linker-payload of claim 182, wherein W2is selected from valine-citrulline, valine-alanine, alanine-alanine, alanine-phenylalanine, phenylalanine-lysine, glycine-valine-citrulline, glycine-glycine-glycine, glutamic acid-valine-citrulline, aspartic acid-valine-citrulline, glutamic acid-valine-alanine, aspartic acid-valine-alanine, glycine-glycine-phenylalanine-glycine (GGFG), –NH-C(H)(CH2C(O)N(R)-(CH2CH2O)bCH3)C(O)-valine-citrulline, –NH-C(H)(CH2CH2C(O)N(R)-(CH2CH2O)bCH3)C(O)-valine-citrulline, –NH-C(H)(CH2C(O)N(R)-(CH2CH2O)bCH3)C(O)-valine-alanine, and –NH-C(H)(CH2CH2C(O)N(R)-(CH2CH2O)bCH3)C(O)-valine-alanine.

184. The linker-payload of any one of claims 172-183, wherein RT is a β-glucuronidase- cleavable β-glucuronide.

185. The linker-payload of any one of claims 172-184, wherein RL is an amide moiety, a maleimide moiety, or an N-hydroxysuccinimide moiety.

186. The conjugate or linker-payload of any one of claims 156-185, wherein at least one payload is a residue of Formula (II) - 546 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCTa pharmaceutically acceptable salt thereof or stereoisomer thereof, wherein one of R3bor R4is, and the other is hydrogen, C1-5 alkyl, or haloalkyl; R1is hydrogen or C1-5alkyl;each R5is independently hydrogen or alkyl;each R7hydrogen or C1-5 alkyl; aa is one or two; R3cis hydrogen, halogen, or CN; L1is a bond or selected from the group consisting,, - 547 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCTwherein m is an integer from one to ten; L is a bond or a linker; andis a protein targeting moiety (PTM).

187. The conjugate or linker-payload of claim 186, whereinis a protein targeting moiety (PTM) having the following chemical formula ,each R100a, R100b, and R100care independently selected from hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, acyl, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, arylalkyl, or heteroaryl; and each X100is independently a halogen selected from the group consisting of bromo, chloro, fluoro, and iodo. - 548 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 188. The compound of claim 155, wherein LL is a bond.

189. The compound of claim 155, wherein LL is a linker.

190. The conjugate or linker-payload of any of claims 186-189, whereinis selected from the group consisting of. - 549 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 191. The conjugate or linker-payload of any one of claims 186-190, according to Formula A, B, C, or D- 550 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCTFormula D or a pharmaceutically acceptable salt thereof.

192. The conjugate or linker-payload of any one of claims 186-191, wherein L is selected from the group consisting of- 551 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT- 552 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT ,, - 553 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT, - 554 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCTX6is oxygen or NR5; each n1, n2, n4, and n5 is independently an integer from one to ten; each R12is independently hydrogen or alkyl; each n3 and n11 is independently one or two; n6, n7, n9, and n12 are independently one, two, or three; n8 and n10 are zero, one, two, or three; each n13 is independently one, two, three, or four; each n14 is zero, one, two, or three; each n15 is independently one, two, or three; each n16 is independently an integer from one to six; and n17 is one, two, three, four, or five.

193. The conjugate or linker-payload of claim 186 or 187, wherein at least one payload or compound of any one of claims 1-141 is a compound in Table 1 or a pharmaceutically acceptable salt thereof.

194. A pharmaceutical composition comprising an effective amount of the compound of any one of claims 1-141 or the conjugate of any one of claims 142-193 in combination with a pharmaceutically acceptable carrier, additive, or excipient.

195. A method of treating a disease or disorder in a patient in need thereof, comprising the step of administering to the patient an effective amount of the compound or pharmaceutical composition of any of the previous claims.

196. The method of claim 195, wherein the disease or disorder is cancer.

197. The method of claim 196, wherein the disease or disorder is selected from squamous- cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, - 555 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor or teratocarcinomas. T-lineage Acute lymphoblastic Leukemia (T-ALL), T-lineage lymphoblastic Lymphoma (T-LL), Peripheral T-cell lymphoma, Adult T-cell Leukemia, Pre-B ALL, Pre-B Lymphomas, Large B-cell Lymphoma, Burkitts Lymphoma, B-cell ALL, Philadelphia chromosome positive ALL, Philadelphia chromosome positive CML, prostate cancer, Kennedy's Disease, breast cancer, Lymphoma, diabetes, diabetes mellitus type I, diabetes mellitus type II, obesity, colorectal cancer, head & neck cancer, immune system disorders, leukemia, stem cell growth, stem cell transplantation, wound healing, atherosclerosis, hepatocellular carcinoma, endometrial cancer, McCune-Albright Syndrome, adenocarcinoma, acute lymphoblastic leukemia, multiple myeloma myeloproliferative diseases, large B-cell lymphoma, and B cell Lymphoma.

198. The compound or composition of any one of the previous claims for use in therapy.

199. The compound or composition of any one of the previous claims for use in the treatment of cancer.

200. A process for making the compound of claim 1, comprising the step of contacting a protein targeting compound with a compound of the formulaunder conditions suitable for forming a bond from L to the protein targeting compound. - 556 - 1104806877\8\AMERICASAttorney Docket No.: 121843.00295 NU-3700 PCT 201. The method of claim 200, wherein the protein targeting compound comprises a reactive group capable of forming a bond with L.

202. The method of claim 200, wherein the protein targeting compound is modified to comprise a reactive group capable of forming a bond with L. - 557 - 1104806877\8\AMERICAS

Images